

**HOSPITAL MEDICINES LIST
RESTRICTIONS CHECKLISTS**
April 2024

HOSPITAL

Therapeutic Groups

Alimentary Tract and Metabolism	3
Blood and Blood Forming Organs	44
Cardiovascular System	74
Dermatologicals	105
Genito-Urinary System	111
Hormone Preparations	116
Infections	130
Musculoskeletal System	219
Nervous System	230
Oncology Agents and Immunosuppressants	261
Respiratory System and Allergies	422
Sensory Organs	434
Various	437
Special Foods	442
Vaccines	467
Index of form numbers	493
Index of titles	496

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Calcium carbonate

INITIATION

Prerequisites (tick box where appropriate)

- Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Budesonide

INITIATION – Crohn’s disease

Prerequisites (tick boxes where appropriate)

Mild to moderate ileal, ileocaecal or proximal Crohn’s disease

and

Diabetes

or

Cushingoid habitus

or

Osteoporosis where there is significant risk of fracture

or

Severe acne following treatment with conventional corticosteroid therapy

or

History of severe psychiatric problems associated with corticosteroid treatment

or

History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high

or

Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)

INITIATION – Collagenous and lymphocytic colitis (microscopic colitis)

Prerequisites (tick box where appropriate)

Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies

INITIATION – Gut Graft versus Host disease

Prerequisites (tick box where appropriate)

Patient has gut Graft versus Host disease following allogenic bone marrow transplantation

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Budesonide - continued

INITIATION – non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has autoimmune hepatitis*
- and
- Patient does not have cirrhosis
- and
- Diabetes
- or
- Cushingoid habitus
- or
- Osteoporosis where there is significant risk of fracture
- or
- Severe acne following treatment with conventional corticosteroid therapy
- or
- History of severe psychiatric problems associated with corticosteroid treatment
- or
- History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high
- or
- Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)
- or
- Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth)

Note: Indications marked with * are unapproved indications.

CONTINUATION – non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- Treatment remains appropriate and the patient is benefitting from the treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ranitidine

INITIATION

Prerequisites (tick boxes where appropriate)

- For continuation use
- or**
- Routine prevention of allergic reactions.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Omeprazole - Tab dispersible 20 mg

INITIATION

Prerequisites (tick box where appropriate)

Only for use in tube-fed patients

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

L-ornithine L-aspartate

INITIATION

Prerequisites (tick box where appropriate)

- For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Rifaximin

INITIATION

Prerequisites (tick box where appropriate)

- For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Diazoxide

INITIATION

Prerequisites (tick box where appropriate)

- For patients with confirmed hypoglycaemia caused by hyperinsulinism

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Dulaglutide

INITIATION

Prerequisites (tick boxes where appropriate)

For continuation use

or

Patient has type 2 diabetes

and

2.2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of ALL of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin (see note a)*

and

Patient is Māori or any Pacific ethnicity*

or

Patient has pre-existing cardiovascular disease or risk equivalent (see note b)*

or

Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*

or

Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*

or

Patient has diabetic kidney disease (see note c)*

Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Due to the ongoing supply issues with GLP-1 agonists, we strongly urge prescribers to consider initiating patients on other hypoglycaemic agents, provided they are not contraindicated. Please also consider discontinuing GLP-1 agonist treatment where the patient is not receiving clinically meaningful benefit.
- b) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- c) Diabetic kidney disease defined as: persistent albuminuria (albumin: creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Liraglutide

INITIATION

Prerequisites (tick boxes where appropriate)

For continuation use

or

Patient has type 2 diabetes

and

Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of ALL of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin (see note a)*

and

Patient is Māori or any Pacific ethnicity*

or

Patient has pre-existing cardiovascular disease or risk equivalent (see note b)*

or

Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*

or

Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*

or

Patient has diabetic kidney disease (see note c)*

Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Due to the ongoing supply issues with GLP-1 agonists, we strongly urge prescribers to consider initiating patients on other hypoglycaemic agents, provided they are not contraindicated. Please also consider discontinuing GLP-1 agonist treatment where the patient is not receiving clinically meaningful benefit.
- b) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- c) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Empagliflozin; Empagliflozin with metformin hydrochloride

INITIATION

Prerequisites (tick boxes where appropriate)

- For continuation use
- or
- Patient has previously had an initial approval for a GLP-1 agonist
- or
- Patient has type 2 diabetes
- and
- Patient is Māori or any Pacific ethnicity*
- or
- Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*
- or
- Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*
- or
- Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*
- or
- Patient has diabetic kidney disease (see note b)*
- and
- Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months

Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ursodeoxycholic acid

INITIATION – Alagille syndrome or progressive familial intrahepatic cholestasis

Prerequisites (tick boxes where appropriate)

- Patient has been diagnosed with Alagille syndrome
or
 Patient has progressive familial intrahepatic cholestasis

INITIATION – Chronic severe drug induced cholestatic liver injury

Prerequisites (tick boxes where appropriate)

- Patient has chronic severe drug induced cholestatic liver injury
and
 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults
and
 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay

INITIATION – Primary biliary cholangitis

Prerequisites (tick boxes where appropriate)

- Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy
and
 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis)

INITIATION – Pregnancy

Prerequisites (tick box where appropriate)

- Patient diagnosed with cholestasis of pregnancy

INITIATION – Haematological transplant

Prerequisites (tick boxes where appropriate)

- Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation
and
 Treatment for up to 13 weeks

INITIATION – Total parenteral nutrition induced cholestasis

Prerequisites (tick boxes where appropriate)

- Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN
and
 Liver function has not improved with modifying the TPN composition

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ursodeoxycholic acid - *continued*

INITIATION – prevention of sinusoidal obstruction syndrome

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The patient is enrolled in the Children's Oncology Group AALL1732 trial
- and**
- The patient has leukaemia/lymphoma and is receiving inotuzumab ozogamicin

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:


NHI:

Methylnaltrexone bromide

INITIATION – Opioid induced constipation

Prerequisites (tick boxes where appropriate)

<input type="radio"/> The patient is receiving palliative care
and
<input type="radio"/> Oral and rectal treatments for opioid induced constipation are ineffective
or
<input type="radio"/> Oral and rectal treatments for opioid induced constipation are unable to be tolerated



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

sodium picosulfate

INITIATION

Prerequisites (tick boxes where appropriate)

- The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable
- and**
- The patient would otherwise require a high-volume bowel cleansing preparation

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Betaine

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has a confirmed diagnosis of homocystinuria

and

- A cystathionine beta-synthase (CBS) deficiency
or
 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency
or
 A disorder of intracellular cobalamin metabolism

and

- An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Levocarnitine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a neurologist, metabolic physician or metabolic disorders dietitian, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sodium phenylbutyrate

INITIATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Biotin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a metabolic physician or metabolic disorders dietitian, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Pyridoxal-5-phosphate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a neurologist, metabolic physician or metabolic disorders dietitian, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Galsulfase

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has been diagnosed with mucopolysaccharidosis VI

and

Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts

or

Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains appropriate for the patient and the patient is benefiting from treatment

and

Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates

and

Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT)

and

Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Alglucosidase Alfa

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease

and

Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells

or

Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides

or

Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene)

or

Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene

and

Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT)

and

Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT

and

Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains appropriate for the patient and the patient is benefiting from treatment

and

Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks

and

Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates

and

Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT

and

Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT

and

There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation

and

There is no evidence of new or progressive cardiomyopathy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Idursulfase

INITIATION

Re-assessment required after 24 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II)

and

- Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts

or

- Detection of a disease causing mutation in the iduronate 2-sulfatase gene

and

- Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant

and

- Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT)

and

- Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Laronidase

INITIATION

Re-assessment required after 24 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H)

and

- Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts
or
 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome

and

- Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant

and

- Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT)

and

- Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Taliglucerase alfa

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis

and

Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT

and

Patient has haematological complications of Gaucher disease

or

Patient has skeletal complications of Gaucher disease

or

Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease

or

Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease

or

Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period

and

Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units)

Note: Indication marked with * is an unapproved indication

CONTINUATION

Re-assessment required after 3 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started

and

Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size

and

RRadiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose

and

Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT

and

Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sapropterin dihydrochloride

INITIATION

Re-assessment required after 1 month

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant
- and
- Treatment with sapropterin is required to support management of PKU during pregnancy
- and
- Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg
- and
- Sapropterin to be used alone or in combination with PKU dietary management
- and
- Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy
- or
- On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy

and

- Patient continues to be pregnant and treatment with sapropterin will not continue after delivery
- or
- Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin
- or
- Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy

and

- Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg
- and
- Sapropterin to be used alone or in combination with PKU dietary management
- and
- Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward: NHI:

Carglumic Acid

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

For the acute in-patient treatment of organic acidaemias as an alternative to haemofiltration

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Coenzyme Q10

INITIATION

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a suspected inborn error of metabolism that may respond to coenzyme Q10 supplementation

CONTINUATION

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation

and

The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Riboflavin

INITIATION

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician or neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation

CONTINUATION

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician or neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation

and

The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Taurine

INITIATION

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a suspected specific mitochondrial disorder that may respond to taurine supplementation

CONTINUATION

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation

and

The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Copper chloride

INITIATION – Moderate to severe burns

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Patient has been hospitalised with moderate to severe burns
and
 Treatment is recommended by a National Burns Unit specialist

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ferric carboxymaltose

INITIATION

Prerequisites (tick box where appropriate)

Treatment with oral iron has proven ineffective or is clinically inappropriate

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Selenium

INITIATION – Moderate to severe burns

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Patient has been hospitalised with moderate to severe burns
and
 Treatment is recommended by a National Burns Unit specialist

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Sodium hyaluronate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by an otolaryngologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Multivitamins - Cap

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient has cystic fibrosis with pancreatic insufficiency
- or
- Patient is an infant or child with liver disease or short gut syndrome
- or
- Patient has severe malabsorption syndrome

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Multivitamins – Powder

INITIATION

Prerequisites (tick box where appropriate)

Patient has inborn errors of metabolism

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Multivitamin and mineral supplement

INITIATION

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

Patient was admitted to hospital with burns

and

Burn size is greater than 15% of total body surface area (BSA) for all types of burns

or

Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns

or

Nutritional status prior to admission or dietary intake is poor

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Multivitamin renal

INITIATION

Prerequisites (tick boxes where appropriate)

- or**
- The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis
 - The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Alpha tocopheryl acetate

INITIATION – Cystic fibrosis

Prerequisites (tick boxes where appropriate)

- Cystic fibrosis patient
and
- Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck)
or
- The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient

INITIATION – Osteoradionecrosis

Prerequisites (tick box where appropriate)

- For the treatment of osteoradionecrosis

INITIATION – Other indications

Prerequisites (tick boxes where appropriate)

- Infant or child with liver disease or short gut syndrome
and
- Requires vitamin supplementation
and
- Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck)
or
- The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Alpha tocopheryl

INITIATION – Cystic fibrosis

Prerequisites (tick boxes where appropriate)

- Cystic fibrosis patient
and
- Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck)
or
- The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient

INITIATION – Osteoradionecrosis

Prerequisites (tick box where appropriate)

- For the treatment of osteoradionecrosis

INITIATION – Other indications

Prerequisites (tick boxes where appropriate)

- Infant or child with liver disease or short gut syndrome
and
- Requires vitamin supplementation
and
- Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck)
or
- The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Epoetin beta

INITIATION – chronic renal failure

Prerequisites (tick boxes where appropriate)

- Patient in chronic renal failure
- and
- Haemoglobin is less than or equal to 100g/L
- and
- Patient does not have diabetes mellitus
- and
- Glomerular filtration rate is less than or equal to 30ml/min
- or
- Patient has diabetes mellitus
- and
- Glomerular filtration rate is less than or equal to 45ml/min
- and
- Patient is on haemodialysis or peritoneal dialysis

INITIATION – myelodysplasia*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has a confirmed diagnosis of myelodysplasia (MDS)
- and
- Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent
- and
- Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)
- and
- Other causes of anaemia such as B12 and folate deficiency have been excluded
- and
- Patient has a serum epoetin level of < 500 IU/L
- and
- The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

CONTINUATION – myelodysplasia*

Re-assessment required after 2 months

Prerequisites (tick boxes where appropriate)

- The patient's transfusion requirement continues to be reduced with epoetin treatment
- and
- Transformation to acute myeloid leukaemia has not occurred
- and
- The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

INITIATION – all other indications

Prerequisites (tick boxes where appropriate)

- Haematologist
- For use in patients where blood transfusion is not a viable treatment alternative
- *Note: Indications marked with * are unapproved indications

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Epoetin alfa

INITIATION – chronic renal failure

Prerequisites (tick boxes where appropriate)

- Patient in chronic renal failure
- and
- Haemoglobin is less than or equal to 100g/L
- and
- Patient does not have diabetes mellitus
- and
- Glomerular filtration rate is less than or equal to 30ml/min
- or
- Patient has diabetes mellitus
- and
- Glomerular filtration rate is less than or equal to 45ml/min
- and
- Patient is on haemodialysis or peritoneal dialysis

INITIATION – myelodysplasia*

Re-assessment required after 2 months

Prerequisites (tick boxes where appropriate)

- Patient has a confirmed diagnosis of myelodysplasia (MDS)
- and
- Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent
- and
- Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)
- and
- Other causes of anaemia such as B12 and folate deficiency have been excluded
- and
- Patient has a serum epoetin level of < 500 IU/L
- and
- The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

CONTINUATION – myelodysplasia*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient's transfusion requirement continues to be reduced with epoetin treatment
- and
- Transformation to acute myeloid leukaemia has not occurred
- and
- The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Epoetin alfa - *continued*

INITIATION – all other indications

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

For use in patients where blood transfusion is not a viable treatment alternative

Note: Indications marked with * are unapproved indications

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aprotinin

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a cardiac anaesthetist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Paediatric patient undergoing cardiopulmonary bypass procedure

or
 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Eltrombopag

INITIATION – idiopathic thrombocytopenic purpura - post-splenectomy

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had a splenectomy

and

Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab)

and

Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding

or

Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding

or

Patient has a platelet count of less than or equal to 10,000 platelets per microlitre

INITIATION – idiopathic thrombocytopenic purpura - preparation for splenectomy

Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient requires eltrombopag treatment as preparation for splenectomy

CONTINUATION – idiopathic thrombocytopenic purpura - post-splenectomy

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

INITIATION – idiopathic thrombocytopenic purpura contraindicated to splenectomy

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has a significant and well-documented contraindication to splenectomy for clinical reasons

and

Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab)

and

Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter

or

Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Eltrombopag - continued

CONTINUATION – idiopathic thrombocytopenic purpura contraindicated to splenectomy

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient's significant contraindication to splenectomy remains
- and The patient has obtained a response from treatment during the initial approval period
- and Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment
- and Further treatment with eltrombopag is required to maintain response

INITIATION – severe aplastic anaemia

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration
- and Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter
- or Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding

CONTINUATION – severe aplastic anaemia

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period
- and Platelet transfusion independence for a minimum of 8 weeks during the initial approval period

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aluminium chloride

INITIATION

Prerequisites (tick box where appropriate)

For use as a haemostatis agent

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Emicizumab

INITIATION – Severe Haemophilia A with or without FVIII inhibitors

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%)

and

Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Idarucizumab

INITIATION

Prerequisites (tick box where appropriate)

- For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Moroctocog alfa [Recombinant factor VIII]

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Octocog alfa [Recombinant factor VIII] (Advate)

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Octocog alfa [Recombinant factor VIII] (Kogenate FS)

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nonacog gamma

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treators Group in conjunction with the National Haemophilia Management Group

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rurioctocog alfa pegol [Recombinant factor VIII]

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Eftrenonacog alfa

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Factor eight inhibitor bypassing fraction

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Eptacog alfa

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bivalirudin

INITIATION

Prerequisites (tick boxes where appropriate)

- For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance
- or
- For use in patients undergoing endovascular procedures

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Danaparoid

INITIATION

Prerequisites (tick box where appropriate)

- For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Defibrotide

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Fondaparinux sodium

INITIATION

Prerequisites (tick box where appropriate)

- For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Lysine acetylsalicylate

INITIATION

Prerequisites (tick boxes where appropriate)

- For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure
- and**
- Administration of oral aspirin would delay the procedure

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Eptifibatide

INITIATION

Prerequisites (tick boxes where appropriate)

- For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention

or

- For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography

or

- For use in patients undergoing intra-cranial intervention

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ticagrelor

INITIATION

Prerequisites (tick box where appropriate)

- Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned

INITIATION – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has had a neurological stenting procedure* in the last 60 days
- or
- Patient is about to have a neurological stenting procedure performed*

and

- Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor

or

- Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event
- or
- Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

CONTINUATION – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient is continuing to benefit from treatment
- and
- Treatment continues to be clinically appropriate

INITIATION – Percutaneous coronary intervention with stent deployment

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has undergone percutaneous coronary intervention
- and
- Patient has had a stent deployed in the previous 4 weeks
- and
- Patient is clopidogrel-allergic**

INITIATION – Stent thrombosis

Prerequisites (tick box where appropriate)

- Patient has experienced cardiac stent thrombosis whilst on clopidogrel

INITIATION – Myocardial infarction

Re-assessment required after 1 week

Prerequisites (tick box where appropriate)

- For short term use while in hospital following ST-elevated myocardial infarction

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ticagrelor - *continued*

Note: Indications marked with * are unapproved indications.

Note: Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Plerixafor

INITIATION – Autologous stem cell transplant

Re-assessment required after 3 days

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is to undergo stem cell transplantation

and

Patient has not had a previous unsuccessful mobilisation attempt with plerixafor

and

Patient is undergoing G-CSF mobilisation

and

Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6/L$ on day 5 after 4 days of G-CSF treatment

or

Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure

or

Patient is undergoing chemotherapy and G-CSF mobilisation

and

Has rising white blood cell counts of $> 5 \times 10^9/L$

and

Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6/L$

or

Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure

or

The peripheral blood CD34 cell counts are decreasing before the target has been received

or

A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pegfilgrastim

INITIATION

Prerequisites (tick box where appropriate)

- For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*)

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Filgrastim

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sodium chloride – Inj

INITIATION

Prerequisites (tick box where appropriate)

For use in flushing of in-situ vascular access devices only

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Captopril - Oral liq 5 mg per ml

INITIATION

Prerequisites (tick boxes where appropriate)

- For use in children under 12 years of age

or

- For use in tube-fed patients

or

- For management of rebound transient hypertension following cardiac surgery

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Sacubitril with valsartan

INITIATION

Prerequisites (tick boxes where appropriate)

Patient has heart failure

and

Patient is in NYHA/WHO functional class II

or

Patient is in NYHA/WHO functional class III

or

Patient is in NYHA/WHO functional class IV

and

Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%

or

An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment

and

Patient is receiving concomitant optimal standard chronic heart failure treatments

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adenosine - Inj 3 mg per ml, 10 ml vial

INITIATION

Prerequisites (tick box where appropriate)

For use in cardiac catheterisation, electrophysiology and MRI

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ajmaline

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a cardiologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:


NHI:

Ivabradine

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient is indicated for computed tomography coronary angiography
- and**
- Patient has a heart rate of greater than 70 beats per minute while taking a maximally tolerated dose of beta blocker
 - Patient is unable to tolerate beta blockers



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Midodrine

INITIATION

Prerequisites (tick box where appropriate)

Patient has disabling orthostatic hypotension not due to drugs

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nicardipine hydrochloride

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an anaesthetist, intensivist, cardiologist or paediatric cardiologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has hypertension requiring urgent treatment with an intravenous agent
- or
- Patient has excessive ventricular afterload
- or
- Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Eplerenone

INITIATION

Prerequisites (tick boxes where appropriate)

<input type="radio"/> Patient has heart failure with ejection fraction less than 40%
and
<input type="radio"/> Patient is intolerant to optimal dosing of spironolactone
or
<input type="radio"/> Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tolvaptan

INITIATION – autosomal dominant polycystic kidney disease

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a renal physician or any relevant practitioner on the recommendation of a renal physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease

and

- Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 mL/min/1.73 m² at treatment initiation

and

- Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m² within one-year
- or**
- Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period

CONTINUATION – autosomal dominant polycystic kidney disease

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a renal physician or any relevant practitioner on the recommendation of a renal physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m²

and

- Patient has not undergone a kidney transplant

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward: NHI:

Rosuvastatin

INITIATION – cardiovascular disease risk

Prerequisites (tick boxes where appropriate)

Patient is considered to be at risk of cardiovascular disease

and

Patient is Māori or any Pacific ethnicity

or

Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years

and

LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin

INITIATION – familial hypercholesterolemia

Prerequisites (tick boxes where appropriate)

Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6)

and

LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin

INITIATION – established cardiovascular disease

Prerequisites (tick boxes where appropriate)

Patient has proven coronary artery disease (CAD)

or

Patient has proven peripheral artery disease (PAD)

or

Patient has experienced an ischaemic stroke

and

LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin

INITIATION – recurrent major cardiovascular events

Prerequisites (tick boxes where appropriate)

Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years

and

LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Levosimendan

INITIATION – Heart transplant

Prerequisites (tick boxes where appropriate)

- For use as a bridge to heart transplant, in patients who have been accepted for transplant
- or**
- For the treatment of heart failure following heart transplant

INITIATION – Heart failure

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a cardiologist or intensivist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Alprostadil

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient has erectile dysfunction
- and**
- Patient is to receive a penile Doppler ultrasonography

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Hydralazine hydrochloride - Tab 25 mg

INITIATION

Prerequisites (tick boxes where appropriate)

- For the treatment of refractory hypertension
- or
- For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

bosentan

INITIATION – PAH monotherapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)*

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Bosentan is to be used as PAH monotherapy

and

- Patient has experienced intolerable side effects on sildenafil

or

- Patient has an absolute contraindication to sildenafil

or

- Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

bosentan - continued

INITIATION – PAH dual therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)*

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Bosentan is to be used as part of PAH dual therapy

and

- Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool**

or

- Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

bosentan - continued

INITIATION – PAH triple therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)*

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Bosentan is to be used as part of PAH triple therapy

and

- Patient is on the lung transplant list

or

- Patient is presenting in NYHA/WHO functional class IV

or

- Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**

and

- Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

bosentan - continued

CONTINUATION

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is continuing to derive benefit from bosentan treatment according to a validated PAH risk stratification tool**

Note: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ambrisentan

INITIATION – PAH monotherapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Ambrisentan is to be used as PAH monotherapy

and

- Patient has experienced intolerable side effects with both sildenafil and bosentan

or

- Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)

or

- Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Ambrisentan - continued

INITIATION – PAH dual therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5})

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Ambrisentan is to be used as PAH dual therapy

and

- Patient has tried a PAH monotherapy (sildenafil or bosentan) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**

or

- Patient has tried PAH dual therapy including bosentan and has experienced intolerable side effects on bosentan

and

- Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy

and

- Patient has an absolute or relative contraindication to bosentan (eg due to current use of a combined oral contraceptive or liver disease)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ambrisentan - continued

INITIATION – PAH triple therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Ambrisentan is to be used as PAH triple therapy

and

- Patient is on the lung transplant list

or

- Patient is presenting in NYHA/WHO functional class IV

and

- Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)

or

- Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**

and

- Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ambrisentan - *continued*

CONTINUATION

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool**

Note: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

sildenafil (Vedafil)

INITIATION – tablets Raynaud’s Phenomenon

Prerequisites (tick boxes where appropriate)

- Patient has Raynaud’s phenomenon
- and Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene)
- and Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs)
- and Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated)

INITIATION – tablets Pulmonary arterial hypertension

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and Patient has pulmonary arterial hypertension (PAH)*
- and PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications
- and PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV
- and PAH is confirmed by right heart catheterisation
- and A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg
- and A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg
- and Pulmonary vascular resistance (PVR) of at least 2 Wood Units or at least 160 International Units (dyn s cm⁻⁵)
- or PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †
- or Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**
- or Patient has PAH other than idiopathic / heritable or drug-associated type
- or Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease
- or Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

sildenafil (Vedafil) - continued

INITIATION – tablets other conditions

Prerequisites (tick boxes where appropriate)

- For use in weaning patients from inhaled nitric oxide
- or
- For perioperative use in cardiac surgery patients
- or
- For use in intensive care as an alternative to nitric oxide
- or
- For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit

INITIATION – injection

Prerequisites (tick boxes where appropriate)

- For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible
- and
- For perioperative use following cardiac surgery
- or
- For use in persistent pulmonary hypertension of the newborn (PPHN)
- or
- For use in congenital diaphragmatic hernia

Note: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Epoprostenol

INITIATION – PAH dual therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5})

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist

and

- Patient is presenting in NYHA/WHO functional class IV

and

- Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Epoprostenol - continued

INITIATION – PAH triple therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Epoprostenol is to be used as PAH triple therapy

and

- Patient is on the lung transplant list

or

- Patient is presenting in NYHA/WHO functional class IV

or

- Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool

and

- Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Epoprostenol - *continued*

CONTINUATION

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is continuing to derive benefit from epoprostenol treatment according to a validated PAH risk stratification tool

Note: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Iloprost

INITIATION – PAH monotherapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5})

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Iloprost is to be used as PAH monotherapy

and

- Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)

or

- Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Iloprost - continued

INITIATION – PAH dual therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist

and

- Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil

or

- Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist

and

- Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**

or

- Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Iloprost - continued

INITIATION – PAH triple therapy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has pulmonary arterial hypertension (PAH)

and

- PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications

and

- PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV

and

- PAH has been confirmed by right heart catheterisation

and

- A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)

and

- A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg

and

- A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)

and

- PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †

or

- Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**

or

- Patient has PAH other than idiopathic / heritable or drug-associated type

or

- Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease

or

- Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and

- Iloprost is to be used as PAH triple therapy

and

- Patient is on the lung transplant list

or

- Patient is presenting in NYHA/WHO functional class IV

or

- Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**

and

- Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Iloprost - *continued*

CONTINUATION

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool

Note: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Mafenide acetate

INITIATION

Prerequisites (tick box where appropriate)

For the treatment of burns patients

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Betamethasone valerate with clioquinol

INITIATION

Prerequisites (tick boxes where appropriate)

- For the treatment of intertrigo
or
 For continuation use

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pimecrolimus

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, paediatrician or ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has atopic dermatitis on the eyelid
and
 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tacrolimus Ointment

INITIATION

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has atopic dermatitis on the face
- and
- Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Methyl aminolevulinate hydrochloride

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a dermatologist or plastic surgeon, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Terbutaline

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by an obstetrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Finasteride

INITIATION

Prerequisites (tick boxes where appropriate)

<input type="radio"/> Patient has symptomatic benign prostatic hyperplasia
and
<input type="radio"/> The patient is intolerant of non-selective alpha blockers or these are contraindicated
or
<input type="radio"/> Symptoms are not adequately controlled with non-selective alpha blockers



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tamsulosin

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient has symptomatic benign prostatic hyperplasia
and
 The patient is intolerant of non-selective alpha blockers or these are contraindicated

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Potassium citrate

INITIATION

Prerequisites (tick boxes where appropriate)

- The patient has recurrent calcium oxalate urolithiasis
and
 The patient has had more than two renal calculi in the two years prior to the application

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Hormone Preparations

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Oxandrolone - Tab 2.5 mg

INITIATION

Prerequisites (tick box where appropriate)

For the treatment of burns patients

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cinacalcet

INITIATION – parathyroid carcinoma or calciphylaxis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a nephrologist or endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has been diagnosed with a parathyroid carcinoma (see Note)
- and
- The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates
- and
- The patient is symptomatic

or

- The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy)
- and
- The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L)
- and
- The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate

CONTINUATION – parathyroid carcinoma or calciphylaxis

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a nephrologist or endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient's serum calcium level has fallen to < 3mmol/L
- and
- The patient has experienced clinically significant symptom improvement

Note: This does not include parathyroid adenomas unless these have become malignant.

INITIATION – primary hyperparathyroidism

Prerequisites (tick boxes where appropriate)

- Patient has primary hyperparathyroidism
- and
- Patient has hypercalcaemia of more than 3 mmol/L with or without symptoms
- or
- Patient has hypercalcaemia of more than 2.85 mmol/L with symptoms
- and
- Surgery is not feasible or has failed
- and
- Patient has other comorbidities, severe bone pain, or calciphylaxis

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cinacalcet - *continued*

INITIATION – secondary or tertiary hyperparathyroidism

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has tertiary hyperparathyroidism and markedly elevated parathyroid hormone (PTH) with hypercalcaemia
or
 Patient has symptomatic secondary hyperparathyroidism and elevated PTH

and

- Patient is on renal replacement therapy

and

- Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations
or
 Parathyroid tissue is surgically inaccessible
or
 Parathyroid surgery is not feasible

CONTINUATION – secondary or tertiary hyperparathyroidism

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically acceptable parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached
or
 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cabergoline

INITIATION

Prerequisites (tick boxes where appropriate)

- Inhibition of lactation
- or Patient has hyperprolactinemia
- or Patient has acromegaly

Note: Indication marked with * is an unapproved indication.

I confirm that the above details are correct:

Signed: Date:

RS1826 - Somatropin

Prader-Willi syndrome - INITIATION	125
Prader-Willi syndrome - CONTINUATION	125
Turner syndrome - INITIATION	122
Turner syndrome - CONTINUATION	123
Adults and adolescents - INITIATION	126
Adults and adolescents - CONTINUATION	127
Growth hormone deficiency in children - INITIATION	122
Growth hormone deficiency in children - CONTINUATION	122
Short stature due to chronic renal insufficiency - INITIATION	124
Short stature due to chronic renal insufficiency - CONTINUATION	124
Short stature without growth hormone deficiency - INITIATION	123
Short stature without growth hormone deficiency - CONTINUATION	123

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Somatropin

INITIATION – growth hormone deficiency in children

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device)

or

- Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985)
- and
- A current bone age is < 14 years (female patients) or < 16 years (male patients)
- and
- Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required
- and
- If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate
- and
- Appropriate imaging of the pituitary gland has been obtained

CONTINUATION – growth hormone deficiency in children

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- A current bone age is 14 years or under (female patients) or 16 years or under (male patients)
- and
- Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985)
- and
- Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months
- and
- No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred
- and
- No malignancy has developed since starting growth hormone

INITIATION – Turner syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has a post-natal genotype confirming Turner Syndrome
- and
- Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985)
- and
- A current bone age is < 14 years

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Somatropin - continued

CONTINUATION – Turner syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts)

and

- Height velocity is greater than or equal to 2 cm per year, calculated over six months

and

- A current bone age is 14 years or under

and

- No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred

and

- No malignancy has developed since starting growth hormone

INITIATION – short stature without growth hormone deficiency

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay

and

- Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985)

and

- A current bone age is < 14 years (female patients) or < 16 years (male patients)

and

- The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity

CONTINUATION – short stature without growth hormone deficiency

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985)

and

- Height velocity is greater than or equal to 2 cm per year as calculated over six months

and

- Current bone age is 14 years or under (female patients) or 16 years or under (male patients)

and

- No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Somatropin - continued

INITIATION – short stature due to chronic renal insufficiency

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient's height is more than 2 standard deviations below the mean
and
 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985)
and
 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients)
and
 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease
and
 The patient is under the supervision of a specialist with expertise in renal medicine

- and
 The patient has a GFR less than or equal to 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²)) in a child who may or may not be receiving dialysis
or
 The patient has received a renal transplant and has received < 5mg/ m² /day of prednisone or equivalent for at least 6 months

CONTINUATION – short stature due to chronic renal insufficiency

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985)
and
 Height velocity is greater than or equal to 2 cm per year as calculated over six months
and
 A current bone age is 14 years or under (female patients) or 16 years or under (male patients)
and
 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred
and
 No malignancy has developed after growth hormone therapy was commenced
and
 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results
and
 The patient has not received renal transplantation since starting growth hormone treatment
and
 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Somatropin - continued

INITIATION – Prader-Willi syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria
- and
- The patient is aged six months or older
- and
- A current bone age is < 14 years (female patients) or < 16 years (male patients)
- and
- Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon

and

- The patient is aged two years or older
- and
- There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months

or

- The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation

CONTINUATION – Prader-Willi syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985)
- and
- Height velocity is greater than or equal to 2 cm per year as calculated over six months
- and
- A current bone age is 14 years or under (female patients) or 16 years or under (male patients)
- and
- No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred
- and
- No malignancy has developed after growth hormone therapy was commenced
- and
- The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Somatropin - continued

INITIATION – adults and adolescents

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour)

and

The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses

and

The patient has severe growth hormone deficiency (see notes)

and

The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex

and

The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®)

Note: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre. The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Somatropin - continued

CONTINUATION – adults and adolescents

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has been treated with somatropin for < 12 months
and
 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline
and
 Serum IGF-I levels have increased to within $\pm 1SD$ of the mean of the normal range for age and sex
and
 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients

or

- The patient has been treated with somatropin for more than 12 months
and
 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors)
and
 Serum IGF-I levels have continued to be maintained within $\pm 1SD$ of the mean of the normal range for age and sex (other than for obvious external factors)
and
 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients

or

- The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication
and
 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses
and
 The patient has severe growth hormone deficiency (see notes)
and
 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex
and
 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®)

Note: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre. The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Liothyronine sodium - Tab 20 mcg

INITIATION

Prerequisites (tick box where appropriate)

- For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Propylthiouracil

INITIATION

Prerequisites (tick boxes where appropriate)

- The patient has hyperthyroidism
and
 The patient is intolerant of carbimazole or carbimazole is contraindicated

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Streptomycin sulphate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Amikacin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Tobramycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tobramycin Solution for inhalation 60 mg per ml, 5 ml

INITIATION

Prerequisites (tick box where appropriate)

Patient has cystic fibrosis

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tobramycin

INITIATION

Prerequisites (tick box where appropriate)

For addition to orthopaedic bone cement

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Paromomycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Imipenem with cilastatin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ertapenem

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Meropenem

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ceftazadime

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cefepime

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ceftaroline

INITIATION – multi-resistant organism salvage therapy

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

For patients where alternative therapies have failed

or

For patients who have a contraindication or hypersensitivity to standard current therapies

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Roxithromycin tab dispersible 50 mg

INITIATION

Prerequisites (tick box where appropriate)

Only for use in patients under 12 years of age

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Clarithromycin

INITIATION – Tab 250 mg and oral liquid

Prerequisites (tick boxes where appropriate)

- Atypical mycobacterial infection
- or Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents
- or Helicobacter pylori eradication
- or Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated

INITIATION – Tab 500 mg

Prerequisites (tick box where appropriate)

- Helicobacter pylori eradication

INITIATION – Infusion

Prerequisites (tick boxes where appropriate)

- Atypical mycobacterial infection
- or Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents
- or Community-acquired pneumonia

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Azithromycin

INITIATION – bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections

Prerequisites (tick boxes where appropriate)

- Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*
- or
- Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*
- or
- Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms*
- or
- Patient has an atypical Mycobacterium infection

Note: Indications marked with * are unapproved indications

INITIATION – non-cystic fibrosis bronchiectasis*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and
- For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*
- and
- Patient is aged 18 and under
- and
- or
 - Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period
 - or
 - Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

CONTINUATION – non-cystic fibrosis bronchiectasis*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and
- The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis
- and
- Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment
- and
- The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note)

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

INITIATION – other indications

Re-assessment required after 5 days

Prerequisites (tick box where appropriate)

- For any other condition

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Azithromycin - *continued*

CONTINUATION – other indications

Re-assessment required after 5 days

Prerequisites (tick box where appropriate)

For any other condition

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ticarcillin with clavulanic acid

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Piperacillin with tazobactam

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ciprofloxacin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Moxifloxacin

INITIATION – Mycobacterium infection

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an infectious disease specialist, clinical microbiologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Active tuberculosis

and

Documented resistance to one or more first-line medications

or

Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents

or

Impaired visual acuity (considered to preclude ethambutol use)

or

Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications

or

Significant documented intolerance and/or side effects following a reasonable trial of first-line medications

or

Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated

or

Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case

INITIATION – Pneumonia

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an infectious disease specialist or clinical microbiologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Immunocompromised patient with pneumonia that is unresponsive to first-line treatment

or

Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics

INITIATION – Penetrating eye injury

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Five days treatment for patients requiring prophylaxis following a penetrating eye injury

INITIATION – Mycoplasma genitalium

Prerequisites (tick boxes where appropriate)

Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic

and

Has tried and failed to clear infection using azithromycin

or

Has laboratory confirmed azithromycin resistance

and

Treatment is only for 7 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tigecycline

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Daptomycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Lincomycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Linezolid

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Sulphadiazine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Teicoplanin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Fosfomycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Pivmecillinam

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Vancomycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aztreonam, Chloramphenicol

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Clindamycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Fusidic acid

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Colistin sulphomethate [Colestimethate]

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ketoconazole - Tab 200 mg

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by an oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Amphotericin B - Inj (liposomal) 50 mg vial

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Proven or probable invasive fungal infection, to be prescribed under an established protocol

or

and

Possible invasive fungal infection

A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Amphotericin B - Inj 50 mg vial

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Fluconazole

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a consultant, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Itraconazole

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Voriconazole

INITIATION – Proven or probable aspergillus infection

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical microbiologist, haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is immunocompromised

and

Patient has proven or probable invasive aspergillus infection

INITIATION – Possible aspergillus infection

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical microbiologist, haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is immunocompromised

and

Patient has possible invasive aspergillus infection

and

A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate

INITIATION – Resistant candidiasis infections and other moulds

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical microbiologist, haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is immunocompromised

and

Patient has fluconazole resistant candidiasis

or

Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp

and

A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Posaconazole

INITIATION

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has acute myeloid leukaemia
or
 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection

and

- Patient is to be treated with high dose remission induction therapy or re-induction therapy

CONTINUATION

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has previously received posaconazole prophylaxis during remission induction therapy

and

- Patient is to be treated with high dose remission re-induction therapy
or
 Patient is to be treated with high dose consolidation therapy
or
 Patient is receiving a high risk stem cell transplant

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Flucytosine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Caspofungin

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Proven or probable invasive fungal infection, to be prescribed under an established protocol

or

and

Possible invasive fungal infection

A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Clofazimine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Dapsone

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cycloserine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Isoniazid with rifampicin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Pyrazinamide

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rifampicin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bedaquiline

INITIATION – multi-drug resistant tuberculosis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- and**
- The person has multi-drug resistant tuberculosis (MDR-TB)
 - Manatū Hauora - Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Isoniazid

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Rifabutin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ethambutol hydrochloride

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Para-aminosalicylic Acid

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Protionamide

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Albendazole

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ivermectin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Artemether with lumefantrine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Artesunate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Atovaquone with proguanil hydrochloride

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Chloroquine phosphate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Mefloquine hydrochloride

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pentamidine isethionate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Primaquine phosphate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Pyrimethamine

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Quinine dihydrochloride

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sodium stibogluconate

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Spiramycin

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a maternal-foetal medicine specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nitazoxanide

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Non-Nucleoside Reverse Transcriptase Inhibitors

INITIATION – Confirmed HIV

Prerequisites (tick box where appropriate)

- Patient has confirmed HIV infection

INITIATION – Prevention of maternal transmission

Prerequisites (tick boxes where appropriate)

- Prevention of maternal foetal transmission
or
 Treatment of the newborn for up to eight weeks

INITIATION – Post-exposure prophylaxis following exposure to HIV

Prerequisites (tick boxes where appropriate)

- Treatment course to be initiated within 72 hours post exposure
and
 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml
or
 Patient has shared intravenous injecting equipment with a known HIV positive person
or
 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required
or
 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au>)

INITIATION – Percutaneous exposure

Prerequisites (tick box where appropriate)

- Patient has percutaneous exposure to blood known to be HIV positive

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nucleoside Reverse Transcriptase Inhibitors

INITIATION – Confirmed HIV

Prerequisites (tick box where appropriate)

- Patient has confirmed HIV infection

INITIATION – Prevention of maternal transmission

Prerequisites (tick boxes where appropriate)

- Prevention of maternal foetal transmission
or
 Treatment of the newborn for up to eight weeks

INITIATION – Post-exposure prophylaxis following exposure to HIV

Prerequisites (tick boxes where appropriate)

- Treatment course to be initiated within 72 hours post exposure
and
 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml
or
 Patient has shared intravenous injecting equipment with a known HIV positive person
or
 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required
or
 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au>)

INITIATION – Percutaneous exposure

Prerequisites (tick box where appropriate)

- Patient has percutaneous exposure to blood known to be HIV positive

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Protease Inhibitors

INITIATION – Confirmed HIV

Prerequisites (tick box where appropriate)

- Patient has confirmed HIV infection

INITIATION – Prevention of maternal transmission

Prerequisites (tick boxes where appropriate)

- Prevention of maternal foetal transmission
or
 Treatment of the newborn for up to eight weeks

INITIATION – Post-exposure prophylaxis following exposure to HIV

Prerequisites (tick boxes where appropriate)

- Treatment course to be initiated within 72 hours post exposure
and
 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml
or
 Patient has shared intravenous injecting equipment with a known HIV positive person
or
 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required
or
 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au>)

INITIATION – Percutaneous exposure

Prerequisites (tick box where appropriate)

- Patient has percutaneous exposure to blood known to be HIV positive

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Strand Transfer Inhibitors

INITIATION – Confirmed HIV

Prerequisites (tick box where appropriate)

- Patient has confirmed HIV infection

INITIATION – Prevention of maternal transmission

Prerequisites (tick boxes where appropriate)

- Prevention of maternal foetal transmission
or
 Treatment of the newborn for up to eight weeks

INITIATION – Post-exposure prophylaxis following exposure to HIV

Prerequisites (tick boxes where appropriate)

- Treatment course to be initiated within 72 hours post exposure
and
 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml
or
 Patient has shared intravenous injecting equipment with a known HIV positive person
or
 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required
or
 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashtm.org.au>)

INITIATION – Percutaneous exposure

Prerequisites (tick box where appropriate)

- Patient has percutaneous exposure to blood known to be HIV positive

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ledipasvir with sofosbuvir

Note: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cidofovir

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Foscarnet sodium

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ganciclovir

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Valganciclovir

INITIATION – Transplant cytomegalovirus prophylaxis

Re-assessment required after 3 months

Prerequisites (tick box where appropriate)

- Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis

CONTINUATION – Transplant cytomegalovirus prophylaxis

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis

and

- Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin

or

- Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis

and

- Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone

INITIATION – Lung transplant cytomegalovirus prophylaxis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has undergone a lung transplant

and

- The donor was cytomegalovirus positive and the patient is cytomegalovirus negative

or

- The recipient is cytomegalovirus positive

and

- Patient has a high risk of CMV disease

INITIATION – Cytomegalovirus in immunocompromised patients

Prerequisites (tick boxes where appropriate)

- Patient is immunocompromised

and

- Patient has cytomegalovirus syndrome or tissue invasive disease

or

- Patient has rapidly rising plasma CMV DNA in absence of disease

or

- Patient has cytomegalovirus retinitis

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Emtricitabine with tenofovir disoproxil

INITIATION – Confirmed HIV

Prerequisites (tick box where appropriate)

- Patient has confirmed HIV infection

INITIATION – Prevention of maternal transmission

Prerequisites (tick boxes where appropriate)

- Prevention of maternal foetal transmission
or
 Treatment of the newborn for up to eight weeks

INITIATION – Post-exposure prophylaxis following non-occupational exposure to HIV

Prerequisites (tick boxes where appropriate)

- Treatment course to be initiated within 72 hours post exposure
and
 Patient has had unprotected receptive anal intercourse with a known HIV positive person
or
 Patient has shared intravenous injecting equipment with a known HIV positive person
or
 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required

INITIATION – Percutaneous exposure

Prerequisites (tick box where appropriate)

- Patient has percutaneous exposure to blood known to be HIV positive

INITIATION – Pre-exposure prophylaxis

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

- Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion
and
 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (<https://ashm.org.au/HIV/P>)

CONTINUATION – Pre-exposure prophylaxis

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

- Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion
and
 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (<https://ashm.org.au/HIV/P>)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Oseltamivir

INITIATION

Prerequisites (tick boxes where appropriate)

- Only for hospitalised patient with known or suspected influenza
- or
- For prophylaxis of influenza in hospitalised patients as part of a Te Whatu Ora Hospital approved infections control plan

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Zanamivir - Powder for inhalation 5 mg

INITIATION

Prerequisites (tick boxes where appropriate)

- Only for hospitalised patient with known or suspected influenza
- or
- For prophylaxis of influenza in hospitalised patients as part of a Te Whatu Ora Hospital approved infections control plan

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

COVID-19 treatments

INITIATION

Prerequisites (tick box where appropriate)

- Only if patient meets access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

COVID-19 treatments

INITIATION

Prerequisites (tick box where appropriate)

- Only if patient meets access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Remdesivir

INITIATION – Treatment of mild to moderate COVID-19

Prerequisites (tick box where appropriate)

- Only if patient meets access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability

INITIATION – COVID-19 in hospitalised patients

Re-assessment required after 5 doses

Prerequisites (tick boxes where appropriate)

- Patient is hospitalised with confirmed (or probable) symptomatic COVID-19
- and Patient is considered to be at high risk of progression to severe disease
- and Patient's symptoms started within the last 7 days
- and Patient does not require, or is not expected to require, mechanical ventilation
- and Not to be used in conjunction with other funded COVID-19 antiviral treatments
- and Treatment not to exceed five days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Interferon gamma

INITIATION

Prerequisites (tick box where appropriate)

Patient has chronic granulomatous disease and requires interferon gamma

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

RS1827 - Pegylated interferon alfa-2a

Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior - INITIATION	216
Chronic hepatitis C - genotype 1 infection - CONTINUATION	216
Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant - INITIATION	216
Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV - INITIATION	217
Hepatitis B - INITIATION	217
Myeloproliferative disorder or cutaneous T cell lymphoma - INITIATION	217
Myeloproliferative disorder or cutaneous T cell lymphoma - CONTINUATION	218
Ocular surface squamous neoplasia - INITIATION	218
Ocular surface squamous neoplasia - CONTINUATION	218
Post-allogenic bone marrow transplant - INITIATION	218
Post-allogenic bone marrow transplant - CONTINUATION	218

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pegylated interferon alfa-2a

INITIATION – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Re-assessment required after 48 weeks

Prerequisites (tick boxes where appropriate)

- Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection
- or
- Patient has chronic hepatitis C and is co-infected with HIV
- or
- Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant

Note: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

CONTINUATION – Chronic hepatitis C - genotype 1 infection

Re-assessment required after 48 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist, infectious disease specialist or general physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and
- Patient has chronic hepatitis C, genotype 1
- and
- Patient has had previous treatment with pegylated interferon and ribavirin
- and
- Patient has responder relapsed
- or
- Patient was a partial responder
- and
- Patient is to be treated in combination with boceprevir

INITIATION – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior

Re-assessment required after 48 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist, infectious disease specialist or general physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and
- Patient has chronic hepatitis C, genotype 1
- and
- Patient has had previous treatment with pegylated interferon and ribavirin
- and
- Patient has responder relapsed
- or
- Patient was a partial responder
- or
- Patient received interferon treatment prior to 2004
- and
- Patient is to be treated in combination with boceprevir

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pegylated interferon alfa-2a - continued

INITIATION – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- Patient has chronic hepatitis C, genotype 2 or 3 infection

INITIATION – Hepatitis B

Re-assessment required after 48 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist, infectious disease specialist or general physician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months)

and

- Patient is Hepatitis B treatment-naive

and

- ALT > 2 times Upper Limit of Normal

and

- HBV DNA < 10 log₁₀ IU/ml

and

- HBeAg positive
or
 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis)

and

- Compensated liver disease

and

- No continuing alcohol abuse or intravenous drug use

and

- Not co-infected with HCV, HIV or HDV

and

- Neither ALT nor AST > 10 times upper limit of normal

and

- No history of hypersensitivity or contraindications to pegylated interferon

INITIATION – myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has a cutaneous T cell lymphoma*

or

- Patient has a myeloproliferative disorder*
and
 Patient is intolerant of hydroxyurea
and
 Treatment with anagrelide and busulfan is not clinically appropriate

or

- Patient has a myeloproliferative disorder
and
 Patient is pregnant, planning pregnancy or lactating

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Pegylated interferon alfa-2a - continued

CONTINUATION – myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- No evidence of disease progression
- and The treatment remains appropriate and patient is benefitting from treatment
- and Patient has a cutaneous T cell lymphoma*
 - or Patient has a myeloproliferative disorder*
 - and Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate
 - or Patient is pregnant, planning pregnancy or lactating

Note: Indications marked with * are unapproved indications

INITIATION – ocular surface squamous neoplasia

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and Patient has ocular surface squamous neoplasia*

CONTINUATION – ocular surface squamous neoplasia

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and The treatment remains appropriate and patient is benefitting from treatment

Note: Indications marked with * are unapproved indications

INITIATION – post-allogenic bone marrow transplant

Re-assessment required after 3 months

Prerequisites (tick box where appropriate)

- Patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse

CONTINUATION – post-allogenic bone marrow transplant

Re-assessment required after 3 months

Prerequisites (tick box where appropriate)

- Patient is responding and ongoing treatment remains appropriate

Note: Indications marked with * are unapproved indications

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Edrophonium chloride

INITIATION

Prerequisites (tick box where appropriate)

For the diagnosis of myasthenia gravis

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Hydroxychloroquine

INITIATION

Prerequisites (tick boxes where appropriate)

- Rheumatoid arthritis
- or Systemic or discoid lupus erythematosus
- or Malaria treatment or suppression
- or Relevant dermatological conditions (cutaneous forms of lupus and lichen planus, cutaneous vasculitides and mucosal ulceration)
- or Sarcoidosis (pulmonary and non-pulmonary)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Denosumab

INITIATION

Prerequisites (tick boxes where appropriate)

The patient has severe, established osteoporosis

and

The patient is female and postmenopausal

or

The patient is male or non-binary

and

History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note)

or

History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons

or

History of two significant osteoporotic fractures demonstrated radiologically

or

Documented T-Score less than or equal to -3.0 (see Note)

or

A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note)

or

Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene

and

Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min

and

The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)

and

The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide

Note:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Raloxifene

INITIATION

Prerequisites (tick boxes where appropriate)

- History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes)
- or
- History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age
- or
- History of two significant osteoporotic fractures demonstrated radiologically
- or
- Documented T-Score greater than or equal to -3.0 (see Notes)
- or
- A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes)
- or
- Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019

Note:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Teriparatide

INITIATION

Re-assessment required after 18 months

Prerequisites (tick boxes where appropriate)

- The patient has severe, established osteoporosis
- and The patient has a documented T-score less than or equal to -3.0 (see Notes)
- and The patient has had two or more fractures due to minimal trauma
- and The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes)

Note:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rasburicase

INITIATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Febuxostat

INITIATION – Gout

Prerequisites (tick boxes where appropriate)

- Patient has been diagnosed with gout
- and
- The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose
- or
- The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose
- or
- The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note)
- or
- The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout.

INITIATION – Tumour lysis syndrome

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and
- Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome
- and
- Patient has a documented history of allopurinol intolerance

CONTINUATION – Tumour lysis syndrome

Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and
- The treatment remains appropriate and patient is benefitting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sugammadex

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable)
- or
- Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required
- or
- Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade
- or
- The duration of the patient's surgery is unexpectedly short
- or
- Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD)
- or
- Patient has a partial residual block after conventional reversal

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etoricoxib

INITIATION

Prerequisites (tick box where appropriate)

For in-vivo investigation of allergy only

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Capsaicin

INITIATION

Prerequisites (tick box where appropriate)

- Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Riluzole

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less

and

- The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application

and

- The patient has not undergone a tracheostomy

and

- The patient has not experienced respiratory failure

and

- The patient is ambulatory

or

- The patient is able to use upper limbs

or

- The patient is able to swallow

CONTINUATION

Re-assessment required after 18 months

Prerequisites (tick boxes where appropriate)

- The patient has not undergone a tracheostomy

and

- The patient has not experienced respiratory failure

and

- The patient is ambulatory

or

- The patient is able to use upper limbs

or

- The patient is able to swallow

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sucrose

INITIATION

Prerequisites (tick box where appropriate)

For use in neonatal patients only

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Methoxyflurane

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient is undergoing a painful procedure with an expected duration of less than one hour
- and**
- Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Paracetamol

INITIATION

Prerequisites (tick box where appropriate)

- Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Capsaicin

INITIATION

Prerequisites (tick box where appropriate)

For post-herpetic neuralgia or diabetic peripheral neuropathy

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Vigabatrin

INITIATION

Re-assessment required after 15 months

Prerequisites (tick boxes where appropriate)

Patient has infantile spasms

or

Patient has epilepsy

and

Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents

or

Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents

or

Patient has tuberous sclerosis complex

and

Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter)

or

It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields

CONTINUATION

Prerequisites (tick boxes where appropriate)

The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life

and

Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin

or

It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Lacosamide

INITIATION

Re-assessment required after 15 months

Prerequisites (tick boxes where appropriate)

- Patient has focal epilepsy
and
 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam, and any two of carbamazepine, lamotrigine, and phenytoin sodium (see Note)

Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.

CONTINUATION

Prerequisites (tick box where appropriate)

- Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Stiripentol

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a paediatric neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has confirmed diagnosis of Dravet syndrome
- and
- Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet

Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.

CONTINUATION

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a paediatric neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Hyoscine hydrobromide - Patch 1.5 mg

INITIATION

Prerequisites (tick boxes where appropriate)

- Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents
- or
- Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective
- or
- For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aprepitant

INITIATION

Prerequisites (tick box where appropriate)

- Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Paliperidone

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection

or

The patient has schizophrenia or other psychotic disorder

and

The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents

and

The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Paliperidone palmitate

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has schizophrenia
and
 The patient has had an initial Special Authority approval for paliperidone once-monthly depot injection

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Olanzapine

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Risperidone

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection

or

The patient has schizophrenia or other psychotic disorder

and

The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents

and

The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aripiprazole

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Patient has a current Special Authority approval for olanzapine depot injection, risperidone depot injection or paliperidone depot injection

and

Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with olanzapine depot injection, risperidone depot injection or paliperidone depot injection

or

Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection. (see Note below for the olanzapine Special Authority criteria for new olanzapine depot injection patients prior to 1 April 2024)

Note: The Olanzapine depot injection Special Authority criteria that apply to criterion 2 in this Aripiprazole Special Authority application are as follows:

- The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- All of the following:
 - The patient has schizophrenia; and
 - The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

The initiation of aripiprazole depot injection has been associated with fewer days of intensive intervention than prior to the initiation of an atypical antipsychotic depot injection

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Multiple Sclerosis

INITIATION – Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist
- and
- Patient has an EDSS score between 0 – 6.0
- and
- Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months

- and
- Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic)
- and
- Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s)
- and
- Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant)
- and
- Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever ($T > 37.5^{\circ}\text{C}$)
- and
- Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point
- or
- Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom)

- and
- Evidence of new inflammatory activity on an MRI scan within the past 24 months

- and
- A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion
- or
- A sign of that new inflammatory activity is a lesion showing diffusion restriction
- or
- A sign of that new inflammatory activity is a T2 lesion with associated local swelling
- or
- A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years
- or
- A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan

- or
- Patient has an active approval for ocrelizumab and does not have primary progressive MS

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Multiple Sclerosis - *continued*

CONTINUATION – Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months)

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Multiple Sclerosis

INITIATION – Multiple Sclerosis - ocrelizumab

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist

and

- Patient has an EDSS score between 0 – 6.0

and

- Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months

and

- Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic)

and

- Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s)

and

- Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant)

and

- Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever ($T > 37.5^{\circ}\text{C}$)

and

- Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point

or

- Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom)

and

- Evidence of new inflammatory activity on an MRI scan within the past 24 months

and

- A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion

or

- A sign of that new inflammatory activity is a lesion showing diffusion restriction

or

- A sign of that new inflammatory activity is a T2 lesion with associated local swelling

or

- A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years

or

- A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan

or

- Patient has an active Special Authority approval for either dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab or teriflunomide

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Multiple Sclerosis - continued

CONTINUATION – Multiple Sclerosis - ocrelizumab

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months)

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

INITIATION – Primary Progressive Multiple Sclerosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Diagnosis of primary progressive multiple sclerosis (PPMS) meets the 2017 McDonald criteria and has been confirmed by a neurologist

and

Patient has an EDSS 2.0 (score equal to or greater than 2 on pyramidal functions) to EDSS 6.5

and

Patient has no history of relapsing remitting multiple sclerosis

CONTINUATION – Primary Progressive Multiple Sclerosis

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an EDSS score of less than or equal to 6.5 at any time in the last six months (ie patient has walked 20 metres with bilateral assistance/aids, without rest in the last six months)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Melatonin

INITIATION – insomnia secondary to neurodevelopmental disorder

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a psychiatrist, paediatrician, neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)

and

- Behavioural and environmental approaches have been tried or are inappropriate

and

- Funded modified-release melatonin is to be given at doses no greater than 10 mg per day

and

- Patient is aged 18 years or under

CONTINUATION – insomnia secondary to neurodevelopmental disorder

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a psychiatrist, paediatrician, neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient is aged 18 years or under

and

- Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined)

and

- Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia

and

- Funded modified-release melatonin is to be given at doses no greater than 10 mg per day

INITIATION – insomnia where benzodiazepines and zopiclone are contraindicated

Prerequisites (tick boxes where appropriate)

- Patient has insomnia and benzodiazepines and zopiclone are contraindicated

and

- For in-hospital use only

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nusinersen

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation
- and
- Patient is 18 years of age or under
- and
- Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age
- or
- Patient is pre-symptomatic
- and
- Patient has three or less copies of SMN2

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- There has been demonstrated maintenance of motor milestone function since treatment initiation
- and
- Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with nusinersen
- and
- Nusinersen not to be administered in combination other SMA disease modifying treatments or gene therapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Risdiplam

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation
- and
- Patient is 18 years of age or under
- and
- Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age
- or
- Patient is pre-symptomatic
- and
- Patient has three or less copies of SMN2

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- There has been demonstrated maintenance of motor milestone function since treatment initiation
- and
- Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with risdiplam
- and
- Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Modafinil

INITIATION – Narcolepsy

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more

and

The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods

or

The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations

and

An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects

or

Methylphenidate and dexamphetamine are contraindicated

CONTINUATION – Narcolepsy

Re-assessment required after 24 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Methylphenidate hydrochloride

INITIATION – ADHD (immediate-release and sustained-release formulations)

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

INITIATION – Narcolepsy (immediate-release and sustained-release formulations)

Re-assessment required after 24 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- Patient suffers from narcolepsy

CONTINUATION – Narcolepsy (immediate-release and sustained-release formulations)

Re-assessment required after 24 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- The treatment remains appropriate and the patient is benefiting from treatment

INITIATION – Extended-release and modified-release formulations

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria
- and**
- Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties
- or**
- There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Dexamphetamine sulphate

INITIATION – ADHD

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

INITIATION – Narcolepsy

Re-assessment required after 24 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient suffers from narcolepsy

CONTINUATION – Narcolepsy

Re-assessment required after 24 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rivastigmine

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The patient has been diagnosed with dementia
and
 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The treatment remains appropriate
and
 The patient has demonstrated a significant and sustained benefit from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Naltrexone hydrochloride

INITIATION – Alcohol dependence

Prerequisites (tick boxes where appropriate)

- Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence
and
 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service

INITIATION – Constipation

Prerequisites (tick box where appropriate)

- For the treatment of opioid-induced constipation

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nicotine

INITIATION

Prerequisites (tick boxes where appropriate)

- For perioperative use in patients who have a 'nil by mouth' instruction
- or
- For use within mental health inpatient units
- or
- Patient would be admitted to a mental health inpatient unit, but is unable to due to COVID-19 self-isolation requirement
- or
- For acute use in agitated patients who are unable to leave the hospital facilities



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Varenicline

INITIATION

Prerequisites (tick boxes where appropriate)

- Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking
- and The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring
- and The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy
- or The patient has tried but failed to quit smoking using bupropion or nortriptyline
- and The patient has not had a Special Authority for varenicline approved in the last 6 months
- and Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this
- and The patient is not pregnant
- and The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Buprenorphine with naloxone

INITIATION – Detoxification

Prerequisites (tick boxes where appropriate)

- Patient is opioid dependent
- and Patient is currently engaged with an opioid treatment service approved by the Ministry of Health
- and Prescriber works in an opioid treatment service approved by the Ministry of Health

INITIATION – Maintenance treatment

Prerequisites (tick boxes where appropriate)

- Patient is opioid dependent
- and Patient will not be receiving methadone
- and Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health
- and Prescriber works in an opioid treatment service approved by the Ministry of Health

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bendamustine hydrochloride

INITIATION – treatment naive CLL

Prerequisites (tick boxes where appropriate)

- The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment
- and The patient is chemotherapy treatment naive
- and The patient is unable to tolerate toxicity of full-dose FCR
- and Patient has ECOG performance status 0-2
- and Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6
- and Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

INITIATION – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- The patient has indolent low grade NHL requiring treatment
- and Patient has a WHO performance status of 0-2
- and
 - Patient is treatment naive
 - and Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+)
- or
 - Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen
 - and Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles
- or
 - The patient has not received prior bendamustine therapy
 - and Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)
 - and Patient has had a rituximab treatment-free interval of 12 months or more
- or Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bendamustine hydrochloride - continued

CONTINUATION – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine
and
 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles

or

- Patients have not received a bendamustine regimen within the last 12 months

and

- Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+)
and
 Patient has had a rituximab treatment-free interval of 12 months or more

or

- Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients

Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.

INITIATION – Hodgkin's lymphoma*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has Hodgkin's lymphoma requiring treatment
and
 Patient has a ECOG performance status of 0-2
and
 Patient has received one prior line of chemotherapy
and
 Patient's disease relapsed or was refractory following prior chemotherapy
and
 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m² twice per cycle, for a maximum of four cycles

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Azacitidine

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome
- or
- The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder)
- or
- The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO)

and

- The patient has performance status (WHO/ECOG) grade 0-2

and

- The patient has an estimated life expectancy of at least 3 months

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- No evidence of disease progression

and

- The treatment remains appropriate and patient is benefitting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pemetrexed

INITIATION – Mesothelioma

Re-assessment required after 8 months

Prerequisites (tick boxes where appropriate)

- Patient has been diagnosed with mesothelioma
and
 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles

CONTINUATION – Mesothelioma

Re-assessment required after 8 months

Prerequisites (tick boxes where appropriate)

- No evidence of disease progression
and
 The treatment remains appropriate and the patient is benefitting from treatment
and
 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles

INITIATION – Non small cell lung cancer

Re-assessment required after 8 months

Prerequisites (tick boxes where appropriate)

- Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma
and
- Patient has chemotherapy-naïve disease
and
 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles
- or**
- Patient has had first-line treatment with platinum based chemotherapy
and
 Patient has not received prior funded treatment with pemetrexed
and
 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles

CONTINUATION – Non small cell lung cancer

Re-assessment required after 8 months

Prerequisites (tick boxes where appropriate)

- No evidence of disease progression
and
 The treatment remains appropriate and the patient is benefitting from treatment
and
 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Mercaptopurine

INITIATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a paediatric haematologist or paediatric oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient requires a total dose of less than one full 50 mg tablet per day

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a paediatric haematologist or paediatric oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient requires a total dose of less than one full 50 mg tablet per day

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Lenalidomide

INITIATION – Relapsed/refractory disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has relapsed or refractory multiple myeloma with progressive disease

and

Patient has not previously been treated with lenalidomide

and

Lenalidomide to be used as third line* treatment for multiple myeloma

or

Lenalidomide to be used as second line treatment for multiple myeloma

and

The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments

and

Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone

CONTINUATION – Relapsed/refractory disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

No evidence of disease progression

and

The treatment remains appropriate and patient is benefitting from treatment

INITIATION – Maintenance following first-line autologous stem cell transplant (SCT)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation

and

Patient has at least a stable disease response in the first 100 days after transplantation

and

Lenalidomide maintenance is to be commenced within 6 months of transplantation

and

Lenalidomide to be administered at a maximum dose of 15 mg/day

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name: Name:

Ward: NHI:

Lenalidomide - *continued*

CONTINUATION – Maintenance following first-line autologous stem cell transplant (SCT)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

No evidence of disease progression

and

The treatment remains appropriate and patient is benefitting from treatment

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Venetoclax

INITIATION – relapsed/refractory chronic lymphocytic leukaemia

Re-assessment required after 7 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has chronic lymphocytic leukaemia requiring treatment

and

Patient has received at least one prior therapy for chronic lymphocytic leukaemia

and

Patient has not previously received funded venetoclax

and

The patient's disease has relapsed within 36 months of previous treatment

and

Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax

and

Patient has an ECOG performance status of 0-2

CONTINUATION – relapsed/refractory chronic lymphocytic leukaemia

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment

and

Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity

INITIATION – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has previously untreated chronic lymphocytic leukaemia

and

There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing

and

Patient has an ECOG performance status of 0-2

CONTINUATION – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Olaparib

INITIATION – Ovarian cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer

and

- There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation

and

- Patient has newly diagnosed, advanced disease
- and
- Patient has received one line** of previous treatment with platinum-based chemotherapy
- and
- Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen

or

- Patient has received at least two lines** of previous treatment with platinum-based chemotherapy
- and
- Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy
- and
- Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen
- and
- Patient has not previously received funded olaparib treatment

and

- Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen

and

- Treatment to be administered as maintenance treatment

and

- Treatment not to be administered in combination with other chemotherapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Olaparib - continued

CONTINUATION – Ovarian cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Treatment remains clinically appropriate and patient is benefitting from treatment

and

No evidence of progressive disease

or

Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion

and

Treatment to be administered as maintenance treatment

and

Treatment not to be administered in combination with other chemotherapy

and

Patient has received one line** of previous treatment with platinum-based chemotherapy

and

Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years

or

Patient has received at least two lines** of previous treatment with platinum-based chemotherapy

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.
**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ibrutinib

INITIATION – chronic lymphocytic leukaemia (CLL)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has chronic lymphocytic leukaemia (CLL) requiring therapy
- and
- Patient has not previously received funded ibrutinib
- and
- Ibrutinib is to be used as monotherapy

- There is documentation confirming that patient has 17p deletion or TP53 mutation
- and
- Patient has experienced intolerable side effects with venetoclax monotherapy

or

- Patient has received at least one prior immunochemotherapy for CLL
- and
- Patient's CLL has relapsed within 36 months of previous treatment
- and
- Patient has experienced intolerable side effects with venetoclax in combination with rituximab regimen

or

- Patient's CLL is refractory to or has relapsed within 36 months of a venetoclax regimen

CONTINUATION – chronic lymphocytic leukaemia (CLL)

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- No evidence of clinical disease progression
- and
- The treatment remains appropriate and the patient is benefitting from treatment

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Temozolomide

INITIATION – gliomas

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Patient has a glioma

CONTINUATION – gliomas

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Treatment remains appropriate and patient is benefitting from treatment

INITIATION – Neuroendocrine tumours

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*
- and
- Temozolomide is to be given in combination with capecitabine
- and
- Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day
- and
- Temozolomide to be discontinued at disease progression

CONTINUATION – Neuroendocrine tumours

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- No evidence of disease progression
- and
- The treatment remains appropriate and the patient is benefitting from treatment

INITIATION – ewing's sarcoma

Re-assessment required after 9 months

Prerequisites (tick box where appropriate)

- Patient has relapse or refractory Ewing's sarcoma

CONTINUATION – ewing's sarcoma

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- No evidence of disease progression
- and
- The treatment remains appropriate and the patient is benefitting from treatment

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Thalidomide

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has multiple myeloma
- or
- The patient has systemic AL amyloidosis*
- or
- The patient has erythema nodosum leprosum

CONTINUATION

Prerequisites (tick box where appropriate)

- Patient has obtained a response from treatment during the initial approval period

Note: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier
Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen
Indication marked with * is an unapproved indication

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bortezomib

INITIATION – multiple myeloma/amyloidosis

Prerequisites (tick boxes where appropriate)

- The patient has symptomatic multiple myeloma
- or
- The patient has symptomatic systemic AL amyloidosis

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pegaspargase

INITIATION – Newly diagnosed ALL

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has newly diagnosed acute lymphoblastic leukaemia
and
 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol

INITIATION – Relapsed ALL

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has relapsed acute lymphoblastic leukaemia
and
 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol

INITIATION – Lymphoma

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Patient has lymphoma requiring L-asparaginase containing protocol (e.g. SMILE)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nilotinib

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase

and

Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI)

or

Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment

and

Maximum nilotinib dose of 800 mg/day

and

Subsidised for use as monotherapy only

Note: *treatment failure as defined by Leukaemia Net Guidelines.

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines

and

Nilotinib treatment remains appropriate and the patient is benefiting from treatment

and

Maximum nilotinib dose of 800 mg/day

and

Subsidised for use as monotherapy only

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Ruxolitinib

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis

and

A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS

or

A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS

and

Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy

and

A maximum dose of 20 mg twice daily is to be given

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The treatment remains appropriate and the patient is benefiting from treatment

and

A maximum dose of 20 mg twice daily is to be given

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Alectinib

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer
- and** There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test
- and** Patient has an ECOG performance score of 0-2

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- No evidence of progressive disease according to RECIST criteria
- and** The patient is benefitting from and tolerating treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Palbociclib (Ibrance)

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has unresectable locally advanced or metastatic breast cancer

and

- There is documentation confirming disease is hormone-receptor positive and HER2-negative

and

- Patient has an ECOG performance score of 0-2

and

second or subsequent line setting

- Disease has relapsed or progressed during prior endocrine therapy

or

first line setting

- Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state

and

- Patient has not received prior systemic treatment for metastatic disease

or

- Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020

and

- Patient has not received prior systemic endocrine treatment for metastatic disease

and

- There is no evidence of progressive disease

and

- Treatment must be used in combination with an endocrine partner

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment must be used in combination with an endocrine partner

and

- No evidence of progressive disease

and

- The treatment remains appropriate and the patient is benefitting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Dasatinib

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist or any relevant practitioner on the recommendation of a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase
and
 Maximum dose of 140 mg/day

or

- The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL)
and
 Maximum dose of 140 mg/day

or

- The patient has a diagnosis of CML in chronic phase
and
 Maximum dose of 100 mg/day
and
 Patient has documented treatment failure* with imatinib
or
 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib
or
 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system
or
 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist or any relevant practitioner on the recommendation of a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Lack of treatment failure while on dasatinib*
and
 Dasatinib treatment remains appropriate and the patient is benefiting from treatment
and
 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up <https://www.cancertrialsnz.ac.nz/kiss/>

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Erlotinib

INITIATION

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)
and
 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase
and
 Patient is treatment naive
or
 The patient has discontinued gefitinib due to intolerance
and
 The cancer did not progress while on gefitinib
and
 Erlotinib is to be given for a maximum of 3 months

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed
and
 Erlotinib is to be given for a maximum of 3 months

CONTINUATION – pandemic circumstances

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

The patient is clinically benefiting from treatment and continued treatment remains appropriate
and
 Erlotinib to be discontinued at progression
and
 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Sunitinib

INITIATION – RCC

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic renal cell carcinoma
and

The patient is treatment naive
or
 The patient has only received prior cytokine treatment
or
 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval
and

The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance
and
 The cancer did not progress whilst on pazopanib

and

The patient has good performance status (WHO/ECOG grade 0-2)
and
 The disease is of predominant clear cell histology
and

Lactate dehydrogenase level > 1.5 times upper limit of normal
and
 Haemoglobin level < lower limit of normal
and
 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L)
and
 Interval of < 1 year from original diagnosis to the start of systemic therapy
and
 Karnofsky performance score of less than or equal to 70
and
 2 or more sites of organ metastasis

and

Sunitinib to be used for a maximum of 2 cycles

Note: RCC - Sunitinib treatment should be stopped if disease progresses.
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

CONTINUATION – RCC

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

No evidence of disease progression
and
 The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sunitinib - continued

INITIATION – GIST

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST)
- and
- The patient's disease has progressed following treatment with imatinib
- or
- The patient has documented treatment-limiting intolerance, or toxicity to, imatinib

CONTINUATION – GIST

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:**
- The patient has had a complete response (disappearance of all lesions and no new lesions)
- or
- The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease)
- or
- The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression
- and
- The treatment remains appropriate and the patient is benefiting from treatment

CONTINUATION – GIST pandemic circumstances

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST)
- and
- The patient is clinically benefiting from treatment and continued treatment remains appropriate
- and
- Sunitinib is to be discontinued at progression
- and
- The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Lapatinib

INITIATION

Prerequisites (tick box where appropriate)

For continuation use only

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib
- and Lapatinib not to be given in combination with trastuzumab
- and Lapatinib to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Pazopanib

INITIATION

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic renal cell carcinoma

and

The patient is treatment naive

or

The patient has only received prior cytokine treatment

or

The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance

and

The cancer did not progress whilst on sunitinib

and

The patient has good performance status (WHO/ECOG grade 0-2)

and

The disease is of predominant clear cell histology

and

Lactate dehydrogenase level > 1.5 times upper limit of normal

and

Haemoglobin level < lower limit of normal

and

Corrected serum calcium level > 10 mg/dL (2.5 mmol/L)

and

Interval of < 1 year from original diagnosis to the start of systemic therapy

and

Karnofsky performance score of less than or equal to 70

and

2 or more sites of organ metastasis

CONTINUATION

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

No evidence of disease progression

and

The treatment remains appropriate and the patient is benefiting from treatment

Note: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Gefitinib

INITIATION

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC)
- and
- Patient is treatment naive
- or
- The patient has discontinued erlotinib due to intolerance
- and
- The cancer did not progress whilst on erlotinib
- and
- There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase
- and
- Gefitinib is to be given for a maximum of 3 months

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed
- and
- Gefitinib is to be given for a maximum of 3 months

CONTINUATION – pandemic circumstances

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The patient is clinically benefiting from treatment and continued treatment remains appropriate
- and
- Gefitinib to be discontinued at progression
- and
- The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Dexrazoxane

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, paediatric oncologist, haematologist or paediatric haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient is to receive treatment with high dose anthracycline given with curative intent

and

Based on current treatment plan, patient's cumulative lifetime dose of anthracycline will exceed 250mg/m² doxorubicin equivalent or greater

and

Dexrazoxane to be administered only whilst on anthracycline treatment

and

- Treatment to be used as a cardioprotectant for a child or young adult
- or
- Treatment to be used as a cardioprotectant for secondary malignancy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Abiraterone acetate

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, radiation oncologist or urologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has prostate cancer

and

- Patient has metastases

and

- Patient's disease is castration resistant

and

- Patient is symptomatic

and

- Patient has disease progression (rising serum PSA) after second line anti-androgen therapy

and

- Patient has ECOG performance score of 0-1

and

- Patient has not had prior treatment with taxane chemotherapy

or

- Patient's disease has progressed following prior chemotherapy containing a taxane

and

- Patient has ECOG performance score of 0-2

and

- Patient has not had prior treatment with abiraterone

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, radiation oncologist or urologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Significant decrease in serum PSA from baseline

and

- No evidence of clinical disease progression

and

- No initiation of taxane chemotherapy with abiraterone

and

- The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Abiraterone acetate - *continued*

CONTINUATION – pandemic circumstances

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The patient is clinically benefiting from treatment and continued treatment remains appropriate
- and Abiraterone acetate to be discontinued at progression
- and No initiation of taxane chemotherapy with abiraterone
- and The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Fulvestrant

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer
- and
- Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease
- and
- Treatment to be given at a dose of 500 mg monthly following loading doses
- and
- Treatment to be discontinued at disease progression

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment remains appropriate and patient is benefitting from treatment
- and
- Treatment to be given at a dose of 500 mg monthly
- and
- No evidence of disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Octreotide

INITIATION – Malignant bowel obstruction

Prerequisites (tick boxes where appropriate)

- The patient has nausea* and vomiting* due to malignant bowel obstruction*
- and Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed
- and Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks

Note: Indications marked with * are unapproved indications

INITIATION – acromegaly

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- The patient has acromegaly
- and Treatment with surgery, radiotherapy and a dopamine agonist has failed
- or Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed
- or The patient is unwilling, or unable, to undergo surgery and/or radiotherapy

CONTINUATION – acromegaly

Prerequisites (tick boxes where appropriate)

- IGF1 levels have decreased since starting octreotide
- and The treatment remains appropriate and the patient is benefiting from treatment

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Octreotide - continued

INITIATION – Other indications

Prerequisites (tick boxes where appropriate)

- VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery
- or
- Gastrinoma
- and
- Patient has failed surgery
- or
- Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed
- or
- Insulinomas
- and
- Surgery is contraindicated or has failed
- or
- For pre-operative control of hypoglycaemia and for maintenance therapy
- or
- Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis)
- and
- Disabling symptoms not controlled by maximal medical therapy

Note: restriction applies only to the long-acting formulations of octreotide

INITIATION – pre-operative acromegaly

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has acromegaly
- and
- Patient has a large pituitary tumour, greater than 10 mm at its widest
- and
- Patient is scheduled to undergo pituitary surgery in the next six months

Note: Indications marked with * are unapproved indications

CONTINUATION – Acromegaly - pandemic circumstances

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has acromegaly
- and
- The patient is clinically benefiting from treatment and continued treatment remains appropriate
- and
- The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aminolevulinic acid hydrochloride

INITIATION – high grade malignant glioma

Prerequisites (tick boxes where appropriate)

- Patient has newly diagnosed, untreated, glioblastoma multiforme
- and** Treatment to be used as adjuvant to fluorescence-guided resection
- and** Patient's tumour is amenable to complete resection

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tacrolimus

INITIATION – organ transplant recipients

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by any specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- For use in organ transplant recipients

INITIATION – non-transplant indications*

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- Patient requires long-term systemic immunosuppression
- and**
- Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response
- or**
- Patient is a child with nephrotic syndrome*

Note: Indications marked with * are unapproved indications

I confirm that the above details are correct:

Signed: Date:

RS1879 - Etanercept

Arthritis - rheumatoid - INITIATION	299
Arthritis - rheumatoid - CONTINUATION	299
Adult-onset Still's disease - INITIATION	304
Adult-onset Still's disease - CONTINUATION	305
Ankylosing spondylitis - INITIATION	300
Ankylosing spondylitis - CONTINUATION	301
Oligoarticular course juvenile idiopathic arthritis - INITIATION	298
Oligoarticular course juvenile idiopathic arthritis - CONTINUATION	298
Polyarticular course juvenile idiopathic arthritis - INITIATION	297
Polyarticular course juvenile idiopathic arthritis - CONTINUATION	297
Psoriatic arthritis - INITIATION	301
Psoriatic arthritis - CONTINUATION	302
Pyoderma gangrenosum - INITIATION	304
Pyoderma gangrenosum - CONTINUATION	304
Severe chronic plaque psoriasis - CONTINUATION	303
Severe chronic plaque psoriasis, prior TNF use - INITIATION	302
Severe chronic plaque psoriasis, treatment-naïve - INITIATION	303
Undifferentiated spondyloarthritis - INITIATION	305
Undifferentiated spondyloarthritis - CONTINUATION	305

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept

INITIATION – polyarticular course juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA)

and

- The patient has experienced intolerable side effects from adalimumab
or
 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA

or

- To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

- Patient has had polyarticular course JIA for 6 months duration or longer

and

- At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose)
or
 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose)
or
 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate

CONTINUATION – polyarticular course juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

- Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline
or
 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept - continued

INITIATION – oligoarticular course juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA)

and

- The patient has experienced intolerable side effects from adalimumab
or
 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA

or

- To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

- Patient has had oligoarticular course JIA for 6 months duration or longer

and

- At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose)
or
 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose)
or
 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate

CONTINUATION – oligoarticular course juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

- Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baselinee
or
 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept - continued

INITIATION – Arthritis - rheumatoid

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis

and

The patient has experienced intolerable side effects

or

The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis

or

Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer

and

Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated)

and

Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated)

and

Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin

or

Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate

and

Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints

or

Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

CONTINUATION – Arthritis - rheumatoid

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

and

Etanercept to be administered at doses no greater than 50 mg every 7 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name: Name:

Ward: NHI:

Etanercept - continued

INITIATION – ankylosing spondylitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis

and

The patient has experienced intolerable side effects from adalimumab

or

The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis

or

Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months

and

Patient has low back pain and stiffness that is relieved by exercise but not by rest

and

Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan

and

Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis

and

Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right)

or

Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes)

and

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale

Note: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept - continued

CONTINUATION – ankylosing spondylitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less

and

Physician considers that the patient has benefited from treatment and that continued treatment is appropriate

and

Etanercept to be administered at doses no greater than 50 mg every 7 days

INITIATION – psoriatic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis

and

The patient has experienced intolerable side effects from adalimumab or secukinumab

or

The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis

or

Patient has had severe active psoriatic arthritis for six months duration or longer

and

Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose

and

Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses)

and

Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints

or

Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

and

Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application

or

Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour

or

ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Etanercept - continued

CONTINUATION – psoriatic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician

and

Etanercept to be administered at doses no greater than 50 mg every 7 days

INITIATION – severe chronic plaque psoriasis, prior TNF use

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis

and

- The patient has experienced intolerable side effects from adalimumab
- or
- The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis

and

Patient must be reassessed for continuation after 3 doses

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept - continued

INITIATION – severe chronic plaque psoriasis, treatment-naive

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis
- or
- Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis

and

Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin

and

A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course

and

The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

CONTINUATION – severe chronic plaque psoriasis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient had "whole body" severe chronic plaque psoriasis at the start of treatment
- and
- Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value
- or
- Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value

or

- Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment
- and
- Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values
- or
- Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value

and

Etanercept to be administered at doses no greater than 50 mg every 7 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept - continued

INITIATION – pyoderma gangrenosum

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has pyoderma gangrenosum*

and

Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response

and

A maximum of 8 doses

Note: Indications marked with * are unapproved indications.

CONTINUATION – pyoderma gangrenosum

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has shown clinical improvement

and

Patient continues to require treatment

and

A maximum of 8 doses

INITIATION – adult-onset Still's disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD)

or

The patient has been started on tocilizumab for AOSD in a Te Whatu Ora Hospital

and

The patient has experienced intolerable side effects from etanercept and/or tocilizumab

or

The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD

or

Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430)

and

Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate

and

Patient has persistent symptoms of disabling poorly controlled and active disease

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Etanercept - continued

CONTINUATION – adult-onset Still’s disease

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- The patient has a sustained improvement in inflammatory markers and functional status

INITIATION – undifferentiated spondyloarthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip
- and**
- Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose
- and**
- Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose)
- and**
- Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose)
- and**
- Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application
- or**
- Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application
- or**
- ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

Note: Indications marked with * are unapproved indications.

CONTINUATION – undifferentiated spondyloarthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Applicant is a rheumatologist
- or**
- Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment
- and**
- Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or**
- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician
- and**
- Etanercept to be administered at doses no greater than 50 mg dose every 7 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Bevacizumab

INITIATION – Recurrent Respiratory Papillomatosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an otolaryngologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Maximum of 6 doses

and

The patient has recurrent respiratory papillomatosis

and

The treatment is for intra-lesional administration

CONTINUATION – Recurrent Respiratory Papillomatosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an otolaryngologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Maximum of 6 doses

and

The treatment is for intra-lesional administration

and

There has been a reduction in surgical treatments or disease regrowth as a result of treatment

INITIATION – ocular conditions

Prerequisites (tick boxes where appropriate)

Ocular neovascularisation

or

Exudative ocular angiopathy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ranibizumab

INITIATION – Wet Age Related Macular Degeneration

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Wet age-related macular degeneration (wet AMD)
or
 Polypoidal choroidal vasculopathy
or
 Choroidal neovascular membrane from causes other than wet AMD

and

- The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab
or
 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart

and

- There is no structural damage to the central fovea of the treated eye
and
 Patient has not previously been treated with aflibercept for longer than 3 months

- or
 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months

CONTINUATION – Wet Age Related Macular Degeneration

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Documented benefit must be demonstrated to continue
and
 Patient's vision is 6/36 or better on the Snellen visual acuity score
and
 There is no structural damage to the central fovea of the treated eye

I confirm that the above details are correct:

Signed: Date:

RS1941 - Infliximab

Crohn's disease (adults) - INITIATION	313
Crohn's disease (adults) - CONTINUATION	313
Crohn's disease (children) - INITIATION	313
Crohn's disease (children) - CONTINUATION	314
Graft vs host disease - INITIATION	309
Inflammatory bowel arthritis (axial) - INITIATION	319
Inflammatory bowel arthritis (axial) - CONTINUATION	319
Inflammatory bowel arthritis (peripheral) - INITIATION	320
Inflammatory bowel arthritis (peripheral) - CONTINUATION	320
Pulmonary sarcoidosis - INITIATION	312
Acute fulminant ulcerative colitis - INITIATION	315
Ankylosing spondylitis - INITIATION	309
Ankylosing spondylitis - CONTINUATION	310
Chronic ocular inflammation - INITIATION	312
Chronic ocular inflammation - CONTINUATION	312
Fistulising Crohn's disease - INITIATION	314
Fistulising Crohn's disease - CONTINUATION	314
Fulminant ulcerative colitis - CONTINUATION	315
Neurosarcoidosis - INITIATION	317
Neurosarcoidosis - CONTINUATION	318
Plaque psoriasis - INITIATION	316
Plaque psoriasis - CONTINUATION	317
Psoriatic arthritis - INITIATION	310
Psoriatic arthritis - CONTINUATION	310
Pyoderma gangrenosum - INITIATION	319
Pyoderma gangrenosum - CONTINUATION	319
Rheumatoid arthritis - INITIATION	309
Rheumatoid arthritis - CONTINUATION	309
Severe Behcet's disease - INITIATION	318
Severe Behcet's disease - CONTINUATION	318
Severe ocular inflammation - INITIATION	311
Severe ocular inflammation - CONTINUATION	311
Ulcerative colitis - INITIATION	315
Ulcerative colitis - CONTINUATION	316

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab

INITIATION – Graft vs host disease

Prerequisites (tick box where appropriate)

- Patient has steroid-refractory acute graft vs. host disease of the gut

INITIATION – rheumatoid arthritis

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis

and

- The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
- Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept

or

and

- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

CONTINUATION – rheumatoid arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

- Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

and

- Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks

INITIATION – ankylosing spondylitis

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis

and

- The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
- Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis

or

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Infliximab - continued

CONTINUATION – ankylosing spondylitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less

and

Physician considers that the patient has benefited from treatment and that continued treatment is appropriate

and

Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks

INITIATION – psoriatic arthritis

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis

and

The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept and/or secukinumab

or

Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

CONTINUATION – psoriatic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician

and

Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Infliximab - continued

INITIATION – severe ocular inflammation

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation

and

The patient has experienced intolerable side effects from adalimumab

or

The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation

or

Patient has severe, vision-threatening ocular inflammation requiring rapid control

and

Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms

or

Patient developed new inflammatory symptoms while receiving high dose steroids

or

Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms

CONTINUATION – severe ocular inflammation

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has had a good clinical response following 3 initial doses

or

Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

or

Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

INITIATION – chronic ocular inflammation

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation

and

The patient has experienced intolerable side effects from adalimumab

or

The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation

or

Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss

and

Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective

or

Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose

or

Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate

CONTINUATION – chronic ocular inflammation

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has had a good clinical response following 3 initial doses

or

Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

or

Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

INITIATION – Pulmonary sarcoidosis

Prerequisites (tick boxes where appropriate)

Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments

and

Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

INITIATION – Crohn’s disease (adults)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has active Crohn’s disease

and

Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10

or

Patient has extensive small intestine disease affecting more than 50 cm of the small intestine

or

Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection

or

Patient has an ileostomy or colostomy, and has intestinal inflammation

and

Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids

CONTINUATION – Crohn’s disease (adults)

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab

or

CDAI score is 150 or less, or HBI is 4 or less

or

The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed

and

Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

INITIATION – Crohn’s disease (children)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Paediatric patient has active Crohn’s disease

and

Patient has a PCDAI score of greater than or equal to 30

or

Patient has extensive small intestine disease

and

Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

CONTINUATION – Crohn’s disease (children)

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab
- or
- PCDAI score is 15 or less
- or
- The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed

and

Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

INITIATION – fistulising Crohn’s disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has confirmed Crohn’s disease

and

- Patient has one or more complex externally draining enterocutaneous fistula(e)
- or
- Patient has one or more rectovaginal fistula(e)
- or
- Patient has complete peri-anal fistula

CONTINUATION – fistulising Crohn’s disease

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The number of open draining fistulae have decreased from baseline by at least 50%
- or
- There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain

and

Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

INITIATION – acute fulminant ulcerative colitis

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has acute, fulminant ulcerative colitis

and

Treatment with intravenous or high dose oral corticosteroids has not been successful

CONTINUATION – fulminant ulcerative colitis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months

and

Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

INITIATION – ulcerative colitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has active ulcerative colitis

and

Patients SCCAI is greater than or equal to 4

or

Patients PUCAI score is greater than or equal to 20

and

Patient has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

CONTINUATION – ulcerative colitis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab
or
 The PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab

and

- Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

INITIATION – plaque psoriasis

Re-assessment required after 3 doses

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis
and
 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab
or
 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis

or

- Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis
or
 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis

and

- Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin

and

- A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course

and

- The most recent PASI assessment is no more than 1 month old at the time of initiation

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

CONTINUATION – plaque psoriasis

Re-assessment required after 3 doses

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient had "whole body" severe chronic plaque psoriasis at the start of treatment
and
 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value

or

Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment
and
 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values
or
 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value

and

Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

INITIATION – neurosarcoidosis

Re-assessment required after 18 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Biopsy consistent with diagnosis of neurosarcoidosis

and

Patient has CNS involvement

and

Patient has steroid-refractory disease

and

IV cyclophosphamide has been tried
or
 Treatment with IV cyclophosphamide is clinically inappropriate

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Infliximab - continued

CONTINUATION – neurosarcoidosis

Re-assessment required after 18 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

A withdrawal period has been tried and the patient has relapsed

or

A withdrawal period has been considered but would not be clinically appropriate

and

There has been a marked reduction in prednisone dose

and

There has been an improvement in MRI appearances

or

Marked improvement in other symptomology

INITIATION – severe Behcet’s disease

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

The patient has severe Behcet’s disease which is significantly impacting the patient’s quality of life (see Notes)

and

The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes)

or

The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes)

and

The patient is experiencing significant loss of quality of life

Note:

- a) Behcet’s disease diagnosed according to the International Study Group for Behcet’s Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.
- b) Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

CONTINUATION – severe Behcet’s disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Patient has had a good clinical response to initial treatment with measurably improved quality of life

and

Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Infliximab - continued

INITIATION – pyoderma gangrenosum

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has pyoderma gangrenosum*

and

Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response

and

A maximum of 8 doses

Note: Indications marked with * are unapproved indications.

CONTINUATION – pyoderma gangrenosum

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has shown clinical improvement

and

Patient continues to require treatment

and

A maximum of 8 doses

INITIATION – Inflammatory bowel arthritis (axial)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Patient has a diagnosis of active ulcerative colitis or active Crohn's disease

and

Patient has had axial inflammatory pain for six months or more

and

Patient is unable to take NSAIDs

and

Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI

and

Patient has not experienced an adequate response to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist

and

Patient has a BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment

CONTINUATION – Inflammatory bowel arthritis (axial)

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Infliximab - continued

INITIATION – Inflammatory bowel arthritis (peripheral)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has a diagnosis of active ulcerative colitis or active Crohn's disease
- and Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular
- and Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated)
- and Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated)
- and Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application
- or Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application
- or ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

CONTINUATION – Inflammatory bowel arthritis (peripheral)

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician

I confirm that the above details are correct:

Signed: Date:

RS1924 - Tocilizumab

Rheumatoid Arthritis - INITIATION	324
Rheumatoid Arthritis - CONTINUATION	326
Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept) - INITIATION	323
Adult-onset Still's disease - INITIATION	325
Adult-onset Still's disease - CONTINUATION	327
Cytokine release syndrome - INITIATION	322
Idiopathic multicentric Castleman's disease - INITIATION	326
Idiopathic multicentric Castleman's disease - CONTINUATION	327
Moderate to severe COVID-19 - INITIATION	326
Polyarticular juvenile idiopathic arthritis - INITIATION	325
Polyarticular juvenile idiopathic arthritis - CONTINUATION	327
Previous use - INITIATION	322
Systemic juvenile idiopathic arthritis - INITIATION	324
Systemic juvenile idiopathic arthritis - CONTINUATION	326

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tocilizumab

INITIATION – cytokine release syndrome

Re-assessment required after 3 doses

Prerequisites (tick boxes where appropriate)

- The patient is enrolled in the Children's Oncology Group AALL1731 trial
- and**
- The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia
- and**
- Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg)

or

- The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial
- and**
- The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma
- and**
- Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses

INITIATION – previous use

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient was being treated with tocilizumab prior to 1 February 2019

and

- Rheumatoid arthritis
- or**
- Systemic juvenile idiopathic arthritis
- or**
- Adult-onset Still's disease
- or**
- Polyarticular juvenile idiopathic arthritis
- or**
- Idiopathic multicentric Castleman's disease

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Tocilizumab - continued

INITIATION – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis

and

The patient has experienced intolerable side effects from adalimumab and/or etanercept

or

The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis

and

The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor

or

The patient has been started on rituximab for rheumatoid arthritis in a Te Whatu Ora Hospital

and

The patient has experienced intolerable side effects from rituximab

or

At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tocilizumab - continued

INITIATION – Rheumatoid Arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer

and

- Tocilizumab is to be used as monotherapy

and

- Treatment with methotrexate is contraindicated
or
 Patient has tried and did not tolerate oral and/or parenteral methotrexate

and

- Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent
or
 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent

and

- Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints
or
 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

and

- Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application
or
 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

INITIATION – systemic juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient diagnosed with systemic juvenile idiopathic arthritis

and

- Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Tocilizumab - continued

INITIATION – adult-onset Still's disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD)
- or
- The patient has been started on tocilizumab for AOSD in a Te Whatu Ora Hospital

and

- The patient has experienced intolerable side effects from adalimumab and/or etanercept
- or
- The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD

or

- Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430)
- and
- Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate
- and
- Patient has persistent symptoms of disabling poorly controlled and active disease

INITIATION – polyarticular juvenile idiopathic arthritis

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA)
- and
- The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab

or

- Treatment with a tumour necrosis factor alpha inhibitor is contraindicated
- and
- Patient has had polyarticular course JIA for 6 months duration or longer
- and
- To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance
- and

- At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose)
- or
- Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose)
- or
- Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tocilizumab - continued

INITIATION – idiopathic multicentric Castleman’s disease

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has severe HHV-8 negative idiopathic multicentric Castleman’s disease
and
 Treatment with an adequate trial of corticosteroids has proven ineffective
and
 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks

INITIATION – moderate to severe COVID-19

Re-assessment required after 1 dose

Prerequisites (tick boxes where appropriate)

- Patient has confirmed (or probable) COVID-19
and
 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen
and
 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated
and
 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose
and
 Tocilizumab is not to be administered in combination with baricitinib

CONTINUATION – Rheumatoid Arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following 6 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
or
 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

CONTINUATION – systemic juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following up to 6 months’ initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline
or
 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tocilizumab - continued

CONTINUATION – adult-onset Still’s disease

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- The patient has a sustained improvement in inflammatory markers and functional status

CONTINUATION – polyarticular juvenile idiopathic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance
- and**
- Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline
- or**
- On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline

CONTINUATION – idiopathic multicentric Castleman’s disease

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and**
- The treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Omalizumab

INITIATION – severe asthma

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a clinical immunologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient must be aged 6 years or older

and

- Patient has a diagnosis of severe asthma

and

- Past or current evidence of atopy, documented by skin prick testing or RAST

and

- Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline

and

- Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated

and

- Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated

or

- Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids

and

- Patient has an Asthma Control Test (ACT) score of 10 or less

and

- Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment

CONTINUATION – severe asthma

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- An increase in the Asthma Control Test (ACT) score of at least 5 from baseline

and

- A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Omalizumab - continued

INITIATION – severe chronic spontaneous urticaria

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical immunologist or dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient must be aged 12 years or older

and

Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above

and

Patient has a Dermatology life quality index (DLQI) of 10 or greater

and

Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks

or

Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months

or

Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin

and

Treatment to be stopped if inadequate response* following 4 doses

or

Complete response* to 6 doses of omalizumab

CONTINUATION – severe chronic spontaneous urticaria

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a clinical immunologist or dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has previously had a complete response* to 6 doses of omalizumab

or

Patient has previously had a complete response* to 6 doses of omalizumab

and

Patient has relapsed after cessation of omalizumab therapy

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Siltuximab

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease
- and
- Treatment with an adequate trial of corticosteroids has proven ineffective
- and
- Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Obinutuzumab

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment

and

The patient is obinutuzumab treatment naive

and

The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min)

and

Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL

and

Patient has good performance status

and

Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles

Note: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $75 \times 10^9/L$

INITIATION – follicular / marginal zone lymphoma

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

Patient has follicular lymphoma

or

Patient has marginal zone lymphoma

and

Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen*

and

Patient has an ECOG performance status of 0-2

and

Patient has been previously treated with no more than four chemotherapy regimens

and

Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy*

Note: * includes unapproved indications

CONTINUATION – follicular / marginal zone lymphoma

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

Patient has no evidence of disease progression following obinutuzumab induction therapy

and

Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years

and

Obinutuzumab to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pertuzumab

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and
- Patient is chemotherapy treatment naive
- or
- Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer
- and
- The patient has good performance status (ECOG grade 0-1)
- and
- Pertuzumab to be administered in combination with trastuzumab
- and
- Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks
- and
- Pertuzumab to be discontinued at disease progression

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and
- The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab
- or
- Patient has previously discontinued treatment with pertuzumab and trastuzumab for reasons other than severe toxicity or disease progression
- and
- Patient has signs of disease progression
- and
- Disease has not progressed during previous treatment with pertuzumab and trastuzumab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Cetuximab

INITIATION

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck
- and**
- Patient is contraindicated to, or is intolerant of, cisplatin
- and**
- Patient has good performance status
- and**
- To be administered in combination with radiation therapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Aflibercept

INITIATION – Wet Age Related Macular Degeneration

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Wet age-related macular degeneration (wet AMD)
or
 Polypoidal choroidal vasculopathy
or
 Choroidal neovascular membrane from causes other than wet AMD

and

- The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab
or
 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart

and

- There is no structural damage to the central fovea of the treated eye
and
 Patient has not previously been treated with ranibizumab for longer than 3 months

or

- Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months
or
 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment

CONTINUATION – Wet Age Related Macular Degeneration

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Documented benefit must be demonstrated to continue
and
 Patient's vision is 6/36 or better on the Snellen visual acuity score
and
 There is no structural damage to the central fovea of the treated eye

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Aflibercept - continued

INITIATION – Diabetic Macular Oedema

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has centre involving diabetic macular oedema (DMO)
- and
- Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly
- and
- Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision
- and
- Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers
- and
- There is no centre-involving sub-retinal fibrosis or foveal atrophy

CONTINUATION – Diabetic Macular Oedema

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- There is stability or two lines of Snellen visual acuity gain
- and
- There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid)
- and
- Patient's vision is 6/36 or better on the Snellen visual acuity score
- and
- There is no centre-involving sub-retinal fibrosis or foveal atrophy
- and
- After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Secukinumab

INITIATION – severe chronic plaque psoriasis, second-line biologic

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialed infliximab in a Te Whatu Ora Hospital, for severe chronic plaque psoriasis

and

- or**
- The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab
 - The patient has received insufficient benefit from adalimumab, etanercept or infliximab

and

A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course

and

The most recent PASI or DLQI assessment is no more than 1 month old at the time of application

CONTINUATION – severe chronic plaque psoriasis, second-line biologic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- or**
- Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab
 - Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab

and

Secukinumab to be administered at a maximum dose of 300 mg monthly

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Secukinumab - continued

INITIATION – severe chronic plaque psoriasis, first-line biologic

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis
- or
- Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis

and

Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin

and

A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course

and

The most recent PASI or DLQI assessment is no more than 1 month old at the time of application

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

CONTINUATION – severe chronic plaque psoriasis, first-line biologic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab
- or
- Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab

and

Secukinumab to be administered at a maximum dose of 300 mg monthly

INITIATION – ankylosing spondylitis, second-line biologic

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis

and

- The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
- or
- Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Secukinumab - continued

CONTINUATION – ankylosing spondylitis, second-line biologic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less

and

Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate

and

Secukinumab to be administered at doses no greater than 150 mg monthly

INITIATION – psoriatic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis

and

Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab

or

Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis

or

Patient has had severe active psoriatic arthritis for six months duration or longer

and

Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose

and

Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses)

and

Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints

or

Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

and

Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application

or

Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour

or

ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Secukinumab - *continued*

CONTINUATION – psoriatic arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician

and

Secukinumab to be administered at doses no greater than 300 mg monthly

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Trastuzumab emtansine

INITIATION – early breast cancer

Prerequisites (tick boxes where appropriate)

- Patient has early breast cancer expressing HER2 IHC3+ or ISH+
- and Documentation of pathological invasive residual disease in the breast and/or auxiliary lymph nodes following completion of surgery
- and Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery
- and Disease has not progressed during neoadjuvant therapy
- and Patient has left ventricular ejection fraction of 45% or greater
- and Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery
- and Trastuzumab emtansine to be discontinued at disease progression
- and Total adjuvant treatment duration must not exceed 42 weeks (14 cycles)

INITIATION – metastatic breast cancer

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and Patient has previously received trastuzumab and chemotherapy, separately or in combination
- and The patient has received prior therapy for metastatic disease*
- or The patient developed disease recurrence during, or within six months of completing adjuvant therapy*
- and Patient has a good performance status (ECOG 0-1)
- and Patient does not have symptomatic brain metastases
- or Patient has brain metastases and has received prior local CNS therapy
- and Patient has not received prior funded trastuzumab emtansine treatment
- and Treatment to be discontinued at disease progression

CONTINUATION – metastatic breast cancer

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine
- and Treatment to be discontinued at disease progression

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

I confirm that the above details are correct:

Signed: Date:

RS1973 - Rituximab

ABO-incompatible organ transplant - INITIATION	349
ANCA associated vasculitis - INITIATION	348
ANCA associated vasculitis - CONTINUATION	348
Antibody-mediated organ transplant rejection - INITIATION	349
B-cell acute lymphoblastic leukaemia/lymphoma* - INITIATION	356
CD20+ low grade or follicular B-cell NHL - INITIATION	354
CD20+ low grade or follicular B-cell NHL - CONTINUATION	355
Chronic lymphocytic leukaemia - INITIATION	344
Chronic lymphocytic leukaemia - CONTINUATION	345
Membranous nephropathy - INITIATION	355
Membranous nephropathy - CONTINUATION	355
Neuromyelitis Optica Spectrum Disorder (NMOSD) - INITIATION	351
Neuromyelitis Optica Spectrum Disorder (NMOSD) - CONTINUATION	351
Severe Refractory Myasthenia Gravis - INITIATION	352
Severe Refractory Myasthenia Gravis - CONTINUATION	352
Severe antisynthetase syndrome - INITIATION	352
Severe antisynthetase syndrome - CONTINUATION	353
Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) - INITIATION	350
Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) - CONTINUATION	350
Steroid resistant nephrotic syndrome (SRNS) - INITIATION	350
Steroid resistant nephrotic syndrome (SRNS) - CONTINUATION	351
Aggressive CD20 positive NHL - INITIATION	343
Aggressive CD20 positive NHL - CONTINUATION	344
Anti-NMDA receptor autoimmune encephalitis - INITIATION	354
Anti-NMDA receptor autoimmune encephalitis - CONTINUATION	354
Desensitisation prior to transplant - INITIATION	356
Graft versus host disease - INITIATION	353
Haemophilia with inhibitors - INITIATION	342
Haemophilia with inhibitors - CONTINUATION	342
Immune thrombocytopenic purpura (ITP) - INITIATION	346
Immune thrombocytopenic purpura (ITP) - CONTINUATION	347
Immunoglobulin G4-related disease (IgG4-RD*) - INITIATION	357
Immunoglobulin G4-related disease (IgG4-RD*) - CONTINUATION	357
Indolent, low-grade lymphomas or hairy cell leukaemia* - INITIATION	343
Indolent, low-grade lymphomas or hairy cell leukaemia* - CONTINUATION	343
Pemphigus* - INITIATION	356
Pemphigus* - CONTINUATION	357
Post-transplant - INITIATION	342
Post-transplant - CONTINUATION	342
Pure red cell aplasia (PRCA) - INITIATION	348
Pure red cell aplasia (PRCA) - CONTINUATION	348
Severe chronic inflammatory demyelinating polyneuropathy - INITIATION	353
Severe chronic inflammatory demyelinating polyneuropathy - CONTINUATION	353
Severe cold haemagglutinin disease (CHAD) - INITIATION	345
Severe cold haemagglutinin disease (CHAD) - CONTINUATION	345
Thrombotic thrombocytopenic purpura (TTP) - INITIATION	347
Thrombotic thrombocytopenic purpura (TTP) - CONTINUATION	347
Treatment refractory systemic lupus erythematosus (SLE) - INITIATION	349
Treatment refractory systemic lupus erythematosus (SLE) - CONTINUATION	349
Warm autoimmune haemolytic anaemia (warm AIHA) - INITIATION	346
Warm autoimmune haemolytic anaemia (warm AIHA) - CONTINUATION	346

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Rituximab (Riximyo)

INITIATION – haemophilia with inhibitors

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has mild congenital haemophilia complicated by inhibitors

or

Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy

or

Patient has acquired haemophilia

CONTINUATION – haemophilia with inhibitors

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient was previously treated with rituximab for haemophilia with inhibitors

and

An initial response lasting at least 12 months was demonstrated

and

Patient now requires repeat treatment

INITIATION – post-transplant

Prerequisites (tick boxes where appropriate)

The patient has B-cell post-transplant lymphoproliferative disorder*

and

To be used for a maximum of 8 treatment cycles

Note: Indications marked with * are unapproved indications.

CONTINUATION – post-transplant

Prerequisites (tick boxes where appropriate)

The patient has had a rituximab treatment-free interval of 12 months or more

and

The patient has B-cell post-transplant lymphoproliferative disorder*

and

To be used for no more than 6 treatment cycles

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy
and
 To be used for a maximum of 6 treatment cycles

or

- The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy
and
 To be used for a maximum of 6 treatment cycles

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

CONTINUATION – indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has had a rituximab treatment-free interval of 12 months or more
and
 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy
and
 To be used for no more than 6 treatment cycles

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

INITIATION – aggressive CD20 positive NHL

Prerequisites (tick boxes where appropriate)

- The patient has treatment naive aggressive CD20 positive NHL
and
 To be used with a multi-agent chemotherapy regimen given with curative intent
and
 To be used for a maximum of 8 treatment cycles

or

- The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy
and
 To be used for a maximum of 6 treatment cycles

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – aggressive CD20 positive NHL

Prerequisites (tick boxes where appropriate)

- The patient has had a rituximab treatment-free interval of 12 months or more
- and The patient has relapsed refractory/aggressive CD20 positive NHL
- and To be used with a multi-agent chemotherapy regimen given with curative intent
- and To be used for a maximum of 4 treatment cycles

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

INITIATION – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment
- and The patient is rituximab treatment naive
- or The patient is chemotherapy treatment naive
- or The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment
- and The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy
- or The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax
- and The patient has good performance status
- and The patient does not have chromosome 17p deletion CLL
- or Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia
- and Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles
- and It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

CONTINUATION – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax

or

The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL

and

The patient has had an interval of 36 months or more since commencement of initial rituximab treatment

and

The patient does not have chromosome 17p deletion CLL

and

It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustin

and

Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

INITIATION – severe cold haemagglutinin disease (CHAD)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has cold haemagglutinin disease*

and

Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms

and

The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

CONTINUATION – severe cold haemagglutinin disease (CHAD)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned

or

Patient was previously treated with rituximab for severe cold haemagglutinin disease*

and

An initial response lasting at least 12 months was demonstrated

and

Patient now requires repeat treatment

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – warm autoimmune haemolytic anaemia (warm AIHA)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has warm autoimmune haemolytic anaemia*

and

One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin

and

The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

CONTINUATION – warm autoimmune haemolytic anaemia (warm AIHA)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned

or

Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*

and

An initial response lasting at least 12 months was demonstrated

and

Patient now requires repeat treatment

Note: Indications marked with * are unapproved indications.

INITIATION – immune thrombocytopenic purpura (ITP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre

or

Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding

and

Treatment with steroids and splenectomy have been ineffective

or

Treatment with steroids has been ineffective and splenectomy is an absolute contraindication

or

Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy)

and

The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

CONTINUATION – immune thrombocytopenic purpura (ITP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned

or

Patient was previously treated with rituximab for immune thrombocytopenic purpura*

and

An initial response lasting at least 12 months was demonstrated

and

Patient now requires repeat treatment

Note: Indications marked with * are unapproved indications.

INITIATION – thrombotic thrombocytopenic purpura (TTP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

and

Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange

or

Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology

Note: Indications marked with * are unapproved indications.

CONTINUATION – thrombotic thrombocytopenic purpura (TTP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*

and

An initial response lasting at least 12 months was demonstrated

and

Patient now requires repeat treatment

and

The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – pure red cell aplasia (PRCA)

Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder

Note: Indications marked with * are unapproved indications.

CONTINUATION – pure red cell aplasia (PRCA)

Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months

Note: Indications marked with * are unapproved indications.

INITIATION – ANCA associated vasculitis

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Patient has been diagnosed with ANCA associated vasculitis*

and The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks

and Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months

or Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g

or Cyclophosphamide and methotrexate are contraindicated

or Patient is a female of child-bearing potential

or Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy

Note: Indications marked with * are unapproved indications.

CONTINUATION – ANCA associated vasculitis

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Patient has been diagnosed with ANCA associated vasculitis*

and Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis

and The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – treatment refractory systemic lupus erythematosus (SLE)

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has severe, immediately life- or organ-threatening SLE*
- and
- The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg
- and
- The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated
- and
- Maximum of four 1000 mg infusions of rituximab

Note: Indications marked with * are unapproved indications.

CONTINUATION – treatment refractory systemic lupus erythematosus (SLE)

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment
- and
- The disease has subsequently relapsed
- and
- Maximum of two 1000 mg infusions of rituximab

Note: Indications marked with * are unapproved indications.

INITIATION – Antibody-mediated organ transplant rejection

Prerequisites (tick box where appropriate)

- Patient has been diagnosed with antibody-mediated organ transplant rejection*

Note: Indications marked with * are unapproved indications.

INITIATION – ABO-incompatible organ transplant

Prerequisites (tick box where appropriate)

- Patient is to undergo an ABO-incompatible solid organ transplant*

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient is a child with SDNS* or FRNS*
- and Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity
- and Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects
- and Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses
- and The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

CONTINUATION – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient who was previously treated with rituximab for nephrotic syndrome*
- and Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment
- and The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

INITIATION – Steroid resistant nephrotic syndrome (SRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective
- and Treatment with tacrolimus for at least 3 months has been ineffective
- and Genetic causes of nephrotic syndrome have been excluded
- and The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Rituximab (Riximyo) - continued

CONTINUATION – Steroid resistant nephrotic syndrome (SRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient who was previously treated with rituximab for nephrotic syndrome*

and

Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment

and

The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

INITIATION – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks

and

The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD)

or

The patient has experienced a breakthrough attack of NMOSD

and

The patient is receiving treatment with mycophenolate

and

The patients is receiving treatment with corticosteroids

CONTINUATION – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks

and

The patients has responded to the most recent course of rituximab

and

The patient has not received rituximab in the previous 6 months

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – Severe Refractory Myasthenia Gravis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

and

Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective

or

Treatment with at least one other immunosuppressant for a period of at least 12 months

and

Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects

CONTINUATION – Severe Refractory Myasthenia Gravis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

and

An initial response lasting at least 12 months was demonstrated

and

The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months

or

The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months

and

Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects

INITIATION – Severe antisynthetase syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Patient has confirmed antisynthetase syndrome

and

Patient has severe, immediately life or organ threatening disease, including interstitial lung disease

and

Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease

or

Rapid treatment is required due to life threatening complications

and

Maximum of four 1,000 mg infusions of rituximab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

CONTINUATION – Severe antisynthetase syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function
- and The patient has not received rituximab in the previous 6 months
- and Maximum of two cycles of 2 x 1,000 mg infusions of rituximab given two weeks apart

INITIATION – graft versus host disease

Prerequisites (tick boxes where appropriate)

- Patient has refractory graft versus host disease following transplant
- and Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease
- and The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

INITIATION – severe chronic inflammatory demyelinating polyneuropathy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD)
- and
 - Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease
 - and At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease
- or Rapid treatment is required due to life threatening complications
- and One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

CONTINUATION – severe chronic inflammatory demyelinating polyneuropathy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline
- and The patient has not received rituximab in the previous 6 months
- and One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – anti-NMDA receptor autoimmune encephalitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has severe anti-NMDA receptor autoimmune encephalitis

and

Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease

and

At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease

or

Rapid treatment is required due to life threatening complications

and

One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

CONTINUATION – anti-NMDA receptor autoimmune encephalitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function

and

The patient has not received rituximab in the previous 6 months

and

The patient has experienced a relapse and now requires further treatment

and

One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

INITIATION – CD20+ low grade or follicular B-cell NHL

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy

and

To be used for a maximum of 6 treatment cycles

or

The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy

and

To be used for a maximum of 6 treatment cycles

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

CONTINUATION – CD20+ low grade or follicular B-cell NHL

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

- Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy
- and
- Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m² every 8 weeks (maximum of 12 cycles)

INITIATION – Membranous nephropathy

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Patient has biopsy-proven primary/idiopathic membranous nephropathy*
- or
- Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m²
- and
- Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note)
- and
- The total rituximab dose would not exceed the equivalent of 375mg/m² of body surface area per week for a total of 4 weeks

CONTINUATION – Membranous nephropathy

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Patient was previously treated with rituximab for membranous nephropathy*
- and
- Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment
- or
- Patient achieved partial response to treatment and requires repeat treatment (see Note)
- and
- The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note:

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – B-cell acute lymphoblastic leukaemia/lymphoma*

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*
- and
- Treatment must be in combination with an intensive chemotherapy protocol with curative intent
- and
- The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses

Note: Indications marked with * are unapproved indications.

INITIATION – desensitisation prior to transplant

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Patient requires desensitisation prior to mismatched allogenic stem cell transplant*
- and
- Patient would receive no more than two doses at 375 mg/m² of body-surface area

Note: Indications marked with * are unapproved indications.

INITIATION – pemphigus*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist or relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has severe rapidly progressive pemphigus
- and
- Is used in combination with systemic corticosteroids (20 mg/day)

and

- Skin involvement is at least 5% body surface area
- or
- Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions
- or
- Involvement of two or more mucosal sites

or

- Patient has pemphigus
- and
- Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

CONTINUATION – pemiphigus*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist or relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement

and

- Patient has not received rituximab in the previous 6 months

Note: Indications marked with * are unapproved indications.

INITIATION – immunoglobulin G4-related disease (IgG4-RD*)

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- Patient has confirmed diagnosis of IgG4-RD*

and

- Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse

or

- Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance

and

- Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart

Note: Indications marked with * are unapproved indications.

CONTINUATION – immunoglobulin G4-related disease (IgG4-RD*)

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed

or

- Patient is receiving maintenance treatment for IgG4-RD*

and

- Rituximab re-treatment not to be given within 6 months of previous course of treatment

and

- Maximum of two 1000 mg infusions of rituximab given two weeks apart

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Mepolizumab

INITIATION – Severe eosinophilic asthma

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a respiratory physician or clinical immunologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient must be aged 12 years or older

and

Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist

and

Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded

and

Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months

and

Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated

and

Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids

or

Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months

and

Treatment is not to be used in combination with subsidised bernalizumab

and

Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment

and

Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma

or

Patient was refractory or intolerant to previous anti-IL5 biological therapy

and

Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment

CONTINUATION – Severe eosinophilic asthma

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a respiratory physician or clinical immunologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

An increase in the Asthma Control Test (ACT) score of at least 5 from baseline

and

Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab

or

Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Casirivimab and imdevimab

INITIATION – Treatment of profoundly immunocompromised patients

Re-assessment required after 2 weeks

Prerequisites (tick boxes where appropriate)

- Patient has confirmed (or probable) COVID-19
- and The patient is in the community (treated as an outpatient) with mild to moderate disease severity*
- and Patient is profoundly immunocompromised** and is at risk of not having mounted an adequate response to vaccination against COVID-19 or is unvaccinated
- and Patient's symptoms started within the last 10 days
- and Patient is not receiving high flow oxygen or assisted/mechanical ventilation
- and Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg

Note: * Mild to moderate disease severity as described on the [Ministry of Health Website](#)
** Examples include B-cell depletive illnesses or patients receiving treatment that is B-Cell depleting.

INITIATION – mild to moderate COVID-19-hospitalised patients

Re-assessment required after 2 weeks

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.
- and Patient has confirmed (or probable) COVID-19
- and Patient is an in-patient in hospital with mild to moderate disease severity*
- and Patient's symptoms started within the last 10 days
- and Patient is not receiving high flow oxygen or assisted/mechanical ventilation
- and Age > 50
- or BMI > 30
- or Patient is Māori or Pacific ethnicity
- or Patient is at increased risk of severe illness from COVID-19, excluding pregnancy, as described on the Ministry of Health website (see Notes)
- and Patient is unvaccinated
- or Patient is seronegative where serology testing is readily available or strongly suspected to be seronegative where serology testing is not available
- and Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg

Note: * Mild to moderate disease severity as described on the [Ministry of Health Website](#)
** (<https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-advice-higher-risk-people>)

I confirm that the above details are correct:

Signed: Date:

RS1940 - Adalimumab (Amgevita)

Arthritis - oligoarticular course juvenile idiopathic - INITIATION	368
Arthritis - oligoarticular course juvenile idiopathic - CONTINUATION	368
Arthritis - polyarticular course juvenile idiopathic - INITIATION	369
Arthritis - polyarticular course juvenile idiopathic - CONTINUATION	369
Arthritis - psoriatic - INITIATION	370
Arthritis - psoriatic - CONTINUATION	370
Arthritis - rheumatoid - INITIATION	371
Arthritis - rheumatoid - CONTINUATION	371
Behcet's disease - severe - INITIATION	361
Crohn's disease - adults - INITIATION	363
Crohn's disease - adults - CONTINUATION	363
Crohn's disease - children - INITIATION	364
Crohn's disease - children - CONTINUATION	364
Crohn's disease - fistulising - INITIATION	364
Crohn's disease - fistulising - CONTINUATION	365
Hidradenitis suppurativa - INITIATION	361
Hidradenitis suppurativa - CONTINUATION	361
Ocular inflammation - chronic - INITIATION	365
Ocular inflammation - chronic - CONTINUATION	365
Ocular inflammation - severe - INITIATION	366
Ocular inflammation - severe - CONTINUATION	366
Plaque psoriasis - severe chronic - INITIATION	362
Plaque psoriasis - severe chronic - CONTINUATION	362
Still's disease - adult-onset (AOSD) - INITIATION	372
Ankylosing spondylitis - INITIATION	367
Ankylosing spondylitis - CONTINUATION	367
Inflammatory bowel arthritis – axial - INITIATION	373
Inflammatory bowel arthritis – axial - CONTINUATION	374
Inflammatory bowel arthritis – peripheral - INITIATION	374
Inflammatory bowel arthritis – peripheral - CONTINUATION	374
Pyoderma gangrenosum - INITIATION	363
Ulcerative colitis - INITIATION	372
Ulcerative colitis - CONTINUATION	372
Undifferentiated spondyloarthritis - INITIATION	373
Undifferentiated spondyloarthritis - CONTINUATION	373

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita)

INITIATION – Behcet’s disease - severe

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has severe Behcet’s disease* that is significantly impacting the patient’s quality of life

and

The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s)

or

The patient has severe gastrointestinal, rheumatological and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s)

Note: Indications marked with * are unapproved indications.

INITIATION – Hidradenitis suppurativa

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas

and

Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics

and

Patient has 3 or more active lesions

and

The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application

CONTINUATION – Hidradenitis suppurativa

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline

and

The patient has a DLQI improvement of 4 or more from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Adalimumab (Amgevita) - continued

INITIATION – Plaque psoriasis - severe chronic

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis
and
 Patient has experienced intolerable side effects
or
 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis

or

Patient has "whole body" severe chronic plaque psoriasis with a (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis
or
 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis

and

Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin

and

A PASI assessment or (DLQI) assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application

CONTINUATION – Plaque psoriasis - severe chronic

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient had "whole body" severe chronic plaque psoriasis at the start of treatment
and
 The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value
or
 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value

or

Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment
and
 The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values
or
 The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Adalimumab (Amgevita) - continued

INITIATION – pyoderma gangrenosum

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has pyoderma gangrenosum*

and

Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response

Note: Indications marked with * are unapproved indications.

INITIATION – Crohn’s disease - adults

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has severe active Crohn’s disease

and

Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10

or

Patient has extensive small intestine disease affecting more than 50 cm of the small intestine

or

Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection

or

Patient has an ileostomy or colostomy and has intestinal inflammation

and

Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids

CONTINUATION – Crohn’s disease - adults

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced 3 points, from when the patient was initiated on adalimumab

or

CDAI score is 150 or less, or HBI is 4 or less

or

The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name: Name:

Ward: NHI:

Adalimumab (Amgevita) - continued

INITIATION – Crohn’s disease - children

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Paediatric patient has active Crohn’s disease

and

Patient has a PCDAI score of greater than or equal to 30

or

Patient has extensive small intestine disease

and

Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids

CONTINUATION – Crohn’s disease - children

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab

or

PCDAI score is 15 or less

or

The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed

INITIATION – Crohn’s disease - fistulising

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has confirmed Crohn’s disease

and

Patient has one or more complex externally draining enterocutaneous fistula(e)

or

Patient has one or more rectovaginal fistula(e)

or

Patient has complex peri-anal fistula

and

A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

CONTINUATION – Crohn’s disease - fistulising

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The number of open draining fistulae have decreased from baseline by at least 50%

or

There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain

INITIATION – Ocular inflammation - chronic

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation

or

Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss

and

Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective

or

Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose

or

Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate

CONTINUATION – Ocular inflammation - chronic

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had a good clinical response following 12 weeks’ initial treatment

or

Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

or

Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Adalimumab (Amgevita) - continued

INITIATION – Ocular inflammation - severe

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation

or

Patient has severe, vision-threatening ocular inflammation requiring rapid control

and

Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms

or

Patient developed new inflammatory symptoms while receiving high dose steroids

or

Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms

CONTINUATION – Ocular inflammation - severe

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had a good clinical response following 3 initial doses

or

Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

or

Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – ankylosing spondylitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis

and

- The patient has experienced intolerable side effects

or

- The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis

or

- Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months

and

- Patient has low back pain and stiffness that is relieved by exercise but not by rest

and

- Patient has bilateral sacroiliitis demonstrated by radiology imaging

and

- Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis

and

- Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right)

or

- Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender

and

- A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application

CONTINUATION – ankylosing spondylitis

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- For applications where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – Arthritis - oligoarticular course juvenile idiopathic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA)
- and
- Patient has experienced intolerable side effects
 - or
 - Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA

or

- To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance
- and
- Patient has had oligoarticular course JIA for 6 months duration or longer
- and
- At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose)
 - or
 - Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose)

CONTINUATION – Arthritis - oligoarticular course juvenile idiopathic

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline
- or
- On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – Arthritis - polyarticular course juvenile idiopathic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA)
- and
- Patient has experienced intolerable side effects
- or
- Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA

or

- To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance
- and
- Patient has had polyarticular course JIA for 6 months duration or longer
- and
- At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose)
- or
- Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose)
- or
- Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate

CONTINUATION – Arthritis - polyarticular course juvenile idiopathic

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline
- or
- On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – Arthritis - psoriatic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis
and
 Patient has experienced intolerable side effects
or
 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis

or

Patient has had active psoriatic arthritis for six months duration or longer
and
 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated)
and
 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated)
and
 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints
or
 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip
and
 Patient has CRP level greater than 15 mg/L measured no more than one month prior to the date of this application
or
 Patient has an elevated ESR greater than 25 mm per hour
or
 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

CONTINUATION – Arthritis - psoriatic

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician
or
 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – Arthritis - rheumatoid

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis

and

The patient has experienced intolerable side effects

or

The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis

or

Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer

and

Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated)

and

Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated)

and

Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin

or

Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate

and

Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints

or

Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

CONTINUATION – Arthritis - rheumatoid

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – Still's disease - adult-onset (AOSD)

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for (AOSD)

and

Patient has experienced intolerable side effects from etanercept and/or tocilizumab

or

Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab

or

Patient diagnosed with AOSD according to the Yamaguchi criteria

and

Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate

and

Patient has persistent symptoms of disabling poorly controlled and active disease

INITIATION – ulcerative colitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has active ulcerative colitis

and

Patient's SCCAI score is greater than or equal to 4

or

Patient's PUCAI score is greater than or equal to 20

and

Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids

and

Surgery (or further surgery) is considered to be clinically inappropriate

CONTINUATION – ulcerative colitis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy

or

The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on biologic therapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

INITIATION – undifferentiated spondyloarthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

and

Patient has tried and not responded to at least three months of each of methotrexate, sulphasalazine and leflunomide, at maximum tolerated doses (unless contraindicated)

and

Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application

or

Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application

or

ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

Note: Indications marked with * are unapproved indications.

CONTINUATION – undifferentiated spondyloarthritis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician

INITIATION – inflammatory bowel arthritis – axial

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has a diagnosis of active ulcerative colitis or active Crohn's disease

and

Patient has axial inflammatory pain for six months or more

and

Patient is unable to take NSAIDs

and

Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI

and

Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist

and

A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Amgevita) - continued

CONTINUATION – inflammatory bowel arthritis – axial

Re-assessment required after 2 years

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less

INITIATION – inflammatory bowel arthritis – peripheral

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has a diagnosis of active ulcerative colitis or active Crohn's disease
- and
- Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular
- and
- Patient has tried and not experienced a response to at least three months of methotrexate, or azathioprine at a maximum tolerated dose (unless contraindicated)
- and
- Patient has tried and not experienced a response to at least three months of sulphasalazine at a maximum tolerated dose (unless contraindicated)

and

- Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application
- or
- Patient has an ESR greater than 25 mm per hour
- or
- ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

CONTINUATION – inflammatory bowel arthritis – peripheral

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- Patient demonstrates at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Gemtuzumab ozogamicin

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient has not received prior chemotherapy for this condition
- and Patient has de novo CD33-positive acute myeloid leukaemia
- and Patient does not have acute promyelocytic leukaemia
- and Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC)
- and Patient is being treated with curative intent
- and Patient's disease risk has been assessed by cytogenetic testing to be good or intermediate
- and Patient must be considered eligible for standard intensive remission induction chemotherapy with standard anthracycline and cytarabine (AraC)
- and Gemtuzumab ozogamicin to be funded for one course only (one dose at 3 mg per m² body surface area or up to 2 vials of 5 mg as separate doses)

Note: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (eg myelodysplasia or myeloproliferative disorder).

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Tixagevimab with cilgavimab

INITIATION

Prerequisites (tick box where appropriate)

- Only if patient meets access criteria (as per <https://pharmac.govt.nz/Evusheld>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Benralizumab

INITIATION – Severe eosinophilic asthma

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory physician or clinical immunologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient must be aged 12 years or older

and

- Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist

and

- Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded

and

- Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months

and

- Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated

and

- Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids

or

- Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months

and

- Treatment is not to be used in combination with subsidised mepolizumab

and

- Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment

and

- Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma

or

- Patient was refractory or intolerant to previous anti-IL5 biological therapy

and

- Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment

CONTINUATION – Severe eosinophilic asthma

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory physician or clinical immunologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- An increase in the Asthma Control Test (ACT) score of at least 5 from baseline

and

- Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab

or

- Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ustekinumab

INITIATION – Crohn’s disease - adults

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment
- or
- Patient has active Crohn’s disease
- and
- Patient has had an initial approval for prior biologic therapy for Crohn’s disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria
- or
- Patient meets the initiation criteria for prior biologic therapies for Crohn’s disease
- and
- Other biologics for Crohn’s disease are contraindicated

CONTINUATION – Crohn’s disease - adults

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy
- or
- CDAI score is 150 or less, or HBI is 4 or less
- or
- The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed
- and
- Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks

INITIATION – Crohn’s disease - children*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment
- or
- Patient has active Crohn’s disease
- and
- Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria
- or
- Patient meets the initiation criteria for prior biologic therapies for Crohn’s disease
- and
- Other biologics for Crohn’s disease are contraindicated

Note: Indication marked with * is an unapproved indication.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ustekinumab - continued

CONTINUATION – Crohn’s disease - children*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy
- or
- PCDAI score is 15 or less
- or
- The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed

- and
- Ustekinumab to administered at a dose no greater than 90 mg every 8 weeks

Note: Indication marked with * is an unapproved indication.

INITIATION – ulcerative colitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment
- or
- Patient has active ulcerative colitis
- and
- Patient has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria
- or
- Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis
- and
- Other biologics for ulcerative colitis are contraindicated

CONTINUATION – ulcerative colitis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy
- or
- PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy*

- and
- Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks

Note: Criterion marked with * is for an unapproved indication.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Vedolizumab

INITIATION – Crohn’s disease - adults

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Patient has active Crohn’s disease

and

- Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated)
- or
- Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10
- or
- Patient has extensive small intestine disease affecting more than 50 cm of the small intestine
- or
- Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection
- or
- Patient has an ileostomy or colostomy, and has intestinal inflammation

and

- Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids
- or
- Patient has experienced intolerable side effects from immunomodulators and corticosteroids
- or
- Immunomodulators and corticosteroids are contraindicated

CONTINUATION – Crohn’s disease - adults

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy
- or
- CDAI score is 150 or less, or HBI is 4 or less
- or
- The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed

and

Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Vedolizumab - continued

INITIATION – Crohn’s disease - children*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Paediatric patient has active Crohn’s disease

and

Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated)

or

Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30

or

Patient has extensive small intestine disease

and

Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids

or

Patient has experienced intolerable side effects from immunomodulators and corticosteroids

or

Immunomodulators and corticosteroids are contraindicated

Note: Indication marked with * is an unapproved indication.

CONTINUATION – Crohn’s disease - children*

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy

or

PCDAI score is 15 or less

or

The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed

and

Vedolizumab to administered at a dose no greater than 300mg every 8 weeks

Note: Indication marked with * is an unapproved indication.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Vedolizumab - continued

INITIATION – ulcerative colitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Patient has active ulcerative colitis

and

Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated)

or

Patient has a SCCAI score is greater than or equal to 4

or

Patient's PUCAI score is greater than or equal to 20*

and

Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids

or

Patient has experienced intolerable side effects from immunomodulators and corticosteroids

or

Immunomodulators and corticosteroids are contraindicated

Note: Indication marked with * is an unapproved indication.

CONTINUATION – ulcerative colitis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy

or

The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy *

and

Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks

Note: Indication marked with * is an unapproved indication.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Brentuximab

INITIATION – relapsed/refractory Hodgkin lymphoma

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy
and
 Patient is ineligible for autologous stem cell transplant

or

- Patient has relapsed/refractory CD30-positive Hodgkin lymphoma
and
 Patient has previously undergone autologous stem cell transplant

and

- Patient has not previously received funded brentuximab vedotin

and

- Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles

and

- Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks

CONTINUATION – relapsed/refractory Hodgkin lymphoma

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles
and
 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated
and
 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment

INITIATION – anaplastic large cell lymphoma

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma
and
 Patient has an ECOG performance status of 0-1
and
 Patient has not previously received brentuximab vedotin
and
 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles
and
 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Brentuximab - *continued*

CONTINUATION – anaplastic large cell lymphoma

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles
- and
- Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated
- and
- Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Trastuzumab (Herzuma)

INITIATION – early breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology)
- and**
- Maximum cumulative dose of 106 mg/kg (12 months' treatment)

CONTINUATION – early breast cancer*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and**
- The patient received prior adjuvant trastuzumab treatment for early breast cancer
- and**
- The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer
- or**
- The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib
- or**
- The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab
- and**
- Trastuzumab will not be given in combination with pertuzumab
- or**
- Trastuzumab to be administered in combination with pertuzumab
- and**
- Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer
- and**
- The patient has good performance status (ECOG grade 0-1)
- and**
- Trastuzumab to be discontinued at disease progression
- or**
- Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression
- and**
- Patient has signs of disease progression
- and**
- Disease has not progressed during previous treatment with trastuzumab

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Trastuzumab (Herzuma) - continued

INITIATION – metastatic breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)

and

The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer

or

The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib

and

Trastuzumab will not be given in combination with pertuzumab

or

Trastuzumab to be administered in combination with pertuzumab

and

Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer

and

The patient has good performance status (ECOG grade 0-1)

and

Trastuzumab to be discontinued at disease progression

CONTINUATION – metastatic breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)

and

The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab

and

Trastuzumab to be discontinued at disease progression

or

Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression

and

Patient has signs of disease progression

and

Disease has not progressed during previous treatment with trastuzumab

INITIATION – gastric, gastro-oesophageal junction and oesophageal cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology)

and

Patient has an ECOG score of 0-2

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Trastuzumab (Herzuma) - continued

CONTINUATION – gastric, gastro-oesophageal junction and oesophageal cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab
and
 Trastuzumab to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Basiliximab

INITIATION

Prerequisites (tick box where appropriate)

For use in solid organ transplants

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Rituximab (Mabthera)

INITIATION – rheumatoid arthritis - prior TNF inhibitor use

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis

and

- The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
or
 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis

and

- Rituximab to be used as an adjunct to methotrexate or leflunomide therapy
or
 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used

and

- Maximum of two 1,000 mg infusions of rituximab given two weeks apart

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Rituximab (Mabthera) - continued

INITIATION – rheumatoid arthritis - TNF inhibitors contraindicated

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated

and

- Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer

and

- Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose

and

- Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses)

and

- Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin

or

- Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold

or

- Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate

and

- Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints

or

- Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip

and

- Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application

or

- C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

and

- Rituximab to be used as an adjunct to methotrexate or leflunomide therapy

or

- Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used

and

- Maximum of two 1,000 mg infusions of rituximab given two weeks apart

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Rituximab (Mabthera) - continued

CONTINUATION – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

and

Rituximab re-treatment not to be given within 6 months of the previous course of treatment

and

- Rituximab to be used as an adjunct to methotrexate or leflunomide therapy
- or
- Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used

and

Maximum of two 1,000 mg infusions of rituximab given two weeks apart

CONTINUATION – rheumatoid arthritis - re-treatment in 'responders' to rituximab

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

and

Rituximab re-treatment not to be given within 6 months of the previous course of treatment

and

- Rituximab to be used as an adjunct to methotrexate or leflunomide therapy
- or
- Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used

and

Maximum of two 1,000 mg infusions of rituximab given two weeks apart

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Trastuzumab (Herceptin)

CONTINUATION – Metastatic breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab
- and Trastuzumab not to be given in combination with lapatinib
- and Trastuzumab to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date:

RS1922 - Adalimumab (Humira - Alternative brand)

Arthritis - polyarticular course juvenile idiopathic - INITIATION	402
Arthritis - polyarticular course juvenile idiopathic - CONTINUATION	402
Arthritis - psoriatic - INITIATION	402
Arthritis - psoriatic - CONTINUATION	403
Arthritis – oligoarticular course juvenile idiopathic - INITIATION	401
Arthritis – oligoarticular course juvenile idiopathic - CONTINUATION	402
Arthritis – rheumatoid - INITIATION	403
Arthritis – rheumatoid - CONTINUATION	403
Behcet's disease – severe - INITIATION	394
Behcet's disease – severe - CONTINUATION	394
Crohn's disease - adult - INITIATION	397
Crohn's disease - adult - CONTINUATION	397
Crohn's disease - children - INITIATION	398
Crohn's disease - children - CONTINUATION	398
Crohn's disease - fistulising - INITIATION	398
Crohn's disease - fistulising - CONTINUATION	399
Hidradenitis suppurativa - INITIATION	394
Hidradenitis suppurativa - CONTINUATION	395
Ocular inflammation – chronic - INITIATION	399
Ocular inflammation – chronic - CONTINUATION	399
Ocular inflammation – severe - INITIATION	400
Ocular inflammation – severe - CONTINUATION	400
Psoriasis - severe chronic plaque - INITIATION	395
Psoriasis - severe chronic plaque - CONTINUATION	396
Pyoderma gangrenosum - INITIATION	396
Pyoderma gangrenosum - CONTINUATION	397
Still's disease – adult-onset (AOSD) - INITIATION	404
Still's disease – adult-onset (AOSD) - CONTINUATION	404
Ankylosing spondylitis - INITIATION	401
Ankylosing spondylitis - CONTINUATION	401

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Adalimumab (Humira - Alternative brand)

INITIATION – Behcet’s disease – severe

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

Patient has received a maximum of 6 months treatment with Amgevita

and

Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

Adalimumab to be administered at doses no greater than 40 mg every 14 days

CONTINUATION – Behcet’s disease – severe

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had a good clinical response to treatment with measurably improved quality of life

and

Adalimumab to be administered at doses no greater than 40 mg every 14 days

INITIATION – Hidradenitis suppurativa

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist or Practitioner on the recommendation of a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

Patient has received a maximum of 6 months treatment with Amgevita

and

Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

Adalimumab to be administered at doses no greater than 40 mg every 7 days. Fortnightly dosing has been considered

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

CONTINUATION – Hidradenitis suppurativa

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist or Practitioner on the recommendation of a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline
- and
- The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline
- and
- Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered

INITIATION – Psoriasis - severe chronic plaque

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist or Practitioner on the recommendation of a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen
- and
- Patient has received a maximum of 6 months treatment with Amgevita
- and
- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication
- and
- Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Adalimumab (Humira - Alternative brand) - continued

CONTINUATION – Psoriasis - severe chronic plaque

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist or Practitioner on the recommendation of a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient had "whole body" severe chronic plaque psoriasis at the start of treatment

and

- Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value
- or
- Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value

or

- Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment

and

- Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values
- or
- Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

INITIATION – Pyoderma gangrenosum

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

- Patient has received a maximum of 6 months treatment with Amgevita

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- A maximum of 8 doses

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

CONTINUATION – Pyoderma gangrenosum

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has demonstrated clinical improvement and continues to require treatment

and

A maximum of 8 doses

INITIATION – Crohn’s disease - adult

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita

or

Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen

or

Patient has Crohn’s and is considered to be at risk of disease destabilisation if there were to be a change to current treatment

and

Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

Adalimumab to be administered at doses no greater than 40 mg every 14 days

CONTINUATION – Crohn’s disease - adult

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab

or

CDAI score is 150 or less

or

The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed

and

Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

INITIATION – Crohn’s disease - children

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen
- or
- Patient has Crohn’s and is considered to be at risk of disease destabilisation if there were to be a change to current treatment

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

CONTINUATION – Crohn’s disease - children

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab
- or
- PCDAI score is 15 or less
- or
- The patient has demonstrated an adequate response to treatment, but PCDAI score cannot be assessed

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

INITIATION – Crohn’s disease - fistulising

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen
- or
- Patient has Crohn’s and is considered to be at risk of disease destabilisation if there were to be a change to current treatment

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

CONTINUATION – Crohn’s disease - fistulising

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The number of open draining fistulae have decreased from baseline by at least 50%
or
 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

INITIATION – Ocular inflammation – chronic

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita
or
 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen
or
 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

CONTINUATION – Ocular inflammation – chronic

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had a good clinical response following 12 weeks’ initial treatment
or
 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)
or
 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Adalimumab (Humira - Alternative brand) - continued

INITIATION – Ocular inflammation – severe

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen
- or
- Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

CONTINUATION – Ocular inflammation – severe

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has had a good clinical response following 3 initial doses
- or
- Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)
- or
- Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

INITIATION – ankylosing spondylitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
or
 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita)

and

- Patient has received a maximum of 6 months treatment with Amgevita

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

CONTINUATION – ankylosing spondylitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

INITIATION – Arthritis – oligoarticular course juvenile idiopathic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
or
 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

- Patient has received a maximum of 6 months treatment with Amgevita

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

CONTINUATION – Arthritis – oligoarticular course juvenile idiopathic

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

For patients that demonstrate at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

INITIATION – Arthritis - polyarticular course juvenile idiopathic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

Patient has received a maximum of 6 months treatment with Amgevita

and

Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

CONTINUATION – Arthritis - polyarticular course juvenile idiopathic

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

For patients that demonstrate at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

INITIATION – Arthritis - psoriatic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

Patient has received a maximum of 6 months treatment with Amgevita

and

Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adalimumab (Humira - Alternative brand) - continued

CONTINUATION – Arthritis - psoriatic

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days

INITIATION – Arthritis – rheumatoid

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
or
 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

- Patient has received a maximum of 6 months treatment with Amgevita

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days
or
 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response

CONTINUATION – Arthritis – rheumatoid

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician

and

- Adalimumab to be administered at doses no greater than 40 mg every 14 days
or
 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Adalimumab (Humira - Alternative brand) - continued

INITIATION – Still's disease – adult-onset (AOSD)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment
- or
- Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen

and

- Patient has received a maximum of 6 months treatment with Amgevita

and

- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication

CONTINUATION – Still's disease – adult-onset (AOSD)

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has demonstrated a sustained improvement in inflammatory markers and functional status

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Abciximab

INITIATION

Prerequisites (tick boxes where appropriate)

- For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention
- or
- For use in patients undergoing intra-cranial intervention

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nivolumab

INITIATION

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV

and

Baseline measurement of overall tumour burden is documented clinically and radiologically

and

The patient has ECOG performance score of 0-2

and

Patient has not received funded pembrolizumab

or

Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance

and

The cancer did not progress while the patient was on pembrolizumab

and

Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses

CONTINUATION – less than 24 months on treatment

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient's disease has had a complete response to treatment

or

Patient's disease has had a partial response to treatment

or

Patient has stable disease

and

Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

The treatment remains clinically appropriate and the patient is benefitting from the treatment

or

Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression

and

Patient has signs of disease progression

and

Disease has not progressed during previous treatment with nivolumab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Nivolumab - continued

CONTINUATION – more than 24 months on treatment

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has been on treatment for more than 24 months

and

Patient's disease has had a complete response to treatment

or

Patient's disease has had a partial response to treatment

or

Patient has stable disease

and

Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period

and

The treatment remains clinically appropriate and the patient is benefitting from the treatment

or

Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression

and

Patient has signs of disease progression

and

Disease has not progressed during previous treatment with nivolumab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pembrolizumab

INITIATION – unresectable or metastatic melanoma

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV

and

Baseline measurement of overall tumour burden is documented clinically and radiologically

and

The patient has ECOG performance score of 0-2

and

Patient has not received funded nivolumab

or

Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance

and

The cancer did not progress while the patient was on nivolumab

and

Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses

CONTINUATION – unresectable or metastatic melanoma, less than 24 months on treatment

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient's disease has had a complete response to treatment

or

Patient's disease has had a partial response to treatment

or

Patient has stable disease

and

Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

The treatment remains clinically appropriate and the patient is benefitting from the treatment

or

Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression

and

Patient has signs of disease progression

and

Disease has not progressed during previous treatment with pembrolizumab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name: Name:

Ward: NHI:

Pembrolizumab - continued

CONTINUATION – unresectable or metastatic melanoma, more than 24 months on treatment

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has been on treatment for more than 24 months

and

- Patient's disease has had a complete response to treatment
- or
- Patient's disease has had a partial response to treatment
- or
- Patient has stable disease

and

Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period

and

The treatment remains clinically appropriate and the patient is benefitting from the treatment

or

Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression

and

Patient has signs of disease progression

and

Disease has not progressed during previous treatment with pembrolizumab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name: Name:

Ward: NHI:

Pembrolizumab - continued

INITIATION – non-small cell lung cancer first-line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer
and
 Patient has not had chemotherapy for their disease in the palliative setting
and
 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC
and
 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain
and
 Pembrolizumab to be used as monotherapy

and

- There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain
or
 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain
and
 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment

and

- Patient has an ECOG 0-2
and
 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks
and
 Baseline measurement of overall tumour burden is documented clinically and radiologically

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pembrolizumab - continued

CONTINUATION – non-small cell lung cancer first-line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient's disease has had a complete response to treatment
or
 Patient's disease has had a partial response to treatment
or
 Patient has stable disease

and

- Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

- No evidence of disease progression

and

- The treatment remains clinically appropriate and patient is benefitting from treatment

and

- Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent)

and

- Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

INITIATION – non-small cell lung cancer first-line combination therapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer

and

- The patient has not had chemotherapy for their disease in the palliative setting

and

- Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC

and

- For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain

and

- Pembrolizumab to be used in combination with platinum-based chemotherapy

and

- Patient has an ECOG 0-2

and

- Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks

and

- Baseline measurement of overall tumour burden is documented clinically and radiologically

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Pembrolizumab - continued

CONTINUATION – non-small cell lung cancer first-line combination therapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient's disease has had a complete response to treatment
or
 Patient's disease has had a partial response to treatment
or
 Patient has stable disease

and

- Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

- No evidence of disease progression

and

- The treatment remains clinically appropriate and patient is benefitting from treatment

and

- Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent)

and

- Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Durvalumab

INITIATION – Non-small cell lung cancer

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC)

and

Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy

and

Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment

and

Patient has a ECOG performance status of 0 or 1

and

Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab

and

Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition

and

Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks

or

Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks

and

Treatment with durvalumab to cease upon signs of disease progression

CONTINUATION – Non-small cell lung cancer

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The treatment remains clinically appropriate and the patient is benefitting from treatment

and

Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks

or

Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks

and

Treatment with durvalumab to cease upon signs of disease progression

and

Total continuous treatment duration must not exceed 12 months

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Atezolizumab

INITIATION – non-small cell lung cancer second line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has locally advanced or metastatic non-small cell lung cancer
- and
- Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC
- and
- For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain
- and
- Patient has an ECOG 0-2
- and
- Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy
- and
- Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks
- and
- Baseline measurement of overall tumour burden is documented clinically and radiologically

CONTINUATION – non-small cell lung cancer second line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient's disease has had a complete response to treatment
- or
- Patient's disease has had a partial response to treatment
- or
- Patient has stable disease
- and
- Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period
- and
- No evidence of disease progression
- and
- The treatment remains clinically appropriate and patient is benefitting from treatment
- and
- Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent)
- and
- Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Everolimus

INITIATION

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a neurologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has tuberous sclerosis
and
 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a neurologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months
and
 The treatment remains appropriate and the patient is benefiting from treatment
and
 Everolimus to be discontinued at progression of SEGAs

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sirolimus

INITIATION

Prerequisites (tick box where appropriate)

- For rescue therapy for an organ transplant recipient

Note: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

INITIATION – severe non-malignant lymphovascular malformations*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has severe non-malignant lymphovascular malformation*
- and
- Malformations are not adequately controlled by sclerotherapy and surgery
- or
- Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate
- or
- Sirolimus is to be used to reduce malformation prior to consideration of surgery
- and
- Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team
- and
- Patient has measurable disease as defined by RECIST version 1.1 (see Note)

CONTINUATION – severe non-malignant lymphovascular malformations*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note)
- or
- Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes
- and
- No evidence of progressive disease
- and
- The treatment remains clinically appropriate and the patient is benefitting from the treatment

Note: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sirolimus - continued

INITIATION – renal angiomyolipoma(s) associated with tuberous sclerosis complex*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a nephrologist or urologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has tuberous sclerosis complex*

and

- Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth

CONTINUATION – renal angiomyolipoma(s) associated with tuberous sclerosis complex*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound

and

- Demonstrated stabilisation or improvement in renal function

and

- The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment

and

- The treatment remains appropriate and the patient is benefitting from treatment

Note: Indications marked with * are unapproved indications

INITIATION – refractory seizures associated with tuberous sclerosis complex*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has epilepsy with a background of documented tuberous sclerosis complex*

and

- Vigabatrin has been trialled and has not adequately controlled seizures

and

- Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note)

or

- Vigabatrin is contraindicated

and

- Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note)

and

- Seizures have a significant impact on quality of life

and

- Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery

Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, and topiramate. Those who can father children are not required to trial sodium valproate.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Sirolimus - *continued*

CONTINUATION – refractory seizures associated with tuberous sclerosis complex*

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment

Note: Indications marked with * are unapproved indications



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bacillus calmette-guerin (BCG)

INITIATION

Prerequisites (tick box where appropriate)

For use in bladder cancer

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Upadacitinib

INITIATION – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis

and

The patient has experienced intolerable side effects from adalimumab and/or etanercept

or

The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis

and

The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor

or

The patient has been started on rituximab for rheumatoid arthritis in a Te Whatu Ora Hospital

and

The patient has experienced intolerable side effects from rituximab

or

At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis

CONTINUATION – Rheumatoid Arthritis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Baricitinib

INITIATION – moderate to severe COVID-19*

Re-assessment required after 14 days

Prerequisites (tick boxes where appropriate)

- Patient has confirmed (or probable) COVID-19*
- and Oxygen saturation of < 92% on room air, or requiring supplemental oxygen
- and Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated
- and Baricitinib is to be administered at doses no greater than 4 mg daily for up to 14 days
- and Baricitinib is not to be administered in combination with tocilizumab

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Icatibant

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a clinical immunologist or relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency

and

- The patient has undergone product training and has agreed upon an action plan for self-administration

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- The treatment remains appropriate and the patient is benefiting from treatment

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Adrenaline

INITIATION – anaphylaxis

Prerequisites (tick boxes where appropriate)

- Patient has experienced a previous anaphylactic reaction which has resulted in presentation to a hospital or emergency department
- or
- Patient has been assessed to be at significant risk of anaphylaxis by a relevant practitioner

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bee venom

INITIATION

Prerequisites (tick boxes where appropriate)

- RAST or skin test positive
and
 Patient has had severe generalised reaction to the sensitising agent

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Paper wasp venom

INITIATION

Prerequisites (tick boxes where appropriate)

- RAST or skin test positive
- and**
- Patient has had severe generalised reaction to the sensitising agent

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Yellow jacket wasp venom

INITIATION

Prerequisites (tick boxes where appropriate)

- RAST or skin test positive

and

- Patient has had severe generalised reaction to the sensitising agent

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward: NHI:

Long-acting muscarinic antagonists with long-acting beta-adrenoceptor agonists

INITIATION

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Patient has been stabilised on a long acting muscarinic antagonist
and
 The prescriber considers that the patient would receive additional benefit from switching to a combination product

CONTINUATION

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Patient is compliant with the medication
and
 Patient has experienced improved COPD symptom control (prescriber determined)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pirfenidone

INITIATION – idiopathic pulmonary fibrosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist

and

- Forced vital capacity is between 50% and 90% predicted

and

- Pirfenidone is to be discontinued at disease progression (See Notes)

and

- Pirfenidone is not to be used in combination with subsidised nintedanib

and

- The patient has not previously received treatment with nintedanib
- or
- Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance
- or
- Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib)

CONTINUATION – idiopathic pulmonary fibrosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment

and

- Pirfenidone is not to be used in combination with subsidised nintedanib

and

- Pirfenidone is to be discontinued at disease progression (See Note)

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Nintedanib

INITIATION – idiopathic pulmonary fibrosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist

and

- Forced vital capacity is between 50% and 90% predicted

and

- Nintedanib is to be discontinued at disease progression (See Note)

and

- Nintedanib is not to be used in combination with subsidised pirfenidone

and

- The patient has not previously received treatment with pirfenidone
- or
- Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance
- or
- Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone)

CONTINUATION – idiopathic pulmonary fibrosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment

and

- Nintedanib is not to be used in combination with subsidised pirfenidone

and

- Nintedanib is to be discontinued at disease progression (See Note)

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ivacaftor

INITIATION

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a respiratory specialist or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient has been diagnosed with cystic fibrosis

and

Patient must have G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on at least 1 allele
or
 Patient must have other gating (class III) mutation (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) in the CFTR gene on at least 1 allele

and

Patients must have a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system

and

Treatment with ivacaftor must be given concomitantly with standard therapy for this condition

and

Patient must not have an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing treatment with ivacaftor

and

The dose of ivacaftor will not exceed one tablet or one sachet twice daily

and

Applicant has experience and expertise in the management of cystic fibrosis

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Ellexacaftor with tezacaftor, ivacaftor and ivacaftor

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient has been diagnosed with cystic fibrosis
- and
- Patient is 6 years of age or older
- and
- Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele)
- or
- Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system
- and
- Patient has a heterozygous or homozygous F508del mutation
- or
- Patient has a G551D mutation or other mutation responsive in vitro to ellexacaftor/tezacaftor/ivacaftor (see note a)
- and
- The treatment must be the sole funded CFTR modulator therapy for this condition
- and
- Treatment with ellexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition

Note:

- a) Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Dornase alfa

INITIATION – cystic fibrosis

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a respiratory physician or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient has a confirmed diagnosis of cystic fibrosis

and

- Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline

and

- Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period
- or
- Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in in the previous 12 month period
- or
- Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of < 22/25
- or
- Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA)

CONTINUATION – cystic fibrosis

Prerequisites (tick box where appropriate)

- Prescribed by, or recommended by a respiratory physician or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The treatment remains appropriate and the patient continues to benefit from treatment

INITIATION – significant mucus production

Re-assessment required after 4 weeks

Prerequisites (tick boxes where appropriate)

- Patient is an in-patient
- and
- The mucus production cannot be cleared by first line chest techniques

INITIATION – pleural emphyema

Re-assessment required after 3 days

Prerequisites (tick boxes where appropriate)

- Patient is an in-patient
- and
- Patient diagnoses with pleural emphyema

I confirm that the above details are correct:

Signed: Date:

Sensory Organs

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Dexamethasone

INITIATION – Diabetic macular oedema

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patients have diabetic macular oedema with pseudophakic lens

and

Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision

and

- Patient's disease has progressed despite 3 injections with bevacizumab
or
 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents

and

Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year

CONTINUATION – Diabetic macular oedema

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patient's vision is stable or has improved (prescriber determined)

and

Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year

INITIATION – Women of child bearing age with diabetic macular oedema

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

Patients have diabetic macular oedema

and

Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision

and

Patient is of child bearing potential and has not yet completed a family

and

Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Dexamethasone - *continued*

CONTINUATION – Women of child bearing age with diabetic macular oedema

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- Patient's vision is stable or has improved (prescriber determined)
- and
- Patient is of child bearing potential and has not yet completed a family
- and
- Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year

I confirm that the above details are correct:

Signed: Date:

Various

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Deferasirox

INITIATION

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia

and

- Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day

and

- Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*
- or
- Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea
- or
- Treatment with deferiprone has resulted in arthritis
- or
- Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per μL)

CONTINUATION

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels

or

- For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Deferiprone

INITIATION

Prerequisites (tick box where appropriate)

- Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Povidone-iodine - Vaginal tab 200 mg

INITIATION

Prerequisites (tick box where appropriate)

Rectal administration pre-prostate biopsy

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Chlorhexidine with cetrimide

INITIATION

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Patient has burns that are greater than 30% of total body surface area (BSA)

and

- For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting

and

- The use of 30 ml ampoules is impractical due to the size of the area to be covered

CONTINUATION

Re-assessment required after 3 months

Prerequisites (tick box where appropriate)

- The treatment remains appropriate for the patient and the patient is benefiting from the treatment

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Carbohydrate

INITIATION – Use as an additive

Prerequisites (tick boxes where appropriate)

- Cystic fibrosis
- or Chronic kidney disease
- or Cancer in children
- or Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years
- or Faltering growth in an infant/child
- or Bronchopulmonary dysplasia
- or Premature and post premature infant
- or Inborn errors of metabolism

INITIATION – Use as a module

Prerequisites (tick box where appropriate)

- For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Fat

INITIATION – Use as an additive

Prerequisites (tick boxes where appropriate)

- Patient has inborn errors of metabolism
- or Faltering growth in an infant/child
- or Bronchopulmonary dysplasia
- or Fat malabsorption
- or Lymphangiectasia
- or Short bowel syndrome
- or Infants with necrotising enterocolitis
- or Biliary atresia
- or For use in a ketogenic diet
- or Chyle leak
- or Ascites
- or Patient has increased energy requirements, and for whom dietary measures have not been successful

INITIATION – Use as a module

Prerequisites (tick box where appropriate)

- For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Protein

INITIATION – Use as an additive

Prerequisites (tick boxes where appropriate)


or	<input type="radio"/> Protein losing enteropathy <input type="radio"/> High protein needs
-----------	--

INITIATION – Use as a module

Prerequisites (tick box where appropriate)

- For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Carbohydrate and fat supplement

INITIATION

Prerequisites (tick boxes where appropriate)

Infant or child aged four years or under

and

Cystic fibrosis

or

Cancer in children

or

Faltering growth

or

Bronchopulmonary dysplasia

or

Premature and post premature infants

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Metabolic Products

INITIATION

Prerequisites (tick boxes where appropriate)

- For the dietary management of inherited metabolic disease

or

- Patient has adrenoleukodystrophy

or

- For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Diabetic Products

INITIATION

Prerequisites (tick boxes where appropriate)

- For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support
- or
- For patients with pancreatic insufficiency
- or
- For patients who have, or are expected to, eat little or nothing for 5 days
- or
- For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism
- or
- For use pre- and post-surgery
- or
- For patients being tube-fed
- or
- For tube-feeding as a transition from intravenous nutrition

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Elemental and Semi-Elemental Products

INITIATION

Prerequisites (tick boxes where appropriate)

- Malabsorption
- or Short bowel syndrome
- or Enterocutaneous fistulas
- or Eosinophilic enteritis (including oesophagitis)
- or Inflammatory bowel disease
- or Acute pancreatitis where standard feeds are not tolerated
- or Patients with multiple food allergies requiring enteral feeding

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Fat-modified feed

INITIATION

Prerequisites (tick boxes where appropriate)

- Patient has metabolic disorders of fat metabolism

or

- Patient has a chyle leak

or

- Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Hepatic Products

INITIATION

Prerequisites (tick box where appropriate)

For children (up to 18 years) who require a liver transplant

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

High Calorie Products

INITIATION

Prerequisites (tick boxes where appropriate)

Patient is fluid volume or rate restricted

or

Patient requires low electrolyte

or

Cystic fibrosis

or

Any condition causing malabsorption

or

Faltering growth in an infant/child

or

Increased nutritional requirements

and

Patient has substantially increased metabolic requirements

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

High protein enteral feed

INITIATION

Prerequisites (tick boxes where appropriate)

- The patient has a high protein requirement
- and**
- Patient has liver disease
- or**
- Patient is obese (BMI > 30) and is undergoing surgery
- or**
- Patient is fluid restricted
- or**
- Patient's needs cannot be more appropriately met using high calorie product

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Extensively hydrolysed formula

INITIATION

Prerequisites (tick boxes where appropriate)

Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content

and

Soy milk formula has been reasonably trialed without resolution of symptoms

or

Soy milk formula is considered clinically inappropriate or contraindicated

or

Severe malabsorption

or

Short bowel syndrome

or

Intractable diarrhoea

or

Biliary atresia

or

Cholestatic liver diseases causing malabsorption

or

Cystic fibrosis

or

Proven fat malabsorption

or

Severe intestinal motility disorders causing significant malabsorption

or

Intestinal failure

or

For step down from Amino Acid Formula

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

CONTINUATION

Prerequisites (tick boxes where appropriate)

An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken

and

The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Preterm formula

INITIATION

Prerequisites (tick box where appropriate)

- For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Paediatric oral/enteral feed 1 kcal/ml

INITIATION – Fluid restricted or volume intolerance with faltering growth

Prerequisites (tick boxes where appropriate)

- The patient is fluid restricted or volume intolerant
or
 The patient has increased nutritional requirements due to faltering growth

- and**
 Patient is under 18 months old and weighs less than 8kg

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Enteral liquid peptide formula

INITIATION

Prerequisites (tick boxes where appropriate)

Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable
and

- Severe malabsorption
- or**
- Short bowel syndrome
- or**
- Intractable diarrhoea
- or**
- Biliary atresia
- or**
- Cholestatic liver diseases causing malabsorption
- or**
- Cystic fibrosis
- or**
- Proven fat malabsorption
- or**
- Severe intestinal motility disorders causing significant malabsorption
- or**
- Intestinal failure

- and**
- The patient is currently receiving funded amino acid formula
 - The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula

- and**
- A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable
 - or**
 - For step down from intravenous nutrition

Note: A reasonable trial is defined as a 2-4 week trial.

CONTINUATION

Prerequisites (tick boxes where appropriate)

- An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken
- and**
- The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward: NHI:

Amino acid formula

INITIATION

Prerequisites (tick boxes where appropriate)

- Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption
- or
- History of anaphylaxis to cows' milk protein formula or dairy products
- or
- Eosinophilic oesophagitis
- or
- Ultra-short gut
- or
- Severe Immune deficiency

CONTINUATION

Prerequisites (tick boxes where appropriate)

- An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken
- and
- The outcome of the assessment is that the infant continues to require an amino acid infant formula
- and
- Amino acid formula is required for a nutritional deficit

INITIATION – patients who are currently funded under RS1502 or SA1557

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- Patient has a valid initiation or renewal approval for extensively hydrolysed formula (RS1502)
- and
- Patient is unable to source funded Aptamil powder at this time
- and
- The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Hospital Restriction RS1502. There is no continuation criteria under this criterion.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

High fat formula

INITIATION

Prerequisites (tick box where appropriate)

- For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Paediatric Products

INITIATION

Prerequisites (tick boxes where appropriate)

Child is aged one to ten years

and

The child is being fed via a tube or a tube is to be inserted for the purposes of feeding

or

Any condition causing malabsorption

or

Faltering growth in an infant/child

or

Increased nutritional requirements

or

The child is being transitioned from TPN or tube feeding to oral feeding

or

The child has eaten, or is expected to eat, little or nothing for 3 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Low electrolyte oral feed

INITIATION

Prerequisites (tick box where appropriate)

For children (up to 18 years) with acute or chronic kidney disease

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Low electrolyte enteral feed 1.8 kcal/ml

INITIATION

Prerequisites (tick box where appropriate)

For patients with acute or chronic kidney disease

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Low electrolyte oral feed

INITIATION

Prerequisites (tick box where appropriate)

For patients with acute or chronic kidney disease

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Preoperative carbohydrate feed 0.5 kcal/ml

INITIATION

Prerequisites (tick box where appropriate)

- Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

High arginine oral feed 1.4 kcal/ml

INITIATION

Prerequisites (tick box where appropriate)

- Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Standard Feeds

INITIATION

Prerequisites (tick boxes where appropriate)

For patients with malnutrition, defined as any of the following:

- BMI < 18.5
- or
- Greater than 10% weight loss in the last 3-6 months
- or
- BMI < 20 with greater than 5% weight loss in the last 3-6 months

- or
- For patients who have, or are expected to, eat little or nothing for 5 days
- or
- For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism
- or
- For use pre- and post-surgery
- or
- For patients being tube-fed
- or
- For tube-feeding as a transition from intravenous nutrition
- or
- For any other condition that meets the community Special Authority criteria

I confirm that the above details are correct:

Signed: Date:

HOSPITAL

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Diphtheria, tetanus, pertussis and polio vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- A single dose for children up to the age of 7 who have completed primary immunisation
- or
- A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation
- or
- An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens
- or
- Five doses will be funded for children requiring solid organ transplantation

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- Up to four doses for children up to and under the age of 10 for primary immunisation
- or
- An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens
- or
- Up to five doses for children up to and under the age of 10 receiving solid organ transplantation

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bacillus calmette-guerin vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

For infants at increased risk of tuberculosis defined as:

- Living in a house or family with a person with current or past history of TB

and

- Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer

and

- During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000

Note: A list of countries with high rates of TB are available at <http://www.health.govt.nz/tuberculosis> (Search for Downloads) or www.bcgatlas.org/index.php

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Diphtheria, tetanus and pertussis vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- A single dose for pregnant women in the second or third trimester of each pregnancy; or
- or A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or
- or A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation
- or An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens
- or A single dose for vaccination of patients aged from 65 years old
- or A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses
- or For vaccination of previously unimmunised or partially immunised patients
- or For revaccination following immunosuppression
- or For boosting of patients with tetanus-prone wounds

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Haemophilus influenzae type B vaccine

INITIATION

Re-assessment required after 1 dose

Prerequisites (tick boxes where appropriate)

- For primary vaccination in children

or

- An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens

or

- For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician



I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name: Name:

Ward: NHI:

Meningococcal (A, C, Y and W-135) conjugate vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant
- or
- One dose for close contacts of meningococcal cases of any group
- or
- One dose for person who has previously had meningococcal disease of any group
- or
- A maximum of two doses for bone marrow transplant patients
- or
- A maximum of two doses for person pre and post-immunosuppression*

or

- Person is aged between 13 and 25 years, inclusive
- and
- One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons
- or
- One dose for individuals who turn 13 years of age while living in boarding school hostels

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Meningococcal C conjugate vaccine

INITIATION – Children under 12 months of age

Prerequisites (tick boxes where appropriate)

- Up to three doses for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant
- or
- Two doses for close contacts of meningococcal cases of any group
- or
- Two doses for child who has previously had meningococcal disease of any group
- or
- A maximum of two doses for bone marrow transplant patients
- or
- A maximum of two doses for child pre- and post-immunosuppression*

Note: children under 12 months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine.
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pneumococcal (PCV10) conjugate vaccine

INITIATION

Prerequisites (tick box where appropriate)

A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pneumococcal (PCV13) conjugate vaccine

INITIATION – Primary course for previously unvaccinated children aged under 5 years

Re-assessment required after 3 doses

Prerequisites (tick box where appropriate)

- A primary course of three doses for previously unvaccinated children up to the age of 59 months inclusive

INITIATION – High risk individuals who have received PCV10

Re-assessment required after 2 doses

Prerequisites (tick box where appropriate)

- Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10

INITIATION – High risk children aged under 5 years

Re-assessment required after 4 doses

Prerequisites (tick boxes where appropriate)

- Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high-risk children aged under 5 years
- and**
- On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response
 - or**
 - Primary immune deficiencies
 - or**
 - HIV infection
 - or**
 - Renal failure, or nephrotic syndrome
 - or**
 - Are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant)
 - or**
 - Cochlear implants or intracranial shunts
 - or**
 - Cerebrospinal fluid leaks
 - or**
 - Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater
 - or**
 - Chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy)
 - or**
 - Pre term infants, born before 28 weeks gestation
 - or**
 - Cardiac disease, with cyanosis or failure
 - or**
 - Diabetes
 - or**
 - Down syndrome
 - or**
 - Who are pre-or post-splenectomy, or with functional asplenia

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Pneumococcal (PCV13) conjugate vaccine - continued

INITIATION – High risk individuals 5 years and over

Re-assessment required after 4 doses

Prerequisites (tick box where appropriate)

- Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency

INITIATION – Testing for primary immunodeficiency diseases

Prerequisites (tick box where appropriate)

- For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pneumococcal (PPV23) polysaccharide vaccine

INITIATION – High risk patients

Re-assessment required after 3 doses

Prerequisites (tick box where appropriate)

- For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency

INITIATION – High risk children

Re-assessment required after 2 doses

Prerequisites (tick boxes where appropriate)

- Patient is a child under 18 years for (re-)immunisation
and
- On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response
 - or
 - With primary immune deficiencies
 - or
 - With HIV infection
 - or
 - With renal failure, or nephrotic syndrome
 - or
 - Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant)
 - or
 - With cochlear implants or intracranial shunts
 - or
 - With cerebrospinal fluid leaks
 - or
 - Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater
 - or
 - With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy)
 - or
 - Pre term infants, born before 28 weeks gestation
 - or
 - With cardiac disease, with cyanosis or failure
 - or
 - With diabetes
 - or
 - With Down syndrome
 - or
 - Who are pre-or post-splenectomy, or with functional asplenia

INITIATION – Testing for primary immunodeficiency diseases

Prerequisites (tick box where appropriate)

- For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Salmonella typhi vaccine

INITIATION

Prerequisites (tick box where appropriate)

For use during typhoid fever outbreaks

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Meningococcal B multicomponent vaccine

INITIATION – Primary immunisation for children up to 12 months of age

Re-assessment required after 3 doses

Prerequisites (tick boxes where appropriate)

- Three doses for children up to 12 months of age (inclusive) for primary immunisation
- or
- Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025

INITIATION – Person is one year of age or over

Prerequisites (tick boxes where appropriate)

- Up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant
- or
- Up to two doses for close contacts of meningococcal cases of any group
- or
- Up to two doses for person who has previously had meningococcal disease of any group
- or
- Up to two doses for bone marrow transplant patients
- or
- Up to two doses for person pre- and post-immunosuppression*

INITIATION – Person is aged between 13 and 25 years (inclusive)

Re-assessment required after 2 doses

Prerequisites (tick boxes where appropriate)

- Person is aged between 13 and 25 years (inclusive)
- and
- Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences, or prisons
- or
- Two doses for individuals who turn 13 years of age while living in boarding school hostels

Note: *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Hepatitis A vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- Two vaccinations for use in transplant patients
- or
- Two vaccinations for use in children with chronic liver disease
- or
- One dose of vaccine for close contacts of known hepatitis A cases

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Hepatitis B recombinant vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers
- or
- For children born to mothers who are hepatitis B surface antigen (HBsAg) positive
- or
- For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination
- or
- For HIV positive patients
- or
- For hepatitis C positive patients
- or
- For patients following non-consensual sexual intercourse
- or
- For patients following immunosuppression
- or
- For solid organ transplant patients
- or
- For post-haematopoietic stem cell transplant (HSCT) patients
- or
- Following needle stick injury
- or
- For dialysis patients
- or
- For liver or kidney transplant patients

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Hepatitis B recombinant vaccine

INITIATION

Prerequisites (tick boxes where appropriate)

- For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers
- or
- For children born to mothers who are hepatitis B surface antigen (HBsAg) positive
- or
- For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination
- or
- For HIV positive patients
- or
- For hepatitis C positive patients
- or
- For patients following non-consensual sexual intercourse
- or
- For patients following immunosuppression
- or
- For solid organ transplant patients
- or
- For post-haematopoietic stem cell transplant (HSCT) patients
- or
- Following needle stick injury

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)

INITIATION – People over 65

Prerequisites (tick box where appropriate)

- The patient is 65 years of age or over

INITIATION – cardiovascular disease

Prerequisites (tick boxes where appropriate)

- Ischaemic heart disease
or
 Congestive heart failure
or
 Rheumatic heart disease
or
 Congenital heart disease
or
 Cerebro-vascular disease

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

INITIATION – chronic respiratory disease

Prerequisites (tick boxes where appropriate)

- Asthma, if on a regular preventative therapy
or
 Other chronic respiratory disease with impaired lung function

Note: asthma not requiring regular preventative therapy is excluded from funding.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) - continued

INITIATION – Other conditions

Prerequisites (tick boxes where appropriate)

- Diabetes
- or Chronic renal disease
- or Any cancer, excluding basal and squamous skin cancers if not invasive
- or Autoimmune disease
- or Immune suppression or immune deficiency
- or HIV
- or Transplant recipient
- or Neuromuscular and CNS diseases/ disorders
- or Haemoglobinopathies
- or Is a child on long term aspirin
- or Has a cochlear implant
- or Errors of metabolism at risk of major metabolic decompensation
- or Pre and post splenectomy
- or Down syndrome
- or Is pregnant
- or Is a child 4 years of age or under (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness

or Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a Public Hospital

INITIATION – Serious mental health conditions or addiction

Prerequisites (tick boxes where appropriate)

- Schizophrenia
- or Major depressive disorder
- or Bipolar disorder
- or Schizoaffective disorder
- or Person is currently accessing secondary or tertiary mental health and addiction services

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Measles, mumps and rubella vaccine

INITIATION – first dose prior to 12 months

Re-assessment required after 3 doses

Prerequisites (tick boxes where appropriate)

- For primary vaccination in children
- or For revaccination following immunosuppression
- or For any individual susceptible to measles, mumps or rubella

INITIATION – first dose after 12 months

Re-assessment required after 2 doses

Prerequisites (tick boxes where appropriate)

- For primary vaccination in children
- or For revaccination following immunosuppression
- or For any individual susceptible to measles, mumps or rubella

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Poliomyelitis vaccine

INITIATION

Re-assessment required after 3 doses

Prerequisites (tick boxes where appropriate)

- For partially vaccinated or previously unvaccinated individuals
- or
- For revaccination following immunosuppression

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Varicella vaccine [Chickenpox vaccine]

INITIATION – infants between 9 and 12 months of age

Re-assessment required after 2 doses

Prerequisites (tick boxes where appropriate)

for non-immune patients:

With chronic liver disease who may in future be candidates for transplantation

or

With deteriorating renal function before transplantation

or

Prior to solid organ transplant

or

Prior to any elective immunosuppression*

or

For post exposure prophylaxis who are immune competent inpatients

or

For patients at least 2 years after bone marrow transplantation, on advice of their specialist

or

For patients at least 6 months after completion of chemotherapy, on advice of their specialist

or

For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist

or

For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella

or

For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella

or

For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Varicella vaccine [Chickenpox vaccine]

INITIATION – primary vaccinations

Re-assessment required after 1 dose

Prerequisites (tick boxes where appropriate)

- Any infant born on or after 1 April 2016
- or
- For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox)

INITIATION – other conditions

Re-assessment required after 2 doses

Prerequisites (tick boxes where appropriate)

- for non-immune patients:**
- With chronic liver disease who may in future be candidates for transplantation
- or
- With deteriorating renal function before transplantation
- or
- Prior to solid organ transplant
- or
- Prior to any elective immunosuppression*
- or
- For post exposure prophylaxis who are immune competent inpatients
- or
- For patients at least 2 years after bone marrow transplantation, on advice of their specialist
- or
- For patients at least 6 months after completion of chemotherapy, on advice of their specialist
- or
- For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist
- or
- For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella
- or
- For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella
- or
- For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]

INITIATION – Children aged 14 years and under

Re-assessment required after 2 doses

Prerequisites (tick box where appropriate)

- Children aged 14 years and under

INITIATION – other conditions

Prerequisites (tick boxes where appropriate)

- Up to 3 doses for people aged 15 to 26 years inclusive
- or
- People aged 9 to 26 years inclusive
- and
- Up to 3 doses for confirmed HIV infection
- or
- Up to 3 doses for transplant (including stem cell) patients
- or
- Up to 4 doses for Post chemotherapy

INITIATION – Recurrent Respiratory Papillomatosis

Prerequisites (tick boxes where appropriate)

- Maximum of two doses for children aged 14 years and under
- or
- Maximum of three doses for people aged 15 years and over
- and
- The patient has recurrent respiratory papillomatosis
- and
- The patient has not previously had an HPV vaccine

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rotavirus oral vaccine

INITIATION

Re-assessment required after 2 doses

Prerequisites (tick boxes where appropriate)

- First dose to be administered in infants aged under 14 weeks of age
and
 No vaccination being administered to children aged 24 weeks or over

HOSPITAL

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Varicella zoster vaccine [shingles vaccine]

INITIATION – people aged 65 years (Zostavax)

Re-assessment required after 1 dose

Prerequisites (tick box where appropriate)

One dose for all people aged 65 years

INITIATION – people aged 65 years (Shingrix)

Re-assessment required after 2 doses

Prerequisites (tick box where appropriate)

Two doses for all people aged 65 years



I confirm that the above details are correct:

Signed: Date:

Index of form numbers

RS1001 Ajmaline	78	RS1155 Hyoscine hydrobromide - Patch 1.5 mg	239
RS1007 Levosimendan	85	RS1169 Dexamphetamine sulphate	255
RS1008 Hydralazine hydrochloride - Tab 25 mg	87	RS1172 Buprenorphine with naloxone	260
RS1015 Edrophonium chloride	220	RS1173 Naltrexone hydrochloride	257
RS1016 Rasburicase	225	RS1175 Sodium hyaluronate	37
RS1027 Omeprazole - Tab dispersible 20 mg	8	RS1176 Alpha tocopheryl acetate	42
RS1028 Diazoxide	11	RS1178 Multivitamins – Powder	39
RS1035 Levocarnitine	20	RS1181 Bivalirudin	62
RS1041 Amikacin	132	RS1182 Danaparoid	63
RS1043 Streptomycin sulphate	131	RS1183 Defibrotide	64
RS1044 Tobramycin	133	RS1184 Fondaparinux sodium	65
RS1045 Ertapenem	138	RS1188 Filgrastim	72
RS1046 Imipenem with cilastatin	137	RS1192 Thalidomide	274
RS1047 Meropenem	139	RS1198 Pazopanib	286
RS1048 Ceftazadime	140	RS1202 Abciximab	405
RS1049 Cefepime	141	RS1203 Basiliximab	388
RS1053 Piperacillin with tazobactam	148	RS1206 Bacillus calmette-guerin (BCG)	419
RS1054 Ticarcillin with clavulanic acid	147	RS1212 Carbohydrate and fat supplement	446
RS1055 Ciprofloxacin	149	RS1214 Standard Feeds	466
RS1059 Tigecycline	151	RS1215 Diabetic Products	448
RS1061 Clindamycin	161	RS1216 Elemental and Semi-Elemental Products	449
RS1062 Colistin sulphomethate [Colestimethate]	163	RS1217 Hepatic Products	451
RS1063 Daptomycin	152	RS1224 Preterm formula	455
RS1064 Fusidic acid	162	RS1225 High fat formula	459
RS1065 Lincomycin	153	RS1227 Low electrolyte oral feed	461
RS1066 Linezolid	154	RS1228 Low electrolyte oral feed	463
RS1067 Sulphadiazine	155	RS1229 Low electrolyte enteral feed 1.8 kcal/ml	462
RS1068 Teicoplanin	156	RS1231 High arginine oral feed 1.4 kcal/ml	465
RS1069 Vancomycin	159	RS1233 Bacillus calmette-guerin vaccine	470
RS1071 Amphotericin B - Inj (liposomal) 50 mg vial	165	RS1243 Salmonella typhi vaccine	479
RS1072 Fluconazole	167	RS1261 L-ornithine L-aspartate	9
RS1073 Itraconazole	168	RS1263 Captopril - Oral liq 5 mg per ml	75
RS1074 Posaconazole	170	RS1266 Adenosine - Inj 3 mg per ml, 10 ml vial	77
RS1075 Voriconazole	169	RS1276 Propylthiouracil	129
RS1076 Caspofungin	172	RS1277 Aztreonam, Chloramphenicol	160
RS1077 Clotazimine	173	RS1279 Flucytosine	171
RS1078 Dapsone	174	RS1281 Isoniazid	180
RS1079 Cycloserine	175	RS1282 Isoniazid with rifampicin	176
RS1080 Ethambutol hydrochloride	182	RS1283 Ivermectin	186
RS1083 Para-aminosalicylic Acid	183	RS1292 Methoxyflurane	233
RS1084 Protionamide	184	RS1294 Methylphenidate hydrochloride	254
RS1085 Pyrazinamide	177	RS1297 Sodium chloride – Inj	73
RS1086 Rifabutin	181	RS1299 Mafenide acetate	106
RS1087 Rifampicin	178	RS1301 Liothyronine sodium - Tab 20 mcg	128
RS1088 Albendazole	185	RS1302 Oxandrolone - Tab 2.5 mg	117
RS1090 Artemether with lumefantrine	187	RS1307 Oseltamivir	209
RS1091 Artesunate	188	RS1309 Capsaicin	229
RS1092 Atovaquone with proguanil hydrochloride	189	RS1315 Fosfomycin	157
RS1093 Chloroquine phosphate	190	RS1316 Amphotericin B - Inj 50 mg vial	166
RS1094 Mefloquine hydrochloride	191	RS1317 High Calorie Products	452
RS1095 Nitazoxanide	198	RS1322 Pivmecillinam	158
RS1096 Pentamidine isethionate	192	RS1327 High protein enteral feed	453
RS1097 Primaquine phosphate	193	RS1330 Biotin	22
RS1098 Pyrimethamine	194	RS1331 Pyridoxal-5-phosphate	23
RS1099 Quinine dihydrochloride	195	RS1332 Aprotinin	48
RS1100 Sodium stibogluconate	196	RS1351 Riluzole	231
RS1101 Spiramycin	197	RS1354 Povidone-iodine - Vaginal tab 200 mg	440
RS1108 Cidofovir	204	RS1369 Zanamivir - Powder for inhalation 5 mg	210
RS1109 Foscarnet sodium	205	RS1370 Sugammadex	227
RS1110 Ganciclovir	206	RS1380 Risperidone	244
RS1113 Interferon gamma	214	RS1381 Paliperidone	241
RS1117 Bee venom	425	RS1387 Diphtheria, tetanus, pertussis and polio vaccine	468
RS1118 Paper wasp venom	426	RS1398 Poliomyelitis vaccine	487
RS1119 Yellow jacket wasp venom	427	RS1410 Ketoconazole - Tab 200 mg	164
RS1125 Betamethasone valerate with clioquinol	107	RS1415 Preoperative carbohydrate feed 0.5 kcal/ml	464
RS1127 Methyl aminolevulinate hydrochloride	110	RS1416 Rifaximin	10
RS1130 Terbutaline	112	RS1417 Ferric carboxymaltose	35
RS1131 Finasteride	113	RS1427 Midodrine	80
RS1132 Tamsulosin	114	RS1435 Tobramycin Solution for inhalation 60 mg per ml, 5 ml	134
RS1133 Potassium citrate	115	RS1436 Rivastigmine	256
RS1143 Teriparatide	224	RS1444 Deferasirox	438
RS1145 Capsaicin	235	RS1445 Deferiprone	439
RS1146 Paracetamol	234	RS1446 Ceftaroline	142
RS1154 Aprepitant	240	RS1467 Carbohydrate	443

INDEX OF FORM NUMBERS

RS1468 Fat	444	RS1732 Fulvestrant	291
RS1469 Protein	445	RS1743 Pegfilgrastim	71
RS1470 Fat-modified feed	450	RS1759 Eptifibatide	67
RS1473 Paediatric Products	460	RS1763 Sucrose	232
RS1475 Tobramycin	135	RS1768 Pneumococcal (PCV10) conjugate vaccine	475
RS1478 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	469	RS1774 Ticagrelor	68
RS1487 Measles, mumps and rubella vaccine	486	RS1775 Enteral liquid peptide formula	457
RS1498 Multivitamin and mineral supplement	40	RS1776 Hydroxychloroquine	221
RS1499 Multivitamin renal	41	RS1777 Varicella vaccine [Chickenpox vaccine]	488
RS1500 Aluminium chloride	51	RS1781 Pimecrolimus	108
RS1501 Icatibant	423	RS1785 Rituximab	389
RS1502 Extensively hydrolysed formula	454	RS1787 Dornase alfa	433
RS1518 Long-acting muscarinic antagonists with long-acting beta-adrenoceptor agonists	428	RS1788 Pegaspargase	276
RS1520 Haemophilus influenzae type B vaccine	472	RS1790 Diphtheria, tetanus and pertussis vaccine	471
RS1525 Siltuximab	330	RS1793 Alglucosidase Alfa	25
RS1528 Ledipasvir with sofosbuvir	203	RS1794 Betaine	19
RS1535 Idarucizumab	53	RS1795 Galsulfase	24
RS1536 Plerixafor	70	RS1796 Sapropterin dihydrochloride	29
RS1546 Idursulfase	26	RS1797 Sodium phenylbutyrate	21
RS1565 Aminolevulinic acid hydrochloride	294	RS1799 Valganciclovir	207
RS1566 Ivabradine	79	RS1803 Modafinil	253
RS1569 Roxithromycin tab dispersible 50 mg	143	RS1811 Everolimus	415
RS1576 Melatonin	250	RS1813 Nintedanib	430
RS1587 Pneumococcal (PPV23) polysaccharide vaccine	478	RS1814 Pirfenidone	429
RS1588 Hepatitis B recombinant vaccine	483	RS1818 Ivacaftor	431
RS1590 Rotavirus oral vaccine	491	RS1824 Ursodeoxycholic acid	15
RS1591 Varicella vaccine [Chickenpox vaccine]	489	RS1826 Somatropin	122
RS1592 Etoricoxib	228	RS1827 Pegylated interferon alfa-2a	216
RS1596 Pemetrexed	265	RS1828 Lapatinib	285
RS1598 Azithromycin	145	RS1831 Carglumic Acid	30
RS1601 Methylnaltrexone bromide	17	RS1832 Coenzyme Q10	31
RS1603 Paromomycin	136	RS1833 Riboflavin	32
RS1606 Dexamethasone	435	RS1834 Taurine	33
RS1607 Laronidase	27	RS1836 Lenalidomide	267
RS1613 Cetuximab	333	RS1843 sodium picosulfate	18
RS1614 Paediatric oral/enteral feed 1 kcal/ml	456	RS1844 Febuxostat	226
RS1620 Multivitamins - Cap	38	RS1852 Empagliflozin; Empagliflozin with metformin hydrochloride	14
RS1632 Alpha tocopheryl	43	RS1855 Cabergoline	120
RS1635 Mercaptopurine	266	RS1859 Tacrolimus Ointment	109
RS1638 Hepatitis A vaccine	481	RS1861 Upadacitinib	420
RS1640 Eplerenone	82	RS1863 Secukinumab	336
RS1644 Moxifloxacin	150	RS1865 Vigabatrin	236
RS1648 Eltrombopag	49	RS1867 Amino acid formula	458
RS1652 Omalizumab	328	RS1868 Rosuvastatin	84
RS1660 Epoetin alfa	46	RS1870 Ranibizumab	307
RS1661 Epoetin beta	45	RS1872 Aflibercept	334
RS1665 Denosumab	222	RS1873 Nicotine	258
RS1666 Raloxifene	223	RS1874 Casirivimab and imdevimab	359
RS1671 Hepatitis B recombinant vaccine	482	RS1876 Baricitinib	421
RS1679 Nonacog gamma	57	RS1879 Etanercept	297
RS1682 Rurioctocog alfa pegol [Recombinant factor VIII]	58	RS1885 Erlotinib	282
RS1683 Chlorhexidine with cetrimide	441	RS1886 Sunitinib	283
RS1684 Eftrenonacog alfa	59	RS1887 Gefitinib	287
RS1685 Dasatinib	281	RS1888 Abiraterone acetate	289
RS1689 Lysine acetylsalicylate	66	RS1889 Octreotide	292
RS1691 Bevacizumab	306	RS1893 COVID-19 treatments	211
RS1693 Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	490	RS1894 COVID-19 treatments	212
RS1695 Dexrazoxane	288	RS1897 Taliglucerase alfa	28
RS1698 Calcium carbonate	4	RS1898 Non-Nucleoside Reverse Transcriptase Inhibitors	199
RS1699 Nicardipine hydrochloride	81	RS1899 Nucleoside Reverse Transcriptase Inhibitors	200
RS1702 Varenicline	259	RS1900 Protease Inhibitors	201
RS1703 Ranitidine	7	RS1901 Strand Transfer Inhibitors	202
RS1704 Eptacog alfa	61	RS1902 Emtricitabine with tenofovir disoproxil	208
RS1705 Factor eight inhibitor bypassing fraction	60	RS1904 Azacitidine	264
RS1706 Moroctocog alfa [Recombinant factor VIII]	54	RS1908 Trastuzumab emtansine	340
RS1707 Octocog alfa [Recombinant factor VIII] (Advate)	55	RS1911 Tixagevimab with cilgavimab	376
RS1708 Octocog alfa [Recombinant factor VIII] (Kogenate FS)	56	RS1912 Remdesivir	213
RS1709 Clarithromycin	144	RS1916 Varicella zoster vaccine [shingles vaccine]	492
RS1712 Alectinib	279	RS1917 Bendamustine hydrochloride	262
RS1713 Venetoclax	269	RS1918 Mepolizumab	358
RS1723 Budesonide	5	RS1919 Obinutuzumab	331
RS1725 Bortezomib	275	RS1920 Benralizumab	377
RS1726 Ruxolitinib	278	RS1922 Adalimumab (Humira - Alternative brand)	394
RS1731 Palbociclib (Ibrance)	280	RS1923 Gemtuzumab ozogamicin	375
		RS1924 Tocilizumab	322
		RS1925 Olaparib	270
		RS1926 Durvalumab	413

INDEX OF FORM NUMBERS

RS1928 Copper chloride	34	RS1989 Stiripentol	238
RS1929 Selenium	36	RS1990 Tacrolimus	295
RS1930 Tolvaptan	83	RS1991 Sirolimus	416
RS1931 Cinacalcet	118	RS1992 Alprostadil	86
RS1932 Paliperidone palmitate	242	RS1993 Multiple Sclerosis	246
RS1933 Ibrutinib	272	RS1994 Temozolomide	273
RS1935 Meningococcal C conjugate vaccine	474	RS1995 Pertuzumab	332
RS1936 Pneumococcal (PCV13) conjugate vaccine	476	RS1997 Multiple Sclerosis	248
RS1938 Nusinersen	251	RS1998 Emicizumab	52
RS1940 Adalimumab (Amgevita)	361	RS1999 Dulaglutide	12
RS1941 Infliximab	309	RS2000 Liraglutide	13
RS1942 Ustekinumab	378	RS2002 Brentuximab	383
RS1943 Vedolizumab	380	RS2003 Trastuzumab (Herceptin)	392
RS1944 Adrenaline	424	RS2005 Trastuzumab (Herzuma)	385
RS1950 Elexacaftor with tezacaftor, ivacaftor and ivacaftor	432	RS2010 Nilotinib	277
RS1954 Risdiplam	252	RS2012 Metabolic Products	447
RS1973 Rituximab	342	RS2013 Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	484
RS1977 Bedaquiline	179	RS2014 Sacubitril with valsartan	76
RS1981 Ambrisentan	92	RS2015 Nivolumab	406
RS1982 bosentan	88	RS2016 Pembrolizumab	408
RS1983 sildenafil (Vedafil)	96	RS2017 Aripiprazole	245
RS1984 Epoprostenol	98	RS2018 Olanzapine	243
RS1985 Iloprost	101	RS2019 Meningococcal (A, C, Y and W-135) conjugate vaccine	473
RS1986 Atezolizumab	414	RS2020 Meningococcal B multicomponent vaccine	480
RS1988 Lacosamide	237		

Index of titles

Abciximab (RS1202)	405	Copper chloride (RS1928)	34
Abiraterone acetate (RS1888)	289	Cycloserine (RS1079)	175
Adalimumab (Amgevita) (RS1940)	361	Danaparoid (RS1182)	63
Adalimumab (Humira - Alternative brand) (RS1922)	394	Dapsone (RS1078)	174
Adenosine - Inj 3 mg per ml, 10 ml vial (RS1266)	77	Daptomycin (RS1063)	152
Adrenaline (RS1944)	424	Dasatinib (RS1685)	281
Aflibercept (RS1872)	334	Deferasirox (RS1444)	438
Ajmaline (RS1001)	78	Deferiprone (RS1445)	439
Albendazole (RS1088)	185	Defibrotide (RS1183)	64
Alectinib (RS1712)	279	Denosumab (RS1665)	222
Alglucosidase Alfa (RS1793)	25	Dexamethasone (RS1606)	435
Alpha tocopheryl (RS1632)	43	Dexamphetamine sulphate (RS1169)	255
Alpha tocopheryl acetate (RS1176)	42	Dexrazoxane (RS1695)	288
Alprostadil (RS1992)	86	Diabetic Products (RS1215)	448
Aluminium chloride (RS1500)	51	Diazoxide (RS1028)	11
Ambrisentan (RS1981)	92	Diphtheria, tetanus and pertussis vaccine (RS1790)	471
Amikacin (RS1041)	132	Diphtheria, tetanus, pertussis and polio vaccine (RS1387)	468
Amino acid formula (RS1867)	458	Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine (RS1478)	469
Aminolevulinic acid hydrochloride (RS1565)	294	Dornase alfa (RS1787)	433
Amphotericin B - Inj (liposomal) 50 mg vial (RS1071)	165	Dulaglutide (RS1999)	12
Amphotericin B - Inj 50 mg vial (RS1316)	166	Durvalumab (RS1926)	413
Aprepitant (RS1154)	240	Edrophonium chloride (RS1015)	220
Aprotinin (RS1332)	48	Eftrenonacog alfa (RS1684)	59
Aripiprazole (RS2017)	245	Elemental and Semi-Elemental Products (RS1216)	449
Artemether with lumefantrine (RS1090)	187	Elexacaftor with tezacaftor, ivacaftor and ivacaftor (RS1950)	432
Artesunate (RS1091)	188	Eltrombopag (RS1648)	49
Atezolizumab (RS1986)	414	Emicizumab (RS1998)	52
Atovaquone with proguanil hydrochloride (RS1092)	189	Empagliflozin; Empagliflozin with metformin hydrochloride (RS1852)	14
Azacitidine (RS1904)	264	Emtricitabine with tenofovir disoproxil (RS1902)	208
Azithromycin (RS1598)	145	Enteral liquid peptide formula (RS1775)	457
Aztreonam, Chloramphenicol (RS1277)	160	Eplerenone (RS1640)	82
Bacillus calmette-guerin (BCG) (RS1206)	419	Epoetin alfa (RS1660)	46
Bacillus calmette-guerin vaccine (RS1233)	470	Epoetin beta (RS1661)	45
Baricitinib (RS1876)	421	Epoprostenol (RS1984)	98
Basiliximab (RS1203)	388	Eptacog alfa (RS1704)	61
Bedaquiline (RS1977)	179	Eptifibatide (RS1759)	67
Bee venom (RS1117)	425	Erlotinib (RS1885)	282
Bendamustine hydrochloride (RS1917)	262	Ertapenem (RS1045)	138
Benralizumab (RS1920)	377	Etanercept (RS1879)	297
Betaine (RS1794)	19	Ethambutol hydrochloride (RS1080)	182
Betamethasone valerate with clioquinol (RS1125)	107	Etoricoxib (RS1592)	228
Bevacizumab (RS1691)	306	Everolimus (RS1811)	415
Biotin (RS1330)	22	Extensively hydrolysed formula (RS1502)	454
Bivalirudin (RS1181)	62	Factor eight inhibitor bypassing fraction (RS1705)	60
Bortezomib (RS1725)	275	Fat (RS1468)	444
Brentuximab (RS2002)	383	Fat-modified feed (RS1470)	450
Budesonide (RS1723)	5	Febuxostat (RS1844)	226
Buprenorphine with naloxone (RS1172)	260	Ferric carboxymaltose (RS1417)	35
COVID-19 treatments (RS1893)	211	Filgrastim (RS1188)	72
COVID-19 treatments (RS1894)	212	Finasteride (RS1131)	113
Cabergoline (RS1855)	120	Fluconazole (RS1072)	167
Calcium carbonate (RS1698)	4	Flucytosine (RS1279)	171
Capsaicin (RS1309)	229	Fondaparinux sodium (RS1184)	65
Capsaicin (RS1145)	235	Foscarnet sodium (RS1109)	205
Captopril - Oral liq 5 mg per ml (RS1263)	75	Fosfomycin (RS1315)	157
Carbohydrate (RS1467)	443	Fulvestrant (RS1732)	291
Carbohydrate and fat supplement (RS1212)	446	Fusidic acid (RS1064)	162
Carglumic Acid (RS1831)	30	Galsulfase (RS1795)	24
Casirivimab and imdevimab (RS1874)	359	Ganciclovir (RS1110)	206
Caspofungin (RS1076)	172	Gefitinib (RS1887)	287
Cefepime (RS1049)	141	Gemtuzumab ozogamicin (RS1923)	375
Ceftaroline (RS1446)	142	Haemophilus influenzae type B vaccine (RS1520)	472
Ceftazadime (RS1048)	140	Hepatic Products (RS1217)	451
Cetuximab (RS1613)	333	Hepatitis A vaccine (RS1638)	481
Chlorhexidine with cetrimide (RS1683)	441	Hepatitis B recombinant vaccine (RS1671)	482
Chloroquine phosphate (RS1093)	190	Hepatitis B recombinant vaccine (RS1588)	483
Cidofovir (RS1108)	204	High Calorie Products (RS1317)	452
Cinacalcet (RS1931)	118	High arginine oral feed 1.4 kcal/ml (RS1231)	465
Ciprofloxacin (RS1055)	149	High fat formula (RS1225)	459
Clarithromycin (RS1709)	144	High protein enteral feed (RS1327)	453
Clindamycin (RS1061)	161	Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] (RS1693)	490
Clofazimine (RS1077)	173	Hydralazine hydrochloride - Tab 25 mg (RS1008)	87
Coenzyme Q10 (RS1832)	31		
Colistin sulphomethate [Colestimethate] (RS1062)	163		

INDEX OF TITLES

Hydroxychloroquine (RS1776)	221	Olanzapine (RS2018)	243
Hyoscine hydrobromide - Patch 1.5 mg (RS1155)	239	Olaparib (RS1925)	270
Ibrutinib (RS1933)	272	Omalizumab (RS1652)	328
Icatibant (RS1501)	423	Omeprazole - Tab dispersible 20 mg (RS1027)	8
Idarucizumab (RS1535)	53	Oseltamivir (RS1307)	209
Idursulfase (RS1546)	26	Oxandrolone - Tab 2.5 mg (RS1302)	117
Iloprost (RS1985)	101	Paediatric Products (RS1473)	460
Imipenem with cilastatin (RS1046)	137	Paediatric oral/enteral feed 1 kcal/ml (RS1614)	456
Infliximab (RS1941)	309	Palbociclib (Ibrance) (RS1731)	280
Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) (RS2013)	484	Paliperidone (RS1381)	241
Interferon gamma (RS1113)	214	Paliperidone palmitate (RS1932)	242
Isoniazid (RS1281)	180	Paper wasp venom (RS1118)	426
Isoniazid with rifampicin (RS1282)	176	Para-aminosalicylic Acid (RS1083)	183
Itraconazole (RS1073)	168	Paracetamol (RS1146)	234
Ivabradine (RS1566)	79	Paromomycin (RS1603)	136
Ivacaftor (RS1818)	431	Pazopanib (RS1198)	286
Ivermectin (RS1283)	186	Pegaspargase (RS1788)	276
Ketoconazole - Tab 200 mg (RS1410)	164	Pegfilgrastim (RS1743)	71
L-ornithine L-aspartate (RS1261)	9	Pegylated interferon alfa-2a (RS1827)	216
Lacosamide (RS1988)	237	Pembrolizumab (RS2016)	408
Lapatinib (RS1828)	285	Pemetrexed (RS1596)	265
Laronidase (RS1607)	27	Pentamidine isethionate (RS1096)	192
Ledipasvir with sofosbuvir (RS1528)	203	Pertuzumab (RS1995)	332
Lenalidomide (RS1836)	267	Pimecrolimus (RS1781)	108
Levocarnitine (RS1035)	20	Piperacillin with tazobactam (RS1053)	148
Levosimendan (RS1007)	85	Pirfenidone (RS1814)	429
Lincomycin (RS1065)	153	Pivmecillinam (RS1322)	158
Linezolid (RS1066)	154	Plerixafor (RS1536)	70
Liothyronine sodium - Tab 20 mcg (RS1301)	128	Pneumococcal (PCV10) conjugate vaccine (RS1768)	475
Liraglutide (RS2000)	13	Pneumococcal (PCV13) conjugate vaccine (RS1936)	476
Long-acting muscarinic antagonists with long-acting beta-adrenoceptor agonists (RS1518)	428	Pneumococcal (PPV23) polysaccharide vaccine (RS1587)	478
Low electrolyte enteral feed 1.8 kcal/ml (RS1229)	462	Poliomyelitis vaccine (RS1398)	487
Low electrolyte oral feed (RS1227)	461	Posaconazole (RS1074)	170
Low electrolyte oral feed (RS1228)	463	Potassium citrate (RS1133)	115
Lysine acetylsalicylate (RS1689)	66	Povidone-iodine - Vaginal tab 200 mg (RS1354)	440
Mafenide acetate (RS1299)	106	Preoperative carbohydrate feed 0.5 kcal/ml (RS1415)	464
Measles, mumps and rubella vaccine (RS1487)	486	Preterm formula (RS1224)	455
Mefloquine hydrochloride (RS1094)	191	Primaquine phosphate (RS1097)	193
Melatonin (RS1576)	250	Propylthiouracil (RS1276)	129
Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019)	473	Protease Inhibitors (RS1900)	201
Meningococcal B multicomponent vaccine (RS2020)	480	Protein (RS1469)	445
Meningococcal C conjugate vaccine (RS1935)	474	Protionamide (RS1084)	184
Mepolizumab (RS1918)	358	Pyrazinamide (RS1085)	177
Mercaptopurine (RS1635)	266	Pyridoxal-5-phosphate (RS1331)	23
Meropenem (RS1047)	139	Pyrimethamine (RS1098)	194
Metabolic Products (RS2012)	447	Quinine dihydrochloride (RS1099)	195
Methoxyflurane (RS1292)	233	Raloxifene (RS1666)	223
Methyl aminolevulinate hydrochloride (RS1127)	110	Ranibizumab (RS1870)	307
Methylalntrexone bromide (RS1601)	17	Ranitidine (RS1703)	7
Methylphenidate hydrochloride (RS1294)	254	Rasburicase (RS1016)	225
Midodrine (RS1427)	80	Remdesivir (RS1912)	213
Modafinil (RS1803)	253	Riboflavin (RS1833)	32
Moroctocog alfa [Recombinant factor VIII] (RS1706)	54	Rifabutin (RS1086)	181
Moxifloxacin (RS1644)	150	Rifampicin (RS1087)	178
Multiple Sclerosis (RS1993)	246	Rifaximin (RS1416)	10
Multiple Sclerosis (RS1997)	248	Riluzole (RS1351)	231
Multivitamin and mineral supplement (RS1498)	40	Risdiplam (RS1954)	252
Multivitamin renal (RS1499)	41	Risperidone (RS1380)	244
Multivitamins - Cap (RS1620)	38	Rituximab (RS1785)	389
Multivitamins - Powder (RS1178)	39	Rituximab (RS1973)	342
Naltrexone hydrochloride (RS1173)	257	Rivastigmine (RS1436)	256
Nicardipine hydrochloride (RS1699)	81	Rosuvastatin (RS1868)	84
Nicotine (RS1873)	258	Rotavirus oral vaccine (RS1590)	491
Nilotinib (RS2010)	277	Roxithromycin tab dispersible 50 mg (RS1569)	143
Nintedanib (RS1813)	430	Ruriococog alfa pegol [Recombinant factor VIII] (RS1682)	58
Nitazoxanide (RS1095)	198	Ruxolitinib (RS1726)	278
Nivolumab (RS2015)	406	Sacubitril with valsartan (RS2014)	76
Non-Nucleoside Reverse Transcriptase Inhibitors (RS1898)	199	Salmonella typhi vaccine (RS1243)	479
Nonacog gamma (RS1679)	57	Sapropterin dihydrochloride (RS1796)	29
Nucleoside Reverse Transcriptase Inhibitors (RS1899)	200	Secukinumab (RS1863)	336
Nusinersen (RS1938)	251	Selenium (RS1929)	36
Obinutuzumab (RS1919)	331	Siltuximab (RS1525)	330
Octocog alfa [Recombinant factor VIII] (Advate) (RS1707)	55	Sirolimus (RS1991)	416
Octocog alfa [Recombinant factor VIII] (Kogenate FS) (RS1708)	56	Sodium chloride - Inj (RS1297)	73
Octreotide (RS1889)	292	Sodium hyaluronate (RS1175)	37
		Sodium phenylbutyrate (RS1797)	21
		Sodium stibogluconate (RS1100)	196

INDEX OF TITLES

Somatropin (RS1826)	122	Tobramycin (RS1044)	133
Spiramycin (RS1101)	197	Tobramycin Solution for inhalation 60 mg per ml, 5 ml (RS1435)	134
Standard Feeds (RS1214)	466	Tocilizumab (RS1924)	322
Stiripentol (RS1989)	238	Tolvaptan (RS1930)	83
Strand Transfer Inhibitors (RS1901)	202	Trastuzumab (Herceptin) (RS2003)	392
Streptomycin sulphate (RS1043)	131	Trastuzumab (Herzuma) (RS2005)	385
Sucrose (RS1763)	232	Trastuzumab emtansine (RS1908)	340
Sugammadex (RS1370)	227	Upadacitinib (RS1861)	420
Sulphadiazine (RS1067)	155	Ursodeoxycholic acid (RS1824)	15
Sunitinib (RS1886)	283	Ustekinumab (RS1942)	378
Tacrolimus (RS1990)	295	Valganciclovir (RS1799)	207
Tacrolimus Ointment (RS1859)	109	Vancomycin (RS1069)	159
Taliglucerase alfa (RS1897)	28	Varenicline (RS1702)	259
Tamsulosin (RS1132)	114	Varicella vaccine [Chickenpox vaccine] (RS1777)	488
Taurine (RS1834)	33	Varicella vaccine [Chickenpox vaccine] (RS1591)	489
Teicoplanin (RS1068)	156	Varicella zoster vaccine [shingles vaccine] (RS1916)	492
Temozolomide (RS1994)	273	Vedolizumab (RS1943)	380
Terbutaline (RS1130)	112	Venetoclax (RS1713)	269
Teriparatide (RS1143)	224	Vigabatrin (RS1865)	236
Thalidomide (RS1192)	274	Voriconazole (RS1075)	169
Ticagrelor (RS1774)	68	Yellow jacket wasp venom (RS1119)	427
Ticarcillin with clavulanic acid (RS1054)	147	Zanamivir - Powder for inhalation 5 mg (RS1369)	210
Tigecycline (RS1059)	151	bosentan (RS1982)	88
Tixagevimab with cilgavimab (RS1911)	376	sildenafil (Vedafil) (RS1983)	96
Tobramycin (RS1475)	135	sodium picosulfate (RS1843)	18